{"nbformat":4,"nbformat_minor":0,"metadata":{"colab":{"provenance":[{"file_id":"1QO2Znb9V2iGQd5u1IWicEVijZCVfpunl","timestamp":1728024761094}],"gpuType":"A100","machine_shape":"hm"},"kernelspec":{"name":"python3","display_name":"Python 3"},"language_info":{"name":"python"},"accelerator":"GPU","widgets":{"application/vnd.jupyter.widget-state+json":{"4211ae33e52f4fdc877b0060ccabb014":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_cf4da7101bdb4ce6a198204d0ed2f1af","IPY_MODEL_db23b100c1af46b2b7d53ca97364ec00","IPY_MODEL_0faa21f7e3364d18adf4c1b36047289c"],"layout":"IPY_MODEL_d6ac1043fcce4c6493d8a735bbae8b04"}},"cf4da7101bdb4ce6a198204d0ed2f1af":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_c15b161f1c9749d2a587e341583e695d","placeholder":"​","style":"IPY_MODEL_be70fdf304b147038fd671719a025f1f","value":"modules.json: 100%"}},"db23b100c1af46b2b7d53ca97364ec00":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_3a756bfdfaef4b3180fd430780e9437f","max":349,"min":0,"orientation":"horizontal","style":"IPY_MODEL_e8d5287fab3a4a12be7899cacb3fb1b5","value":349}},"0faa21f7e3364d18adf4c1b36047289c":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_4f519f8acda44d4898dd1f5b526c02da","placeholder":"​","style":"IPY_MODEL_73cc9b0295fe49738e4cdb5f1942c58c","value":" 349/349 [00:00&lt;00:00, 28.3kB/s]"}},"d6ac1043fcce4c6493d8a735bbae8b04":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"c15b161f1c9749d2a587e341583e695d":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"be70fdf304b147038fd671719a025f1f":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"3a756bfdfaef4b3180fd430780e9437f":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"e8d5287fab3a4a12be7899cacb3fb1b5":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"4f519f8acda44d4898dd1f5b526c02da":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"73cc9b0295fe49738e4cdb5f1942c58c":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"b49fbd4cf77946afaccb286f9dd3d295":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_0f2389e1d63842768424bace1160bb33","IPY_MODEL_70b58d440cb0409ba5a9181b3ebbc092","IPY_MODEL_cdb53f86b5b648c090a33b6913285cfe"],"layout":"IPY_MODEL_ebe42bb7ad3b458083bb0a144956e56d"}},"0f2389e1d63842768424bace1160bb33":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_93546bc6410c40a19369ef8caf125323","placeholder":"​","style":"IPY_MODEL_a66c6fd3e24f4a29895363e4ed439223","value":"config_sentence_transformers.json: 100%"}},"70b58d440cb0409ba5a9181b3ebbc092":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_1020d3e61659407fb9fdf10e0061ad52","max":116,"min":0,"orientation":"horizontal","style":"IPY_MODEL_8df0063cb75a47ad9a038fbc6788e0d5","value":116}},"cdb53f86b5b648c090a33b6913285cfe":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_986d9bb88acb43c0a07351d649aa4182","placeholder":"​","style":"IPY_MODEL_4fb26b0b46804ea88064cad71b9fc315","value":" 116/116 [00:00&lt;00:00, 9.55kB/s]"}},"ebe42bb7ad3b458083bb0a144956e56d":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"93546bc6410c40a19369ef8caf125323":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"a66c6fd3e24f4a29895363e4ed439223":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"1020d3e61659407fb9fdf10e0061ad52":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"8df0063cb75a47ad9a038fbc6788e0d5":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"986d9bb88acb43c0a07351d649aa4182":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"4fb26b0b46804ea88064cad71b9fc315":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"8e36796876a14a31b1b27181b3cbecd4":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_0b579b5bc0194f10aeb051b12229d66c","IPY_MODEL_ac922208fde24c34bfccd75fac1e300c","IPY_MODEL_8fd270f50ec94c40adbbca40a60bbc41"],"layout":"IPY_MODEL_d36b19ba1f2f40a281c0dd9d3783fd49"}},"0b579b5bc0194f10aeb051b12229d66c":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_13357110c5f349f89d0c95699c799f13","placeholder":"​","style":"IPY_MODEL_20d7b909f8ec430b9946ee3f0f9068ec","value":"README.md: 100%"}},"ac922208fde24c34bfccd75fac1e300c":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_f444709cd1214ad3b749162841843a80","max":10659,"min":0,"orientation":"horizontal","style":"IPY_MODEL_0e420d36933c43c394445b5deb4fc793","value":10659}},"8fd270f50ec94c40adbbca40a60bbc41":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_328ddc806d8c40c4ae2f661dcfc30464","placeholder":"​","style":"IPY_MODEL_920b95f8e38b4c5b8012855ae9a4089f","value":" 10.7k/10.7k [00:00&lt;00:00, 796kB/s]"}},"d36b19ba1f2f40a281c0dd9d3783fd49":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"13357110c5f349f89d0c95699c799f13":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"20d7b909f8ec430b9946ee3f0f9068ec":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"f444709cd1214ad3b749162841843a80":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"0e420d36933c43c394445b5deb4fc793":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"328ddc806d8c40c4ae2f661dcfc30464":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"920b95f8e38b4c5b8012855ae9a4089f":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"3e28bdb1beeb4cdab35d5e6b6644c187":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_dc144432eaaf4775a16cfb322b40cba4","IPY_MODEL_b92bfc8c3b3a4a74a29b8979bf8ec280","IPY_MODEL_f0951b5631de443ea326bb6dc3da45cd"],"layout":"IPY_MODEL_5d63c1400b654c20aaf3a90287301e48"}},"dc144432eaaf4775a16cfb322b40cba4":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_0940d72f64d941619f36012e4cdc3b94","placeholder":"​","style":"IPY_MODEL_5d88ea830548477984f0a7226611d405","value":"sentence_bert_config.json: 100%"}},"b92bfc8c3b3a4a74a29b8979bf8ec280":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_71fffd780b6049d28d42e54deda0cd9e","max":53,"min":0,"orientation":"horizontal","style":"IPY_MODEL_225348cbbfb2465eb06c29aa7edb438c","value":53}},"f0951b5631de443ea326bb6dc3da45cd":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_b54670b45c894630bf74a19bc7be7160","placeholder":"​","style":"IPY_MODEL_e42db1887e374ed89b50475c0c8b2a44","value":" 53.0/53.0 [00:00&lt;00:00, 4.33kB/s]"}},"5d63c1400b654c20aaf3a90287301e48":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"0940d72f64d941619f36012e4cdc3b94":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"5d88ea830548477984f0a7226611d405":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"71fffd780b6049d28d42e54deda0cd9e":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"225348cbbfb2465eb06c29aa7edb438c":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"b54670b45c894630bf74a19bc7be7160":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"e42db1887e374ed89b50475c0c8b2a44":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"e05161452d0644319bbe22777c5d41f0":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_822450bcff1a463e8ee44ae024c5a054","IPY_MODEL_a851bf85215a413798e37bc2d90a9d1f","IPY_MODEL_8872a29ee77c4683bc6343e81726d14a"],"layout":"IPY_MODEL_0846f6fecc3248bb894532e2dbd57794"}},"822450bcff1a463e8ee44ae024c5a054":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_a8201b1d1e504887841e2e455ca022b3","placeholder":"​","style":"IPY_MODEL_8820d0f8a3f44c9ba65a9fb4607ab6ea","value":"config.json: 100%"}},"a851bf85215a413798e37bc2d90a9d1f":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_19711df6e61b4efab8dd42c1bc76e805","max":612,"min":0,"orientation":"horizontal","style":"IPY_MODEL_73978240b07a4fc9a0769fad14a1ea65","value":612}},"8872a29ee77c4683bc6343e81726d14a":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_fc18d0a6182e4e8dbf7acd66492ff304","placeholder":"​","style":"IPY_MODEL_9daf2843ea8843e3ab71c613f7e6a983","value":" 612/612 [00:00&lt;00:00, 48.2kB/s]"}},"0846f6fecc3248bb894532e2dbd57794":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"a8201b1d1e504887841e2e455ca022b3":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"8820d0f8a3f44c9ba65a9fb4607ab6ea":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"19711df6e61b4efab8dd42c1bc76e805":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"73978240b07a4fc9a0769fad14a1ea65":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"fc18d0a6182e4e8dbf7acd66492ff304":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"9daf2843ea8843e3ab71c613f7e6a983":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"2a28c6860ac04b3faabf9e2ab96efb06":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_44d5e6ba7fc94a5fb32a69a5fe6b7809","IPY_MODEL_2e4d22a8490b40ea931b36cc4f21c040","IPY_MODEL_dd2a6c4fb28a4b23a74a143aeaf2b884"],"layout":"IPY_MODEL_21406de8607345a4aece73f0b4e5759d"}},"44d5e6ba7fc94a5fb32a69a5fe6b7809":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_85a157d3a66e4258bec0a8755f6ec9a0","placeholder":"​","style":"IPY_MODEL_2f66985cf70449959e7e9b9a320243a1","value":"model.safetensors: 100%"}},"2e4d22a8490b40ea931b36cc4f21c040":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_5a1b2035cc3c47a4b3a813d127b1f2f8","max":90868376,"min":0,"orientation":"horizontal","style":"IPY_MODEL_ba96df39b9aa49fca113f3d9a97feb8c","value":90868376}},"dd2a6c4fb28a4b23a74a143aeaf2b884":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_d390266d8c9f4ca68366acd33e9b1ba8","placeholder":"​","style":"IPY_MODEL_5439ffc7d2f044188b0468389760660a","value":" 90.9M/90.9M [00:00&lt;00:00, 108MB/s]"}},"21406de8607345a4aece73f0b4e5759d":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"85a157d3a66e4258bec0a8755f6ec9a0":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"2f66985cf70449959e7e9b9a320243a1":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"5a1b2035cc3c47a4b3a813d127b1f2f8":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"ba96df39b9aa49fca113f3d9a97feb8c":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"d390266d8c9f4ca68366acd33e9b1ba8":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"5439ffc7d2f044188b0468389760660a":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"75198861280441b09980027bb0814172":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_145dcab7b7f348e493bc05a6a8dfde28","IPY_MODEL_b40820cbaacf4d28b4ab2ef438f7705d","IPY_MODEL_d8a7449659ce4bbeb987dacd5e6a3836"],"layout":"IPY_MODEL_79c3cfacdb5a4604b18429d590932eb5"}},"145dcab7b7f348e493bc05a6a8dfde28":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_d96fbec9d9eb42eebf2327d56950d71f","placeholder":"​","style":"IPY_MODEL_d5763b79a5714fcc8b5d0fc2ddf35f85","value":"tokenizer_config.json: 100%"}},"b40820cbaacf4d28b4ab2ef438f7705d":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_2528c679aee94df7a7d879473d4d47c6","max":350,"min":0,"orientation":"horizontal","style":"IPY_MODEL_4f7381c4496d47b5b321c06d13f418ba","value":350}},"d8a7449659ce4bbeb987dacd5e6a3836":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_1c28917930de4b6f80d1f5fad27bcf55","placeholder":"​","style":"IPY_MODEL_45d9eb307032411b82a5394ff3599980","value":" 350/350 [00:00&lt;00:00, 25.6kB/s]"}},"79c3cfacdb5a4604b18429d590932eb5":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"d96fbec9d9eb42eebf2327d56950d71f":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"d5763b79a5714fcc8b5d0fc2ddf35f85":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"2528c679aee94df7a7d879473d4d47c6":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"4f7381c4496d47b5b321c06d13f418ba":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"1c28917930de4b6f80d1f5fad27bcf55":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"45d9eb307032411b82a5394ff3599980":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"50e06c6af1014a6c92e0147f18245ff5":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_ccb80c8bc9824893b3f2c2ada19fc44d","IPY_MODEL_b368db5f25fb423cbef4fbfed47c99fc","IPY_MODEL_0bd3b36e1439449c8e8a381e1d3a26c9"],"layout":"IPY_MODEL_0fe3eb3370e54d09bafa821febd92b4e"}},"ccb80c8bc9824893b3f2c2ada19fc44d":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_97bb065783824c09a07e4b583d3f7227","placeholder":"​","style":"IPY_MODEL_6ca549bed7ff4e7aa7b003ed29cf1c3c","value":"vocab.txt: 100%"}},"b368db5f25fb423cbef4fbfed47c99fc":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_3fa004ceb1884ee4813a81937c2e0f47","max":231508,"min":0,"orientation":"horizontal","style":"IPY_MODEL_9b1cd1f3a18d4cf58d80aa92040ba80b","value":231508}},"0bd3b36e1439449c8e8a381e1d3a26c9":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_ab201612496440929bc48be7dd48b519","placeholder":"​","style":"IPY_MODEL_2a1a9bffef654052953b9abca78e2344","value":" 232k/232k [00:00&lt;00:00, 512kB/s]"}},"0fe3eb3370e54d09bafa821febd92b4e":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"97bb065783824c09a07e4b583d3f7227":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"6ca549bed7ff4e7aa7b003ed29cf1c3c":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"3fa004ceb1884ee4813a81937c2e0f47":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"9b1cd1f3a18d4cf58d80aa92040ba80b":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"ab201612496440929bc48be7dd48b519":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"2a1a9bffef654052953b9abca78e2344":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"65af5a7f0e4043b4b794ed6b2f873484":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_6423189258364d18a2ebb8ecff893e6a","IPY_MODEL_d37a4a55320e43e88f099455ae93d619","IPY_MODEL_b59ce70721104e17b4552f9e9ecdc04a"],"layout":"IPY_MODEL_9d655e85f0e84f0480b75afc27d55d30"}},"6423189258364d18a2ebb8ecff893e6a":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_f69d11ad7a094f94b07359c57f8d20d8","placeholder":"​","style":"IPY_MODEL_d91408b70f04487f92cb4416561b09ef","value":"tokenizer.json: 100%"}},"d37a4a55320e43e88f099455ae93d619":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_041c687e570848bb9a47b7915c101389","max":466247,"min":0,"orientation":"horizontal","style":"IPY_MODEL_d1318a6872834d97b9043da4e26448fb","value":466247}},"b59ce70721104e17b4552f9e9ecdc04a":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_85b4103950714ad9b8cf66c25deeea5d","placeholder":"​","style":"IPY_MODEL_2f1018dd1cbb42e19f73b91c55e14066","value":" 466k/466k [00:00&lt;00:00, 2.05MB/s]"}},"9d655e85f0e84f0480b75afc27d55d30":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"f69d11ad7a094f94b07359c57f8d20d8":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"d91408b70f04487f92cb4416561b09ef":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"041c687e570848bb9a47b7915c101389":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"d1318a6872834d97b9043da4e26448fb":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"85b4103950714ad9b8cf66c25deeea5d":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"2f1018dd1cbb42e19f73b91c55e14066":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"e0540e1c59b442609e93a9c3c4f774d3":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_4eacfe6c6c26424abc5262530f17ac34","IPY_MODEL_06c259a31a46421ba524c8bed43829a7","IPY_MODEL_3cc832a69fca4af7a5bba8ece02f8e5a"],"layout":"IPY_MODEL_56acfd8104544aff84005539bc327609"}},"4eacfe6c6c26424abc5262530f17ac34":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_326494218f5a4b95b6d5313e746f8a20","placeholder":"​","style":"IPY_MODEL_98e189444b0144c1b06040e775cfe760","value":"special_tokens_map.json: 100%"}},"06c259a31a46421ba524c8bed43829a7":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_4b4fa6f93e174814bbebf507b1c51f19","max":112,"min":0,"orientation":"horizontal","style":"IPY_MODEL_9286d333861e4007810193a9eaa793f8","value":112}},"3cc832a69fca4af7a5bba8ece02f8e5a":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_0aee5eb0a0f54f5484b8800399dc4771","placeholder":"​","style":"IPY_MODEL_cf6bd3d6a69d4632bf8e574099686259","value":" 112/112 [00:00&lt;00:00, 9.68kB/s]"}},"56acfd8104544aff84005539bc327609":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"326494218f5a4b95b6d5313e746f8a20":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"98e189444b0144c1b06040e775cfe760":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"4b4fa6f93e174814bbebf507b1c51f19":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"9286d333861e4007810193a9eaa793f8":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"0aee5eb0a0f54f5484b8800399dc4771":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"cf6bd3d6a69d4632bf8e574099686259":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"cceb44821bd74ff4b4806d56649e46fb":{"model_module":"@jupyter-widgets/controls","model_name":"HBoxModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HBoxModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HBoxView","box_style":"","children":["IPY_MODEL_c2f9aa1ac88d4471b66f30a11b4e6fef","IPY_MODEL_1ca59832bc464fc39ac4c7093fa5ef24","IPY_MODEL_bafb86534ddc475ea3f5faae2b2ddefd"],"layout":"IPY_MODEL_19847e10d21843cd9964ef434ddc128a"}},"c2f9aa1ac88d4471b66f30a11b4e6fef":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_ffec4a9f58d84d189aaefc99daece456","placeholder":"​","style":"IPY_MODEL_e34d6993f7f24ce8b29d4312c758affe","value":"1_Pooling/config.json: 100%"}},"1ca59832bc464fc39ac4c7093fa5ef24":{"model_module":"@jupyter-widgets/controls","model_name":"FloatProgressModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"FloatProgressModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"ProgressView","bar_style":"success","description":"","description_tooltip":null,"layout":"IPY_MODEL_b75a90b5dc6b43da8ee2902bb45ecd94","max":190,"min":0,"orientation":"horizontal","style":"IPY_MODEL_17aa81a73e9d4dea90714fba32c2e6c4","value":190}},"bafb86534ddc475ea3f5faae2b2ddefd":{"model_module":"@jupyter-widgets/controls","model_name":"HTMLModel","model_module_version":"1.5.0","state":{"_dom_classes":[],"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"HTMLModel","_view_count":null,"_view_module":"@jupyter-widgets/controls","_view_module_version":"1.5.0","_view_name":"HTMLView","description":"","description_tooltip":null,"layout":"IPY_MODEL_ec8fc85206e242a3852b65f37d577c57","placeholder":"​","style":"IPY_MODEL_02e1752bbb0748bc9e3e1915f37c06e2","value":" 190/190 [00:00&lt;00:00, 16.7kB/s]"}},"19847e10d21843cd9964ef434ddc128a":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"ffec4a9f58d84d189aaefc99daece456":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"e34d6993f7f24ce8b29d4312c758affe":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}},"b75a90b5dc6b43da8ee2902bb45ecd94":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"17aa81a73e9d4dea90714fba32c2e6c4":{"model_module":"@jupyter-widgets/controls","model_name":"ProgressStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"ProgressStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","bar_color":null,"description_width":""}},"ec8fc85206e242a3852b65f37d577c57":{"model_module":"@jupyter-widgets/base","model_name":"LayoutModel","model_module_version":"1.2.0","state":{"_model_module":"@jupyter-widgets/base","_model_module_version":"1.2.0","_model_name":"LayoutModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"LayoutView","align_content":null,"align_items":null,"align_self":null,"border":null,"bottom":null,"display":null,"flex":null,"flex_flow":null,"grid_area":null,"grid_auto_columns":null,"grid_auto_flow":null,"grid_auto_rows":null,"grid_column":null,"grid_gap":null,"grid_row":null,"grid_template_areas":null,"grid_template_columns":null,"grid_template_rows":null,"height":null,"justify_content":null,"justify_items":null,"left":null,"margin":null,"max_height":null,"max_width":null,"min_height":null,"min_width":null,"object_fit":null,"object_position":null,"order":null,"overflow":null,"overflow_x":null,"overflow_y":null,"padding":null,"right":null,"top":null,"visibility":null,"width":null}},"02e1752bbb0748bc9e3e1915f37c06e2":{"model_module":"@jupyter-widgets/controls","model_name":"DescriptionStyleModel","model_module_version":"1.5.0","state":{"_model_module":"@jupyter-widgets/controls","_model_module_version":"1.5.0","_model_name":"DescriptionStyleModel","_view_count":null,"_view_module":"@jupyter-widgets/base","_view_module_version":"1.2.0","_view_name":"StyleView","description_width":""}}}}},"cells":[{"cell_type":"code","execution_count":null,"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"lDHA7P_643yP","executionInfo":{"status":"ok","timestamp":1728014084770,"user_tz":-480,"elapsed":13852,"user":{"displayName":"Paris Kang","userId":"15453206198277055555"}},"outputId":"2dd7b178-e59f-4a77-887b-60f0cb837cdd"},"outputs":[{"output_type":"stream","name":"stdout","text":["Collecting bertopic\n","  Downloading bertopic-0.16.3-py3-none-any.whl.metadata (23 kB)\n","Collecting hdbscan>=0.8.29 (from bertopic)\n","  Downloading hdbscan-0.8.38.post1-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (15 kB)\n","Requirement already satisfied: numpy>=1.20.0 in /usr/local/lib/python3.10/dist-packages (from bertopic) (1.26.4)\n","Requirement already satisfied: pandas>=1.1.5 in /usr/local/lib/python3.10/dist-packages (from bertopic) (2.2.2)\n","Requirement already satisfied: plotly>=4.7.0 in /usr/local/lib/python3.10/dist-packages (from bertopic) (5.24.1)\n","Requirement already satisfied: scikit-learn>=0.22.2.post1 in /usr/local/lib/python3.10/dist-packages (from bertopic) (1.5.2)\n","Collecting sentence-transformers>=0.4.1 (from bertopic)\n","  Downloading sentence_transformers-3.1.1-py3-none-any.whl.metadata (10 kB)\n","Requirement already satisfied: tqdm>=4.41.1 in /usr/local/lib/python3.10/dist-packages (from bertopic) (4.66.5)\n","Collecting umap-learn>=0.5.0 (from bertopic)\n","  Downloading umap_learn-0.5.6-py3-none-any.whl.metadata (21 kB)\n","Requirement already satisfied: scipy>=1.0 in /usr/local/lib/python3.10/dist-packages (from hdbscan>=0.8.29->bertopic) (1.13.1)\n","Requirement already satisfied: joblib>=1.0 in /usr/local/lib/python3.10/dist-packages (from hdbscan>=0.8.29->bertopic) (1.4.2)\n","Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas>=1.1.5->bertopic) (2.8.2)\n","Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas>=1.1.5->bertopic) (2024.2)\n","Requirement already satisfied: tzdata>=2022.7 in /usr/local/lib/python3.10/dist-packages (from pandas>=1.1.5->bertopic) (2024.2)\n","Requirement already satisfied: tenacity>=6.2.0 in /usr/local/lib/python3.10/dist-packages (from plotly>=4.7.0->bertopic) (9.0.0)\n","Requirement already satisfied: packaging in /usr/local/lib/python3.10/dist-packages (from plotly>=4.7.0->bertopic) (24.1)\n","Requirement already satisfied: threadpoolctl>=3.1.0 in /usr/local/lib/python3.10/dist-packages (from scikit-learn>=0.22.2.post1->bertopic) (3.5.0)\n","Requirement already satisfied: transformers<5.0.0,>=4.38.0 in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=0.4.1->bertopic) (4.44.2)\n","Requirement already satisfied: torch>=1.11.0 in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=0.4.1->bertopic) (2.4.1+cu121)\n","Requirement already satisfied: huggingface-hub>=0.19.3 in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=0.4.1->bertopic) (0.24.7)\n","Requirement already satisfied: Pillow in /usr/local/lib/python3.10/dist-packages (from sentence-transformers>=0.4.1->bertopic) (10.4.0)\n","Requirement already satisfied: numba>=0.51.2 in /usr/local/lib/python3.10/dist-packages (from umap-learn>=0.5.0->bertopic) (0.60.0)\n","Collecting pynndescent>=0.5 (from umap-learn>=0.5.0->bertopic)\n","  Downloading pynndescent-0.5.13-py3-none-any.whl.metadata (6.8 kB)\n","Requirement already satisfied: filelock in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (3.16.1)\n","Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (2024.6.1)\n","Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (6.0.2)\n","Requirement already satisfied: requests in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (2.32.3)\n","Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (4.12.2)\n","Requirement already satisfied: llvmlite<0.44,>=0.43.0dev0 in /usr/local/lib/python3.10/dist-packages (from numba>=0.51.2->umap-learn>=0.5.0->bertopic) (0.43.0)\n","Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas>=1.1.5->bertopic) (1.16.0)\n","Requirement already satisfied: sympy in /usr/local/lib/python3.10/dist-packages (from torch>=1.11.0->sentence-transformers>=0.4.1->bertopic) (1.13.3)\n","Requirement already satisfied: networkx in /usr/local/lib/python3.10/dist-packages (from torch>=1.11.0->sentence-transformers>=0.4.1->bertopic) (3.3)\n","Requirement already satisfied: jinja2 in /usr/local/lib/python3.10/dist-packages (from torch>=1.11.0->sentence-transformers>=0.4.1->bertopic) (3.1.4)\n","Requirement already satisfied: regex!=2019.12.17 in /usr/local/lib/python3.10/dist-packages (from transformers<5.0.0,>=4.38.0->sentence-transformers>=0.4.1->bertopic) (2024.9.11)\n","Requirement already satisfied: safetensors>=0.4.1 in /usr/local/lib/python3.10/dist-packages (from transformers<5.0.0,>=4.38.0->sentence-transformers>=0.4.1->bertopic) (0.4.5)\n","Requirement already satisfied: tokenizers<0.20,>=0.19 in /usr/local/lib/python3.10/dist-packages (from transformers<5.0.0,>=4.38.0->sentence-transformers>=0.4.1->bertopic) (0.19.1)\n","Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2->torch>=1.11.0->sentence-transformers>=0.4.1->bertopic) (2.1.5)\n","Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (3.3.2)\n","Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (3.10)\n","Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (2.2.3)\n","Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests->huggingface-hub>=0.19.3->sentence-transformers>=0.4.1->bertopic) (2024.8.30)\n","Requirement already satisfied: mpmath<1.4,>=1.1.0 in /usr/local/lib/python3.10/dist-packages (from sympy->torch>=1.11.0->sentence-transformers>=0.4.1->bertopic) (1.3.0)\n","Downloading bertopic-0.16.3-py3-none-any.whl (143 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m143.5/143.5 kB\u001b[0m \u001b[31m14.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading hdbscan-0.8.38.post1-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (4.2 MB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m4.2/4.2 MB\u001b[0m \u001b[31m100.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading sentence_transformers-3.1.1-py3-none-any.whl (245 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m245.3/245.3 kB\u001b[0m \u001b[31m22.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading umap_learn-0.5.6-py3-none-any.whl (85 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m85.7/85.7 kB\u001b[0m \u001b[31m8.1 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading pynndescent-0.5.13-py3-none-any.whl (56 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m56.9/56.9 kB\u001b[0m \u001b[31m5.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hInstalling collected packages: pynndescent, hdbscan, umap-learn, sentence-transformers, bertopic\n","Successfully installed bertopic-0.16.3 hdbscan-0.8.38.post1 pynndescent-0.5.13 sentence-transformers-3.1.1 umap-learn-0.5.6\n","Requirement already satisfied: pandas in /usr/local/lib/python3.10/dist-packages (2.2.2)\n","Requirement already satisfied: numpy>=1.22.4 in /usr/local/lib/python3.10/dist-packages (from pandas) (1.26.4)\n","Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas) (2.8.2)\n","Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas) (2024.2)\n","Requirement already satisfied: tzdata>=2022.7 in /usr/local/lib/python3.10/dist-packages (from pandas) (2024.2)\n","Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas) (1.16.0)\n","Collecting litellm\n","  Downloading litellm-1.48.12-py3-none-any.whl.metadata (32 kB)\n","Requirement already satisfied: aiohttp in /usr/local/lib/python3.10/dist-packages (from litellm) (3.10.8)\n","Requirement already satisfied: click in /usr/local/lib/python3.10/dist-packages (from litellm) (8.1.7)\n","Requirement already satisfied: importlib-metadata>=6.8.0 in /usr/local/lib/python3.10/dist-packages (from litellm) (8.4.0)\n","Requirement already satisfied: jinja2<4.0.0,>=3.1.2 in /usr/local/lib/python3.10/dist-packages (from litellm) (3.1.4)\n","Requirement already satisfied: jsonschema<5.0.0,>=4.22.0 in /usr/local/lib/python3.10/dist-packages (from litellm) (4.23.0)\n","Collecting openai>=1.51.0 (from litellm)\n","  Downloading openai-1.51.0-py3-none-any.whl.metadata (24 kB)\n","Requirement already satisfied: pydantic<3.0.0,>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from litellm) (2.9.2)\n","Collecting python-dotenv>=0.2.0 (from litellm)\n","  Downloading python_dotenv-1.0.1-py3-none-any.whl.metadata (23 kB)\n","Requirement already satisfied: requests<3.0.0,>=2.31.0 in /usr/local/lib/python3.10/dist-packages (from litellm) (2.32.3)\n","Collecting tiktoken>=0.7.0 (from litellm)\n","  Downloading tiktoken-0.8.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (6.6 kB)\n","Requirement already satisfied: tokenizers in /usr/local/lib/python3.10/dist-packages (from litellm) (0.19.1)\n","Requirement already satisfied: zipp>=0.5 in /usr/local/lib/python3.10/dist-packages (from importlib-metadata>=6.8.0->litellm) (3.20.2)\n","Requirement already satisfied: MarkupSafe>=2.0 in /usr/local/lib/python3.10/dist-packages (from jinja2<4.0.0,>=3.1.2->litellm) (2.1.5)\n","Requirement already satisfied: attrs>=22.2.0 in /usr/local/lib/python3.10/dist-packages (from jsonschema<5.0.0,>=4.22.0->litellm) (24.2.0)\n","Requirement already satisfied: jsonschema-specifications>=2023.03.6 in /usr/local/lib/python3.10/dist-packages (from jsonschema<5.0.0,>=4.22.0->litellm) (2023.12.1)\n","Requirement already satisfied: referencing>=0.28.4 in /usr/local/lib/python3.10/dist-packages (from jsonschema<5.0.0,>=4.22.0->litellm) (0.35.1)\n","Requirement already satisfied: rpds-py>=0.7.1 in /usr/local/lib/python3.10/dist-packages (from jsonschema<5.0.0,>=4.22.0->litellm) (0.20.0)\n","Requirement already satisfied: anyio<5,>=3.5.0 in /usr/local/lib/python3.10/dist-packages (from openai>=1.51.0->litellm) (3.7.1)\n","Requirement already satisfied: distro<2,>=1.7.0 in /usr/lib/python3/dist-packages (from openai>=1.51.0->litellm) (1.7.0)\n","Collecting httpx<1,>=0.23.0 (from openai>=1.51.0->litellm)\n","  Downloading httpx-0.27.2-py3-none-any.whl.metadata (7.1 kB)\n","Collecting jiter<1,>=0.4.0 (from openai>=1.51.0->litellm)\n","  Downloading jiter-0.5.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (3.6 kB)\n","Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from openai>=1.51.0->litellm) (1.3.1)\n","Requirement already satisfied: tqdm>4 in /usr/local/lib/python3.10/dist-packages (from openai>=1.51.0->litellm) (4.66.5)\n","Requirement already satisfied: typing-extensions<5,>=4.11 in /usr/local/lib/python3.10/dist-packages (from openai>=1.51.0->litellm) (4.12.2)\n","Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.0.0->litellm) (0.7.0)\n","Requirement already satisfied: pydantic-core==2.23.4 in /usr/local/lib/python3.10/dist-packages (from pydantic<3.0.0,>=2.0.0->litellm) (2.23.4)\n","Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.31.0->litellm) (3.3.2)\n","Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.31.0->litellm) (3.10)\n","Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.31.0->litellm) (2.2.3)\n","Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3.0.0,>=2.31.0->litellm) (2024.8.30)\n","Requirement already satisfied: regex>=2022.1.18 in /usr/local/lib/python3.10/dist-packages (from tiktoken>=0.7.0->litellm) (2024.9.11)\n","Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->litellm) (2.4.3)\n","Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp->litellm) (1.3.1)\n","Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp->litellm) (1.4.1)\n","Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp->litellm) (6.1.0)\n","Requirement already satisfied: yarl<2.0,>=1.12.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->litellm) (1.13.1)\n","Requirement already satisfied: async-timeout<5.0,>=4.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->litellm) (4.0.3)\n","Requirement already satisfied: huggingface-hub<1.0,>=0.16.4 in /usr/local/lib/python3.10/dist-packages (from tokenizers->litellm) (0.24.7)\n","Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio<5,>=3.5.0->openai>=1.51.0->litellm) (1.2.2)\n","Collecting httpcore==1.* (from httpx<1,>=0.23.0->openai>=1.51.0->litellm)\n","  Downloading httpcore-1.0.6-py3-none-any.whl.metadata (21 kB)\n","Collecting h11<0.15,>=0.13 (from httpcore==1.*->httpx<1,>=0.23.0->openai>=1.51.0->litellm)\n","  Downloading h11-0.14.0-py3-none-any.whl.metadata (8.2 kB)\n","Requirement already satisfied: filelock in /usr/local/lib/python3.10/dist-packages (from huggingface-hub<1.0,>=0.16.4->tokenizers->litellm) (3.16.1)\n","Requirement already satisfied: fsspec>=2023.5.0 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub<1.0,>=0.16.4->tokenizers->litellm) (2024.6.1)\n","Requirement already satisfied: packaging>=20.9 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub<1.0,>=0.16.4->tokenizers->litellm) (24.1)\n","Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub<1.0,>=0.16.4->tokenizers->litellm) (6.0.2)\n","Downloading litellm-1.48.12-py3-none-any.whl (6.2 MB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m6.2/6.2 MB\u001b[0m \u001b[31m77.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading openai-1.51.0-py3-none-any.whl (383 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m383.5/383.5 kB\u001b[0m \u001b[31m32.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading python_dotenv-1.0.1-py3-none-any.whl (19 kB)\n","Downloading tiktoken-0.8.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (1.2 MB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m1.2/1.2 MB\u001b[0m \u001b[31m64.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading httpx-0.27.2-py3-none-any.whl (76 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m76.4/76.4 kB\u001b[0m \u001b[31m7.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading httpcore-1.0.6-py3-none-any.whl (78 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m78.0/78.0 kB\u001b[0m \u001b[31m7.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading jiter-0.5.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (318 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m318.9/318.9 kB\u001b[0m \u001b[31m28.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading h11-0.14.0-py3-none-any.whl (58 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m58.3/58.3 kB\u001b[0m \u001b[31m6.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hInstalling collected packages: python-dotenv, jiter, h11, tiktoken, httpcore, httpx, openai, litellm\n","Successfully installed h11-0.14.0 httpcore-1.0.6 httpx-0.27.2 jiter-0.5.0 litellm-1.48.12 openai-1.51.0 python-dotenv-1.0.1 tiktoken-0.8.0\n","Requirement already satisfied: openai in /usr/local/lib/python3.10/dist-packages (1.51.0)\n","Requirement already satisfied: anyio<5,>=3.5.0 in /usr/local/lib/python3.10/dist-packages (from openai) (3.7.1)\n","Requirement already satisfied: distro<2,>=1.7.0 in /usr/lib/python3/dist-packages (from openai) (1.7.0)\n","Requirement already satisfied: httpx<1,>=0.23.0 in /usr/local/lib/python3.10/dist-packages (from openai) (0.27.2)\n","Requirement already satisfied: jiter<1,>=0.4.0 in /usr/local/lib/python3.10/dist-packages (from openai) (0.5.0)\n","Requirement already satisfied: pydantic<3,>=1.9.0 in /usr/local/lib/python3.10/dist-packages (from openai) (2.9.2)\n","Requirement already satisfied: sniffio in /usr/local/lib/python3.10/dist-packages (from openai) (1.3.1)\n","Requirement already satisfied: tqdm>4 in /usr/local/lib/python3.10/dist-packages (from openai) (4.66.5)\n","Requirement already satisfied: typing-extensions<5,>=4.11 in /usr/local/lib/python3.10/dist-packages (from openai) (4.12.2)\n","Requirement already satisfied: idna>=2.8 in /usr/local/lib/python3.10/dist-packages (from anyio<5,>=3.5.0->openai) (3.10)\n","Requirement already satisfied: exceptiongroup in /usr/local/lib/python3.10/dist-packages (from anyio<5,>=3.5.0->openai) (1.2.2)\n","Requirement already satisfied: certifi in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->openai) (2024.8.30)\n","Requirement already satisfied: httpcore==1.* in /usr/local/lib/python3.10/dist-packages (from httpx<1,>=0.23.0->openai) (1.0.6)\n","Requirement already satisfied: h11<0.15,>=0.13 in /usr/local/lib/python3.10/dist-packages (from httpcore==1.*->httpx<1,>=0.23.0->openai) (0.14.0)\n","Requirement already satisfied: annotated-types>=0.6.0 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1.9.0->openai) (0.7.0)\n","Requirement already satisfied: pydantic-core==2.23.4 in /usr/local/lib/python3.10/dist-packages (from pydantic<3,>=1.9.0->openai) (2.23.4)\n"]}],"source":["!pip install bertopic\n","!pip install pandas\n","!pip install litellm\n","!pip install openai"]},{"cell_type":"code","source":["!pip install datasets"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"eSMT_0srF9mX","executionInfo":{"status":"ok","timestamp":1728014058613,"user_tz":-480,"elapsed":4639,"user":{"displayName":"Paris Kang","userId":"15453206198277055555"}},"outputId":"c5e66e4d-fdcd-45cc-b34e-6eaa57a1f7b0"},"execution_count":null,"outputs":[{"output_type":"stream","name":"stdout","text":["Collecting datasets\n","  Downloading datasets-3.0.1-py3-none-any.whl.metadata (20 kB)\n","Requirement already satisfied: filelock in /usr/local/lib/python3.10/dist-packages (from datasets) (3.16.1)\n","Requirement already satisfied: numpy>=1.17 in /usr/local/lib/python3.10/dist-packages (from datasets) (1.26.4)\n","Requirement already satisfied: pyarrow>=15.0.0 in /usr/local/lib/python3.10/dist-packages (from datasets) (16.1.0)\n","Collecting dill<0.3.9,>=0.3.0 (from datasets)\n","  Downloading dill-0.3.8-py3-none-any.whl.metadata (10 kB)\n","Requirement already satisfied: pandas in /usr/local/lib/python3.10/dist-packages (from datasets) (2.2.2)\n","Requirement already satisfied: requests>=2.32.2 in /usr/local/lib/python3.10/dist-packages (from datasets) (2.32.3)\n","Requirement already satisfied: tqdm>=4.66.3 in /usr/local/lib/python3.10/dist-packages (from datasets) (4.66.5)\n","Collecting xxhash (from datasets)\n","  Downloading xxhash-3.5.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (12 kB)\n","Collecting multiprocess (from datasets)\n","  Downloading multiprocess-0.70.17-py310-none-any.whl.metadata (7.2 kB)\n","Requirement already satisfied: fsspec<=2024.6.1,>=2023.1.0 in /usr/local/lib/python3.10/dist-packages (from fsspec[http]<=2024.6.1,>=2023.1.0->datasets) (2024.6.1)\n","Requirement already satisfied: aiohttp in /usr/local/lib/python3.10/dist-packages (from datasets) (3.10.8)\n","Requirement already satisfied: huggingface-hub>=0.22.0 in /usr/local/lib/python3.10/dist-packages (from datasets) (0.24.7)\n","Requirement already satisfied: packaging in /usr/local/lib/python3.10/dist-packages (from datasets) (24.1)\n","Requirement already satisfied: pyyaml>=5.1 in /usr/local/lib/python3.10/dist-packages (from datasets) (6.0.2)\n","Requirement already satisfied: aiohappyeyeballs>=2.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (2.4.3)\n","Requirement already satisfied: aiosignal>=1.1.2 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (1.3.1)\n","Requirement already satisfied: attrs>=17.3.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (24.2.0)\n","Requirement already satisfied: frozenlist>=1.1.1 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (1.4.1)\n","Requirement already satisfied: multidict<7.0,>=4.5 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (6.1.0)\n","Requirement already satisfied: yarl<2.0,>=1.12.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (1.13.1)\n","Requirement already satisfied: async-timeout<5.0,>=4.0 in /usr/local/lib/python3.10/dist-packages (from aiohttp->datasets) (4.0.3)\n","Requirement already satisfied: typing-extensions>=3.7.4.3 in /usr/local/lib/python3.10/dist-packages (from huggingface-hub>=0.22.0->datasets) (4.12.2)\n","Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests>=2.32.2->datasets) (3.3.2)\n","Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests>=2.32.2->datasets) (3.10)\n","Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests>=2.32.2->datasets) (2.2.3)\n","Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests>=2.32.2->datasets) (2024.8.30)\n","INFO: pip is looking at multiple versions of multiprocess to determine which version is compatible with other requirements. This could take a while.\n","  Downloading multiprocess-0.70.16-py310-none-any.whl.metadata (7.2 kB)\n","Requirement already satisfied: python-dateutil>=2.8.2 in /usr/local/lib/python3.10/dist-packages (from pandas->datasets) (2.8.2)\n","Requirement already satisfied: pytz>=2020.1 in /usr/local/lib/python3.10/dist-packages (from pandas->datasets) (2024.2)\n","Requirement already satisfied: tzdata>=2022.7 in /usr/local/lib/python3.10/dist-packages (from pandas->datasets) (2024.2)\n","Requirement already satisfied: six>=1.5 in /usr/local/lib/python3.10/dist-packages (from python-dateutil>=2.8.2->pandas->datasets) (1.16.0)\n","Downloading datasets-3.0.1-py3-none-any.whl (471 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m471.6/471.6 kB\u001b[0m \u001b[31m30.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading dill-0.3.8-py3-none-any.whl (116 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m116.3/116.3 kB\u001b[0m \u001b[31m10.8 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading multiprocess-0.70.16-py310-none-any.whl (134 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m134.8/134.8 kB\u001b[0m \u001b[31m13.0 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading xxhash-3.5.0-cp310-cp310-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (194 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m194.1/194.1 kB\u001b[0m \u001b[31m17.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hInstalling collected packages: xxhash, dill, multiprocess, datasets\n","Successfully installed datasets-3.0.1 dill-0.3.8 multiprocess-0.70.16 xxhash-3.5.0\n"]}]},{"cell_type":"code","source":["!pip install wandb"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"rx44gLFxQr-T","executionInfo":{"status":"ok","timestamp":1728014049889,"user_tz":-480,"elapsed":6478,"user":{"displayName":"Paris Kang","userId":"15453206198277055555"}},"outputId":"71c78411-39b9-4105-9cea-6bf017e52623"},"execution_count":null,"outputs":[{"output_type":"stream","name":"stdout","text":["Collecting wandb\n","  Downloading wandb-0.18.3-py3-none-manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (9.7 kB)\n","Requirement already satisfied: click!=8.0.0,>=7.1 in /usr/local/lib/python3.10/dist-packages (from wandb) (8.1.7)\n","Collecting docker-pycreds>=0.4.0 (from wandb)\n","  Downloading docker_pycreds-0.4.0-py2.py3-none-any.whl.metadata (1.8 kB)\n","Collecting gitpython!=3.1.29,>=1.0.0 (from wandb)\n","  Downloading GitPython-3.1.43-py3-none-any.whl.metadata (13 kB)\n","Requirement already satisfied: platformdirs in /usr/local/lib/python3.10/dist-packages (from wandb) (4.3.6)\n","Requirement already satisfied: protobuf!=4.21.0,!=5.28.0,<6,>=3.19.0 in /usr/local/lib/python3.10/dist-packages (from wandb) (3.20.3)\n","Requirement already satisfied: psutil>=5.0.0 in /usr/local/lib/python3.10/dist-packages (from wandb) (5.9.5)\n","Requirement already satisfied: pyyaml in /usr/local/lib/python3.10/dist-packages (from wandb) (6.0.2)\n","Requirement already satisfied: requests<3,>=2.0.0 in /usr/local/lib/python3.10/dist-packages (from wandb) (2.32.3)\n","Collecting sentry-sdk>=1.0.0 (from wandb)\n","  Downloading sentry_sdk-2.15.0-py2.py3-none-any.whl.metadata (9.7 kB)\n","Collecting setproctitle (from wandb)\n","  Downloading setproctitle-1.3.3-cp310-cp310-manylinux_2_5_x86_64.manylinux1_x86_64.manylinux_2_17_x86_64.manylinux2014_x86_64.whl.metadata (9.9 kB)\n","Requirement already satisfied: setuptools in /usr/local/lib/python3.10/dist-packages (from wandb) (71.0.4)\n","Requirement already satisfied: six>=1.4.0 in /usr/local/lib/python3.10/dist-packages (from docker-pycreds>=0.4.0->wandb) (1.16.0)\n","Collecting gitdb<5,>=4.0.1 (from gitpython!=3.1.29,>=1.0.0->wandb)\n","  Downloading gitdb-4.0.11-py3-none-any.whl.metadata (1.2 kB)\n","Requirement already satisfied: charset-normalizer<4,>=2 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2.0.0->wandb) (3.3.2)\n","Requirement already satisfied: idna<4,>=2.5 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2.0.0->wandb) (3.10)\n","Requirement already satisfied: urllib3<3,>=1.21.1 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2.0.0->wandb) (2.2.3)\n","Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.10/dist-packages (from requests<3,>=2.0.0->wandb) (2024.8.30)\n","Collecting smmap<6,>=3.0.1 (from gitdb<5,>=4.0.1->gitpython!=3.1.29,>=1.0.0->wandb)\n","  Downloading smmap-5.0.1-py3-none-any.whl.metadata (4.3 kB)\n","Downloading wandb-0.18.3-py3-none-manylinux_2_17_x86_64.manylinux2014_x86_64.whl (13.0 MB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m13.0/13.0 MB\u001b[0m \u001b[31m112.5 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading docker_pycreds-0.4.0-py2.py3-none-any.whl (9.0 kB)\n","Downloading GitPython-3.1.43-py3-none-any.whl (207 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m207.3/207.3 kB\u001b[0m \u001b[31m20.7 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading sentry_sdk-2.15.0-py2.py3-none-any.whl (310 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m311.0/311.0 kB\u001b[0m \u001b[31m26.2 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading setproctitle-1.3.3-cp310-cp310-manylinux_2_5_x86_64.manylinux1_x86_64.manylinux_2_17_x86_64.manylinux2014_x86_64.whl (30 kB)\n","Downloading gitdb-4.0.11-py3-none-any.whl (62 kB)\n","\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m62.7/62.7 kB\u001b[0m \u001b[31m6.3 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n","\u001b[?25hDownloading smmap-5.0.1-py3-none-any.whl (24 kB)\n","Installing collected packages: smmap, setproctitle, sentry-sdk, docker-pycreds, gitdb, gitpython, wandb\n","Successfully installed docker-pycreds-0.4.0 gitdb-4.0.11 gitpython-3.1.43 sentry-sdk-2.15.0 setproctitle-1.3.3 smmap-5.0.1 wandb-0.18.3\n"]}]},{"cell_type":"code","source":["# ============================== #\n","# Section 1: Import Necessary Libraries and Set Environment\n","# ============================== #\n","\n","import os\n","import pandas as pd\n","import numpy as np\n","import re\n","from bertopic import BERTopic\n","from litellm import completion\n","from sklearn.metrics import silhouette_score, calinski_harabasz_score, davies_bouldin_score\n","from sklearn.decomposition import PCA\n","from sentence_transformers import SentenceTransformer\n","from transformers import AutoTokenizer, AutoModelForSequenceClassification, Trainer, TrainingArguments, AutoModel\n","from datasets import Dataset\n","import torch\n","from sklearn.model_selection import train_test_split\n","\n","# Set environment variables for API keys (ensure your API keys are set securely)\n","os.environ[\"OPENAI_API_KEY\"] = \"sk-xyz\"\n","os.environ[\"OPENAI_API_BASE\"] = \"xyz\"\n","\n","# ============================== #\n","# Section 2: Load Data\n","# ============================== #\n","\n","# Load data from Excel file\n","data = pd.read_excel('psoriasis_papers_cleaned.xlsx')\n","documents = data['Info'].astype(str).tolist()"],"metadata":{"id":"ytHMEukQj4FV"},"execution_count":null,"outputs":[]},{"cell_type":"code","source":[],"metadata":{"id":"mNFTG12FrGCY"},"execution_count":null,"outputs":[]},{"cell_type":"code","source":["# ============================== #\n","# Section 3: Initialize Embedding Model\n","# ============================== #\n","\n","# Initialize the embedding model\n","embedding_model = SentenceTransformer('all-MiniLM-L6-v2')\n"],"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":369,"referenced_widgets":["4211ae33e52f4fdc877b0060ccabb014","cf4da7101bdb4ce6a198204d0ed2f1af","db23b100c1af46b2b7d53ca97364ec00","0faa21f7e3364d18adf4c1b36047289c","d6ac1043fcce4c6493d8a735bbae8b04","c15b161f1c9749d2a587e341583e695d","be70fdf304b147038fd671719a025f1f","3a756bfdfaef4b3180fd430780e9437f","e8d5287fab3a4a12be7899cacb3fb1b5","4f519f8acda44d4898dd1f5b526c02da","73cc9b0295fe49738e4cdb5f1942c58c","b49fbd4cf77946afaccb286f9dd3d295","0f2389e1d63842768424bace1160bb33","70b58d440cb0409ba5a9181b3ebbc092","cdb53f86b5b648c090a33b6913285cfe","ebe42bb7ad3b458083bb0a144956e56d","93546bc6410c40a19369ef8caf125323","a66c6fd3e24f4a29895363e4ed439223","1020d3e61659407fb9fdf10e0061ad52","8df0063cb75a47ad9a038fbc6788e0d5","986d9bb88acb43c0a07351d649aa4182","4fb26b0b46804ea88064cad71b9fc315","8e36796876a14a31b1b27181b3cbecd4","0b579b5bc0194f10aeb051b12229d66c","ac922208fde24c34bfccd75fac1e300c","8fd270f50ec94c40adbbca40a60bbc41","d36b19ba1f2f40a281c0dd9d3783fd49","13357110c5f349f89d0c95699c799f13","20d7b909f8ec430b9946ee3f0f9068ec","f444709cd1214ad3b749162841843a80","0e420d36933c43c394445b5deb4fc793","328ddc806d8c40c4ae2f661dcfc30464","920b95f8e38b4c5b8012855ae9a4089f","3e28bdb1beeb4cdab35d5e6b6644c187","dc144432eaaf4775a16cfb322b40cba4","b92bfc8c3b3a4a74a29b8979bf8ec280","f0951b5631de443ea326bb6dc3da45cd","5d63c1400b654c20aaf3a90287301e48","0940d72f64d941619f36012e4cdc3b94","5d88ea830548477984f0a7226611d405","71fffd780b6049d28d42e54deda0cd9e","225348cbbfb2465eb06c29aa7edb438c","b54670b45c894630bf74a19bc7be7160","e42db1887e374ed89b50475c0c8b2a44","e05161452d0644319bbe22777c5d41f0","822450bcff1a463e8ee44ae024c5a054","a851bf85215a413798e37bc2d90a9d1f","8872a29ee77c4683bc6343e81726d14a","0846f6fecc3248bb894532e2dbd57794","a8201b1d1e504887841e2e455ca022b3","8820d0f8a3f44c9ba65a9fb4607ab6ea","19711df6e61b4efab8dd42c1bc76e805","73978240b07a4fc9a0769fad14a1ea65","fc18d0a6182e4e8dbf7acd66492ff304","9daf2843ea8843e3ab71c613f7e6a983","2a28c6860ac04b3faabf9e2ab96efb06","44d5e6ba7fc94a5fb32a69a5fe6b7809","2e4d22a8490b40ea931b36cc4f21c040","dd2a6c4fb28a4b23a74a143aeaf2b884","21406de8607345a4aece73f0b4e5759d","85a157d3a66e4258bec0a8755f6ec9a0","2f66985cf70449959e7e9b9a320243a1","5a1b2035cc3c47a4b3a813d127b1f2f8","ba96df39b9aa49fca113f3d9a97feb8c","d390266d8c9f4ca68366acd33e9b1ba8","5439ffc7d2f044188b0468389760660a","75198861280441b09980027bb0814172","145dcab7b7f348e493bc05a6a8dfde28","b40820cbaacf4d28b4ab2ef438f7705d","d8a7449659ce4bbeb987dacd5e6a3836","79c3cfacdb5a4604b18429d590932eb5","d96fbec9d9eb42eebf2327d56950d71f","d5763b79a5714fcc8b5d0fc2ddf35f85","2528c679aee94df7a7d879473d4d47c6","4f7381c4496d47b5b321c06d13f418ba","1c28917930de4b6f80d1f5fad27bcf55","45d9eb307032411b82a5394ff3599980","50e06c6af1014a6c92e0147f18245ff5","ccb80c8bc9824893b3f2c2ada19fc44d","b368db5f25fb423cbef4fbfed47c99fc","0bd3b36e1439449c8e8a381e1d3a26c9","0fe3eb3370e54d09bafa821febd92b4e","97bb065783824c09a07e4b583d3f7227","6ca549bed7ff4e7aa7b003ed29cf1c3c","3fa004ceb1884ee4813a81937c2e0f47","9b1cd1f3a18d4cf58d80aa92040ba80b","ab201612496440929bc48be7dd48b519","2a1a9bffef654052953b9abca78e2344","65af5a7f0e4043b4b794ed6b2f873484","6423189258364d18a2ebb8ecff893e6a","d37a4a55320e43e88f099455ae93d619","b59ce70721104e17b4552f9e9ecdc04a","9d655e85f0e84f0480b75afc27d55d30","f69d11ad7a094f94b07359c57f8d20d8","d91408b70f04487f92cb4416561b09ef","041c687e570848bb9a47b7915c101389","d1318a6872834d97b9043da4e26448fb","85b4103950714ad9b8cf66c25deeea5d","2f1018dd1cbb42e19f73b91c55e14066","e0540e1c59b442609e93a9c3c4f774d3","4eacfe6c6c26424abc5262530f17ac34","06c259a31a46421ba524c8bed43829a7","3cc832a69fca4af7a5bba8ece02f8e5a","56acfd8104544aff84005539bc327609","326494218f5a4b95b6d5313e746f8a20","98e189444b0144c1b06040e775cfe760","4b4fa6f93e174814bbebf507b1c51f19","9286d333861e4007810193a9eaa793f8","0aee5eb0a0f54f5484b8800399dc4771","cf6bd3d6a69d4632bf8e574099686259","cceb44821bd74ff4b4806d56649e46fb","c2f9aa1ac88d4471b66f30a11b4e6fef","1ca59832bc464fc39ac4c7093fa5ef24","bafb86534ddc475ea3f5faae2b2ddefd","19847e10d21843cd9964ef434ddc128a","ffec4a9f58d84d189aaefc99daece456","e34d6993f7f24ce8b29d4312c758affe","b75a90b5dc6b43da8ee2902bb45ecd94","17aa81a73e9d4dea90714fba32c2e6c4","ec8fc85206e242a3852b65f37d577c57","02e1752bbb0748bc9e3e1915f37c06e2"]},"id":"ARvvmR_0nScX","executionInfo":{"status":"ok","timestamp":1728014512548,"user_tz":-480,"elapsed":10574,"user":{"displayName":"Paris Kang","userId":"15453206198277055555"}},"outputId":"1289f70f-1805-47c9-e9cb-fecf2ede05d4"},"execution_count":null,"outputs":[{"output_type":"display_data","data":{"text/plain":["modules.json:   0%|          | 0.00/349 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"4211ae33e52f4fdc877b0060ccabb014"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["config_sentence_transformers.json:   0%|          | 0.00/116 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"b49fbd4cf77946afaccb286f9dd3d295"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["README.md:   0%|          | 0.00/10.7k [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"8e36796876a14a31b1b27181b3cbecd4"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["sentence_bert_config.json:   0%|          | 0.00/53.0 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"3e28bdb1beeb4cdab35d5e6b6644c187"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["config.json:   0%|          | 0.00/612 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"e05161452d0644319bbe22777c5d41f0"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["model.safetensors:   0%|          | 0.00/90.9M [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"2a28c6860ac04b3faabf9e2ab96efb06"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["tokenizer_config.json:   0%|          | 0.00/350 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"75198861280441b09980027bb0814172"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["vocab.txt:   0%|          | 0.00/232k [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"50e06c6af1014a6c92e0147f18245ff5"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["tokenizer.json:   0%|          | 0.00/466k [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"65af5a7f0e4043b4b794ed6b2f873484"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["special_tokens_map.json:   0%|          | 0.00/112 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"e0540e1c59b442609e93a9c3c4f774d3"}},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["1_Pooling/config.json:   0%|          | 0.00/190 [00:00<?, ?B/s]"],"application/vnd.jupyter.widget-view+json":{"version_major":2,"version_minor":0,"model_id":"cceb44821bd74ff4b4806d56649e46fb"}},"metadata":{}}]},{"cell_type":"code","source":["# ============================== #\n","# Section 4: Initial Topic Modeling with BERTopic\n","# ============================== #\n","\n","# Initialize BERTopic model with the embedding model\n","topic_model = BERTopic(embedding_model=embedding_model, language=\"english\", calculate_probabilities=True)\n","topics, probabilities = topic_model.fit_transform(documents)\n","\n","# Get initial topic information\n","initial_topics = topic_model.get_topic_info()\n"],"metadata":{"id":"OY9NNxgesNEj"},"execution_count":null,"outputs":[]},{"cell_type":"code","source":["# ============================== #\n","# Section 5: Iterative Refinement with GPT-4 Feedback\n","# ============================== #\n","\n","# Store models and metrics for each iteration\n","models = []\n","metrics = []\n","topic_summaries_list = []\n","\n","for iteration in range(1, 4):\n","    print(f\"\\n--- Iteration {iteration} ---\\n\")\n","    # ------------------------------ #\n","    # Step 1: Generate Topic Summaries\n","    # ------------------------------ #\n","    topic_summaries = {}\n","    for topic_id in topic_model.get_topic_info()['Topic']:\n","        if topic_id == -1:\n","            continue  # Skip outlier topic\n","        topic_words = topic_model.get_topic(topic_id)\n","        if topic_words:\n","            words = [word for word, _ in topic_words]\n","            prompt = f\"Please provide a brief summary or label for a topic that includes the following keywords: {', '.join(words)}.\"\n","            # Call GPT-4 to get topic summary\n","            response = completion(\n","                model=\"gpt-4\",\n","                messages=[{\"content\": prompt, \"role\": \"user\"}]\n","            )\n","            summary = response['choices'][0]['message']['content'].strip()\n","            topic_summaries[topic_id] = summary\n","            print(f\"Topic {topic_id}: {summary}\")\n","\n","    # Store the summaries for this iteration\n","    topic_summaries_list.append(topic_summaries)\n","\n","    # ------------------------------ #\n","    # Step 2: Get GPT-4 Feedback for Merging or Splitting Topics\n","    # ------------------------------ #\n","    all_topics_summary = \"Here are the topics and their summaries:\\n\"\n","    for topic_id, summary in topic_summaries.items():\n","        all_topics_summary += f\"Topic {topic_id}: {summary}\\n\"\n","\n","    # Create prompt for GPT-4\n","    prompt = all_topics_summary + \"\"\"\n","Based on the above summaries, please advise if any topics should be merged or split. If so, please list the topics to be merged or split, and explain briefly why.\n","\n","Please format your response as:\n","\n","- Topics to Merge: [(Topic IDs to merge), ...]\n","- Topics to Split: [Topic IDs to split]\n","\n","Example:\n","\n","- Topics to Merge: [(1, 2), (3, 4)]\n","- Topics to Split: [5, 6]\n","\"\"\"\n","\n","    # Get GPT-4's advice\n","    response = completion(\n","        model=\"gpt-4\",\n","        messages=[{\"content\": prompt, \"role\": \"user\"}]\n","    )\n","    advice = response['choices'][0]['message']['content'].strip()\n","    print(\"\\nGPT-4's advice:\")\n","    print(advice)\n","\n","    # ------------------------------ #\n","    # Step 3: Parse GPT-4's Feedback and Implement Suggestions\n","    # ------------------------------ #\n","    topics_to_merge = []\n","    topics_to_split = []\n","\n","    # Parse the advice using regular expressions\n","    merge_match = re.search(r'Topics to Merge:\\s*(\\[.*?\\])', advice, re.DOTALL)\n","    if merge_match:\n","        merge_str = merge_match.group(1)\n","        try:\n","            topics_to_merge = eval(merge_str)\n","        except Exception as e:\n","            print(\"Error parsing Topics to Merge:\", e)\n","\n","    split_match = re.search(r'Topics to Split:\\s*(\\[.*?\\])', advice, re.DOTALL)\n","    if split_match:\n","        split_str = split_match.group(1)\n","        try:\n","            topics_to_split = eval(split_str)\n","        except Exception as e:\n","            print(\"Error parsing Topics to Split:\", e)\n","\n","    # Apply merge operations\n","    for merge_pair in topics_to_merge:\n","        if isinstance(merge_pair, (tuple, list)) and len(merge_pair) >= 2:\n","            merge_topics = list(merge_pair)\n","            try:\n","                topic_model.merge_topics(documents, merge_topics)\n","                print(f\"Merged topics {merge_topics}\")\n","            except Exception as e:\n","                print(f\"Error merging topics {merge_topics}: {e}\")\n","        else:\n","            print(f\"Invalid merge pair: {merge_pair}\")\n","\n","    # Update topics after merging\n","    # Ensure that embedding_model is not None\n","    if topic_model.embedding_model is None:\n","        topic_model.embedding_model = embedding_model  # Reassign the embedding model\n","    topics, probabilities = topic_model.transform(documents)\n","\n","    # Apply split operations\n","    for topic_id in topics_to_split:\n","        # Get indices of documents belonging to the topic\n","        indices = [i for i, t in enumerate(topics) if t == topic_id]\n","        if not indices:\n","            continue\n","        # Extract documents to split\n","        docs_to_split = [documents[i] for i in indices]\n","        # Perform new topic modeling on these documents\n","        sub_topic_model = BERTopic(embedding_model=embedding_model, language=\"english\", calculate_probabilities=True)\n","        sub_topics, sub_probs = sub_topic_model.fit_transform(docs_to_split)\n","        # Update the original topics\n","        for idx, doc_idx in enumerate(indices):\n","            topics[doc_idx] = f\"{topic_id}_{sub_topics[idx]}\"\n","        print(f\"Split topic {topic_id} into subtopics\")\n","\n","    # Update topics after splitting\n","    # No need to update embeddings here, as we have updated 'topics' list\n","\n","    # ------------------------------ #\n","    # Step 4: Fine-Tune the Language Model Based on New Topics\n","    # ------------------------------ #\n","\n","    # Prepare data for fine-tuning\n","    # Create a mapping from topic labels to integers\n","    unique_topics = list(set(topics))\n","    topic_label_map = {topic: idx for idx, topic in enumerate(unique_topics)}\n","    labels = [topic_label_map[topic] for topic in topics]\n","\n","    # Prepare dataset\n","    dataset = pd.DataFrame({'text': documents, 'label': labels})\n","\n","    # Split the dataset into train and test sets\n","    train_texts, test_texts, train_labels, test_labels = train_test_split(\n","        dataset['text'].tolist(),\n","        dataset['label'].tolist(),\n","        test_size=0.1,\n","        random_state=42\n","    )\n","\n","    # Load pre-trained model and tokenizer\n","    model_name = 'sentence-transformers/all-MiniLM-L6-v2'\n","    tokenizer = AutoTokenizer.from_pretrained(model_name)\n","    num_labels = len(unique_topics)\n","    model = AutoModelForSequenceClassification.from_pretrained(model_name, num_labels=num_labels)\n","\n","    # Create datasets\n","    train_encodings = tokenizer(train_texts, truncation=True, padding=True)\n","    test_encodings = tokenizer(test_texts, truncation=True, padding=True)\n","\n","    class TopicDataset(torch.utils.data.Dataset):\n","        def __init__(self, encodings, labels):\n","            self.encodings = encodings\n","            self.labels = labels\n","\n","        def __getitem__(self, idx):\n","            item = {key: torch.tensor(val[idx]) for key, val in self.encodings.items()}\n","            item['labels'] = torch.tensor(self.labels[idx])\n","            return item\n","\n","        def __len__(self):\n","            return len(self.labels)\n","\n","    train_dataset = TopicDataset(train_encodings, train_labels)\n","    eval_dataset = TopicDataset(test_encodings, test_labels)\n","\n","    # Define training arguments\n","    training_args = TrainingArguments(\n","        output_dir=f'./results_iteration_{iteration}',\n","        num_train_epochs=10,\n","        per_device_train_batch_size=16,\n","        per_device_eval_batch_size=16,\n","        warmup_steps=100,\n","        evaluation_strategy='epoch',\n","        save_strategy='epoch',\n","        logging_dir=f'./logs_iteration_{iteration}',\n","        load_best_model_at_end=True,\n","        metric_for_best_model='accuracy',\n","        greater_is_better=True,\n","    )\n","\n","    # Define compute metrics function\n","    from sklearn.metrics import accuracy_score, precision_recall_fscore_support\n","    def compute_metrics(eval_pred):\n","        logits, labels = eval_pred\n","        predictions = np.argmax(logits, axis=-1)\n","        precision, recall, f1, _ = precision_recall_fscore_support(labels, predictions, average='weighted')\n","        acc = accuracy_score(labels, predictions)\n","        return {'accuracy': acc, 'f1': f1, 'precision': precision, 'recall': recall}\n","\n","    # Initialize Trainer\n","    trainer = Trainer(\n","        model=model,\n","        args=training_args,\n","        train_dataset=train_dataset,\n","        eval_dataset=eval_dataset,\n","        compute_metrics=compute_metrics,\n","    )\n","\n","    # Fine-tune the model\n","    trainer.train()\n","\n","    # Save the fine-tuned model\n","    model.save_pretrained(f'./fine-tuned-model-iteration-{iteration}')\n","    tokenizer.save_pretrained(f'./fine-tuned-model-iteration-{iteration}')\n","\n","    # ------------------------------ #\n","    # Step 5: Recompute Embeddings with Fine-Tuned Model\n","    # ------------------------------ #\n","\n","    # Load the fine-tuned model for encoding\n","    encoder = AutoModel.from_pretrained(f'./fine-tuned-model-iteration-{iteration}')\n","    tokenizer = AutoTokenizer.from_pretrained(f'./fine-tuned-model-iteration-{iteration}')\n","\n","    # Create custom embedding model with the fine-tuned model\n","    class CustomEmbeddingModel:\n","        def __init__(self, model, tokenizer):\n","            self.model = model\n","            self.tokenizer = tokenizer\n","\n","        def embed_documents(self, documents, verbose=False):\n","            embeddings = []\n","            batch_size = 16\n","            for i in range(0, len(documents), batch_size):\n","                batch_texts = documents[i:i+batch_size]\n","                inputs = self.tokenizer(batch_texts, padding=True, truncation=True, return_tensors=\"pt\")\n","                with torch.no_grad():\n","                    outputs = self.model(**inputs)\n","                batch_embeddings = outputs.last_hidden_state.mean(dim=1)\n","                embeddings.extend(batch_embeddings.cpu().numpy())\n","            return np.array(embeddings)\n","\n","    custom_embedding_model = CustomEmbeddingModel(model=encoder, tokenizer=tokenizer)\n","\n","    # ------------------------------ #\n","    # Step 6: Refit Topic Model with New Embeddings\n","    # ------------------------------ #\n","\n","    # Reinitialize BERTopic with the fine-tuned embeddings\n","    topic_model = BERTopic(embedding_model=custom_embedding_model, language=\"english\", calculate_probabilities=True)\n","    topics, probabilities = topic_model.fit_transform(documents)\n","\n","    # ------------------------------ #\n","    # Step 7: Evaluate the Model\n","    # ------------------------------ #\n","\n","    # Get embeddings for evaluation\n","    embeddings = custom_embedding_model.embed_documents(documents)\n","\n","    # Reduce dimensions for evaluation metrics\n","    pca = PCA(n_components=2)\n","    embeddings_2d = pca.fit_transform(embeddings)\n","\n","    # Map topics to integers if they are strings\n","    unique_topics = list(set(topics))\n","    topic_int_map = {topic: idx for idx, topic in enumerate(unique_topics)}\n","    topics_int = [topic_int_map[topic] for topic in topics]\n","\n","    # Compute evaluation metrics\n","    silhouette_avg = silhouette_score(embeddings_2d, topics_int)\n","    calinski_harabasz = calinski_harabasz_score(embeddings_2d, topics_int)\n","    davies_bouldin = davies_bouldin_score(embeddings_2d, topics_int)\n","\n","    print(f\"Silhouette Score: {silhouette_avg}\")\n","    print(f\"Calinski-Harabasz Index: {calinski_harabasz}\")\n","    print(f\"Davies-Bouldin Index: {davies_bouldin}\")\n","\n","    # Store metrics\n","    metrics.append({\n","        'iteration': iteration,\n","        'silhouette_score': silhouette_avg,\n","        'calinski_harabasz_index': calinski_harabasz,\n","        'davies_bouldin_index': davies_bouldin\n","    })\n","\n","    # Store the model\n","    models.append({\n","        'iteration': iteration,\n","        'topic_model': topic_model,\n","        'embeddings': embeddings,\n","        'topics': topics,\n","        'topic_summaries': topic_summaries\n","    })\n","\n","    # Update the embedding_model for next iteration\n","    embedding_model = custom_embedding_model  # Use the fine-tuned embedding model for next iteration\n"],"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":1000},"id":"5Y356GXhsVdy","executionInfo":{"status":"ok","timestamp":1728017303801,"user_tz":-480,"elapsed":1935135,"user":{"displayName":"Paris Kang","userId":"15453206198277055555"}},"outputId":"84a4e75c-21fd-4928-f155-3768031c2de1"},"execution_count":null,"outputs":[{"output_type":"stream","name":"stdout","text":["\n","--- Iteration 1 ---\n","\n","Topic 0: **Topic Summary: \"Impact of Enthesitis on Disease Activity in Psoriatic Arthritis Patients\"**\n","\n","This topic explores the relationship between enthesitis and disease activity in individuals with psoriatic arthritis, focusing on how this condition affects joint function and overall patient outcomes.\n","Topic 1: **Topic Summary: Treatment of Axial Spondyloarthritis in Patients with Psoriatic Arthritis** \n","\n","This topic explores the management of axial spondyloarthritis (axSpa) in patients diagnosed with psoriatic arthritis (PsA) and rheumatoid arthritis (RA), focusing on the effectiveness of tumor necrosis factor inhibitors (TNFi) in improving outcomes for these individuals.\n","Topic 2: **Topic Summary: Topical Formulation of Drug-Loaded Nanoparticles in Gel for Enhanced Skin Delivery and Release** \n","\n","This topic explores the development of a gel-based formulation that employs drug-loaded nanoparticles to improve the topical delivery and controlled release of therapeutic agents through the skin.\n","Topic 3: **Topic: Post-Pandemic COVID-19 Vaccination Strategies and SARS-CoV-2 Infection Control** \n","\n","This topic encompasses the ongoing strategies for COVID-19 vaccinations, the impact of vaccines on infection rates, and the broader implications of SARS-CoV-2 following the pandemic. It explores the effectiveness of vaccines in managing outbreaks and preventing severe cases of infection.\n","Topic 4: **Topic Summary: Comparative Safety and Efficacy of Jak and TyK2 Inhibitors in Targeting Janus Kinases: A Study on Deucravacitinib vs. Tofacitinib and Placebo Outcomes**\n","Topic 5: **Topic Summary: \"The Role of Gut Microbiota and Microbiome in Skin Health: Understanding Dysbiosis, Probiotics, and the Impact of Staphylococcus aureus\"**\n","\n","This topic explores the interconnectedness of gut microbiota and skin health, focusing on how dysbiosis (imbalance of microbial communities) in the gut can influence skin conditions. It examines the potential of probiotics to restore microbial balance and combat pathogens like Staphylococcus aureus, which are implicated in various skin disorders.\n","Topic 6: **Topic Summary: Genetic Variability in HLA Alleles: SNPs and Their Association with Disease**\n","\n","This topic explores the role of genetic polymorphisms, particularly single nucleotide polymorphisms (SNPs), in human leukocyte antigen (HLA) genes. It examines how variations in alleles and genotypes of these genes are associated with various diseases, highlighting the significance of specific variants in disease susceptibility and immune response.\n","Topic 7: **Topic Summary: \"Induction of Inflammatory Responses in Human Keratinocytes (HaCaT) by Imiquimod in a Murine Model\"**\n","\n","This topic explores the effects of imiquimod (IMQ) on skin inflammation, focusing on its role in inducing inflammatory responses in human keratinocyte cell lines (HaCaT) and how these processes are modeled in mice. It examines the cytokine interleukin (IL) profiles associated with IMQ-induced skin inflammation, highlighting the relevance of this research for understanding dermatological conditions.\n","Topic 8: **Title: \"Assessing Genetic Risk Associations through Mendelian Randomization: A 95% Confidence Interval Analysis\"**\n","\n","**Summary:** This topic explores the use of Mendelian Randomization (MR) to evaluate the causal relationships between genetic variations and risk factors. Utilizing Inverse Variance Weighting (IVW) methods, the analysis aims to determine significant associations with a robust confidence interval (CI) of 95%, providing insights into how genetic predispositions can influence health outcomes.\n","Topic 9: **Topic Summary: \"The Paradox of TNF Inhibitors in Inflammatory Bowel Disease: Assessing the Risk of Necrosis with Adalimumab\"**\n","\n","This topic explores the role of tumor necrosis factor (TNF) inhibitors (TNFi) like adalimumab in the treatment of inflammatory bowel disease (IBD), focusing on the paradoxical effects that can arise, particularly the risk of necrosis and other adverse events associated with their use.\n","Topic 10: **Topic: Cardiovascular Risk in Psoriasis Patients: The Link to Atherosclerosis and Coronary Artery Disease**\n","\n","This topic explores the relationship between psoriasis and increased cardiovascular risk, focusing on how chronic inflammation associated with psoriasis contributes to atherosclerosis and enhances the likelihood of developing coronary artery disease in affected patients.\n","Topic 11: **Topic Summary: Gene Hub Analysis of Differentially Expressed Genes (DEGs)**\n","\n","This topic focuses on the identification and analysis of differentially expressed genes (DEGs) within a biological network. It involves exploring gene hubs through enrichment analysis to understand their roles in gene expression patterns and interactions. The aim is to uncover key regulatory elements and their influence on cellular processes in various contexts, such as disease or treatment responses.\n","Topic 12: **Title: Induced Differentiation and Proliferation of Keratinocytes in Epidermal Skin Development**\n","\n","**Summary:** This topic explores the role of keratinocytes in the epidermis, focusing on their expression patterns and the processes that induce their proliferation and differentiation during skin development and healing.\n","Topic 13: **Topic: Epidemiological Overview of Psoriasis Prevalence and Incidence**\n","\n","This topic examines the prevalence and incidence of psoriasis among patients, focusing on age-related factors and comorbidities. It aims to provide statistical insights over a period of years, highlighting key data points such as a 95% confidence interval (CI) for a comprehensive understanding of the condition's impact on various age groups.\n","Topic 14: **Topic: Topical Treatment Combining Calcipotriol and Betamethasone for Psoriasis Management**\n","\n","This topic covers the use of a foam formulation containing calcipotriol and betamethasone dipropionate (BDP) for the topical treatment of psoriasis. The cream is designed for effective delivery to affected areas, providing both anti-inflammatory and keratinolytic properties, which help in managing symptoms and promoting skin health.\n","Topic 15: **Topic Summary: Efficacy of Guselkumab in Psoriasis Treatment**\n","\n","This topic explores a clinical study evaluating the effectiveness of guselkumab, a treatment for psoriasis, over a 24-week period. Key metrics include the Psoriasis Area Severity Index (PASI) score improvements in patients receiving guselkumab compared to those on placebo, with significant results noted by week 100.\n","Topic 16: **Topic: Erythroderma Diagnosis and Cutaneous Examination**\n","\n","This topic focuses on the diagnostic process for erythroderma, a severe skin condition characterized by widespread redness. It includes an examination of cutaneous features such as papules and vascular involvement, highlighting common dermatoses associated with this condition. Key elements include clinical evaluation techniques and distinguishing characteristics that aid in diagnosis.\n","Topic 17: **Title: Quality of Life Assessment in Psoriasis Patients: Evaluating Treatment Satisfaction and Outcomes**\n","\n","**Summary:** This topic explores the impact of psoriasis on patients' quality of life (QoL) using tools such as the Dermatology Life Quality Index (DLQI) and Psoriasis Area Severity Index (PASI). It examines patient satisfaction with various treatments and how these factors influence overall well-being and life quality for individuals living with psoriasis.\n","Topic 18: **Title: \"Serum miR-125a Expression and Its Role in Cell Proliferation: An Analysis of 3p and 5p Isoforms\"**\n","\n","**Summary:** This topic explores the expression levels of serum microRNAs (miRNAs), specifically focusing on the 3p and 5p isoforms of miR-125a, and their correlation with cell proliferation. It highlights the significance of miR-125a in regulating biological processes and its potential implications in disease states.\n","Topic 19: **Title: \"Antioxidant Activities of Plant Extracts: The Role of Oils and Flavonoid Compounds\"**\n","\n","**Summary:** This topic explores the antioxidant properties of various plant oils and extracts, focusing on the beneficial flavonoid compounds within them. It examines how these natural extracts exhibit anti-oxidative activities, contributing to health and wellness.\n","Topic 20: **Topic Summary: \"Combination Treatments for Disease Management: Efficacy and Toxicity of Methotrexate (MTX), Metformin, and Dimethyl Fumarate (DMF) Over a Week\"**\n","\n","This topic explores the oral administration of methotrexate (MTX), metformin, and dimethyl fumarate (DMF) in the context of their combined use in treatment regimens. It focuses on evaluating their efficacy and potential toxicity when used together over a specific week-long period.\n","Topic 21: **Topic Summary: \"Evaluating the Safety and Efficacy of Secukinumab in Patients with Psoriasis: Insights from PASI 75, 90, and 300 After Initial Weeks of Treatment\"** \n","\n","This topic focuses on the assessment of secukinumab, a treatment for psoriasis, particularly its safety profile and effectiveness in achieving PASI (Psoriasis Area and Severity Index) scores of 75 and 90 among patients within a defined period of weeks.\n","Topic 22: **Topic: Narrowband UVB Phototherapy for Skin Cancer Treatment**\n","\n","Summary: This topic explores the use of narrowband ultraviolet B (NB-UVB) light in phototherapy as a treatment modality for skin conditions, including certain types of skin cancer. It examines the effectiveness and mechanisms of UVB light, particularly how it targets skin cells while minimizing damage, along with the role of blue light in therapeutic applications.\n","Topic 23: **Topic Summary: Evaluating Immune-Related Adverse Events in Cutaneous Cancer Immunotherapy Using ICIs** \n","\n","This topic focuses on the implications of immune checkpoint inhibitors (ICIs) in the treatment of cutaneous cancers, examining the immune-related adverse events (IRAEs) and toxicities associated with these therapies. The discussion includes strategies for effective management of these side effects to optimize patient outcomes in immunotherapy.\n","Topic 24: **Topic Summary: Survival and Persistence of Biologics in Treatment Discontinuation: A Focus on Ustekinumab and Ixekizumab** \n","\n","This topic explores the survival rates and long-term persistence of biologic drugs, specifically ustekinumab and ixekizumab, in treatment regimens. It examines factors influencing drug discontinuation and the implications for ongoing patient care and therapeutic effectiveness in chronic conditions.\n","Topic 25: **Topic: Efficacy of Tralokinumab vs. Dupilumab in Treating Atopic Conditions in Children**\n","\n","This topic explores the comparative effectiveness of tralokinumab and dupilumab in managing asthma, eczema, and food allergies in children, as measured by the Eczema Area and Severity Index (EASI) and other clinical outcomes related to atopic diseases.\n","Topic 26: **Title: \"Real-World Safety and Efficacy of Apremilast in Patients with Active Psoriatic Arthritis: A Multi-Month Treatment Analysis\"**\n","\n","**Summary:** This topic explores the safety and efficacy of apremilast, an oral treatment for active psoriatic arthritis, in real-world patient settings over several months. It covers the incidence of adverse effects and overall patient outcomes to assess the medication's long-term impact.\n","Topic 27: **Topic Summary: Pediatric Psoriasis Treatment with Etanercept**  \n","This topic explores the use of etanercept, a systemic therapy, for the treatment of psoriasis in children. It examines the efficacy, safety, and impact of this biologic medication on childhood psoriasis management and compares it with other treatment options available for pediatric patients.\n","Topic 28: **Topic: Serum 25-Hydroxyvitamin D Levels and Deficiency**\n","\n","This topic focuses on the measurement of serum 25-hydroxyvitamin D (25(OH)D) levels, expressed in ng/mL, to assess vitamin D deficiency. It explores the impact of vitamin D receptor (VDR) signaling and the implications of varying serum 25(OH)D concentrations for health outcomes.\n","Topic 29: **Topic: Role of IL-17 Cytokines in Autoimmune Diseases**\n","\n","This topic covers the functions of various Interleukin-17 (IL-17) cytokines, including IL-17A, IL-17F, and IL-17RA, in immune cell signaling and the development of autoimmune diseases. It highlights the involvement of the RORγt transcription factor in mediating these processes within T-helper cells, emphasizing the pathophysiological mechanisms and potential therapeutic targets in autoimmune conditions.\n","Topic 30: **Topic Summary: Understanding the Risk of Fibrosis in Autoimmune and Metabolic Syndromes Associated with NAFLD**\n","\n","This topic explores the relationship between non-alcoholic fatty liver disease (NAFLD), characterized by hepatic steatosis, and the risk of fibrosis development in individuals with autoimmune conditions and metabolic syndrome (MS). It examines the mechanisms underlying liver inflammation and fibrosis, highlighting the intersection of these factors and their implications for liver health and disease progression.\n","Topic 31: **Topic: Efficacy of Interleukin 17 Inhibitors in Patients with HR-Positive Breast Cancer**\n","\n","This topic explores the role of IL-17 inhibitors (specifically IL-17i) and their potential impact on treatment outcomes for patients with hormone receptor (HR) positive breast cancer, highlighting the efficacy of anti-IL-17 therapies in clinical settings. It also considers biomarkers and patient response rates to enhance therapeutic strategies.\n","Topic 32: **Topic: Ocular Inflammation and Symptoms in Patients with Uveitis and Associated Conditions**\n","\n","This topic explores the relationship between uveitis and various ocular conditions, including anterior uveitis and dry eyes, as well as the prevalence of blepharitis and retinal complications in affected patients.\n","Topic 33: **Cost Comparison of Adalimumab and Biosimilars for Treatment: An Analysis of Per-Responder Expenses in Secured Environments**\n","Topic 34: **Topic: Immune Cell Dynamics in Synovial Fluid of Patients with Arthritis**\n","\n","**Summary**: This topic explores the role of CD8+ T cells in the synovial fluid (SF) of patients with osteoarthritis (OA) and psoriatic arthritis (PsA). It examines the regulatory mechanisms (reg) governing these immune responses and how they contribute to the inflammation and symptomatology associated with these arthritic conditions. Insights into these cellular dynamics could lead to novel therapeutic strategies for managing arthritis.\n","Topic 35: **Topic Label:** \"The Role of EEF2K in Melanoma Immunotherapy: Exploring PD-L1's Impact on Tumor and Immune Cell Dynamics\"\n","\n","**Summary:** This topic investigates the interplay between EEF2K expression and tumor cells in melanoma, focusing on how PD-L1 modulation affects immune cell responses in the context of immunotherapy strategies. It aims to uncover potential therapeutic targets to enhance immune activation and improve treatment outcomes for melanoma patients.\n","Topic 36: ### Summary: Efficacy and Safety of Risankizumab at 16 and 52 Weeks in PASI 90 Response\n","\n","This topic discusses the efficacy and safety profile of risankizumab in achieving a Psoriasis Area Severity Index (PASI) 90 response over 16 and 52 weeks, highlighting the treatment's effectiveness and safety assessments during these timeframes.\n","Topic 37: **Topic: Therapeutic Applications of Mesenchymal Stem Cell-Derived Exosomes in Regenerative Medicine**\n","\n","This topic explores the role of exosomes derived from human umbilical cord mesenchymal stem cells (hUC-MSCs) as therapeutic extracellular vesicles (EVs) in regenerative medicine, highlighting their potential in cellular communication, tissue repair, and treatment of various diseases.\n","Topic 38: **Summary: Topical PDE4 Inhibitors for Plaque Management**\n","\n","This topic explores the use of topical medications, specifically roflumilast and orismilast, which are PDE4 inhibitors, in the treatment of plaque-related conditions. It examines clinical trials assessing the efficacy of these formulations, including a vehicle cream comparison, and highlights the potential benefits of me3183 in dermatological applications.\n","Topic 39: **Topic: Genetic Variants in Generalized Pustular Psoriasis Associated with IL36RN and GPP Mutations**\n","\n","Summary: This topic explores the role of genetic mutations in the IL36RN gene and other variants, such as ACH and MPO, in the development of generalized pustular psoriasis (GPP). It focuses on how specific mutations (including those linked to IL36RN) contribute to the severity and presentation of this inflammatory skin condition.\n","Topic 40: **Topic: Mental Health in Psoriasis Patients**\n","\n","This topic explores the intersection of mental health challenges, specifically depression, anxiety, and suicidality, in patients suffering from psoriasis. It examines the prevalence of depressive symptoms, suicidal ideation, and risks associated with these mental health issues in this patient population. Understanding the psychological impact of psoriasis is crucial for improving overall patient care and outcomes.\n","Topic 41: **Topic Summary: Impact of Hidradenitis Suppurativa on Patient Pain, Drainage, and Fertility in Individuals with ADHD: A Hurley Stage Perspective**\n","\n","This topic explores the complexities faced by patients with hidradenitis suppurativa (HS), particularly focusing on the pain and drainage associated with the condition. The discussion will consider how these factors impact individuals who also have attention-deficit/hyperactivity disorder (ADHD) and their fertility, analyzed through the lens of the Hurley classification system for HS severity.\n","Topic 42: **Topic: \"Navigating Self-Stigmatization and Its Impact on Psychological Well-Being\"**\n","\n","This topic explores the interplay between self-stigmatization and its effects on psychological health, including aspects like depression, anger, and self-esteem. It delves into coping strategies that individuals employ to manage stigma-related challenges, ultimately influencing their overall quality of life.\n","Topic 43: **Topic: The Impact of Intermittent Fasting and Mediterranean Diets on Metabolic Health and Nutritional Intake**\n","\n","**Summary:** This topic explores the effects of intermittent fasting and Mediterranean dietary patterns on metabolic health and nutritional intake. It examines how these dietary approaches can influence weight loss, promote healthy eating habits, and support overall wellness, particularly for people living with pre-existing lifestyle-related problems (PLWP).\n","Topic 44: **Topic Summary: Acitretin and Herbal Medicine for Psoriasis: A Meta-Analysis**\n","\n","This study examines the efficacy of acitretin compared to herbal remedies for treating psoriasis vulgaris (PV) through a rigorous meta-analysis. It assesses the quality of evidence using a confidence interval (CI) of 95% and explores the implications of using traditional Chinese medicine in treatment regimens. The review highlights relative risk (RR) analysis to determine the effectiveness and safety profiles of both treatment approaches.\n","Topic 45: **Topic Summary: Pustular Psoriasis and its Treatment**\n","\n","This topic explores palmoplantar pustulosis (PPP), characterized by pustules on the palms and soles. It discusses the PPP Autoimmune Severity Index (PPPASI) for assessing disease severity. The role of spesolimab, a targeted treatment for pustulous skin conditions, is examined as a therapeutic option for patients suffering from PPP.\n","Topic 46: **Topic Summary: Efficacy and Safety of Bimekizumab in Psoriasis Treatment** \n","\n","This topic focuses on the analysis of bimekizumab (BKZ), a treatment for psoriasis, examining its efficacy (measured by PASI scores) and safety over a period of 16 weeks at a dosage of 100 mg compared to certolizumab pegol (CZP). Key findings from clinical trials highlight the drug's performance and safety profile during this treatment window.\n","Topic 47: **Topic Summary: Safety and Efficacy of Tildrakizumab and Mirikizumab dosages at 100 mg over various weeks in PASI Assessment** \n","\n","This topic focuses on the comparative safety profiles and efficacy of tildrakizumab and mirikizumab dosages, specifically the 100 mg administration over a series of weeks, evaluated through the Psoriasis Area Severity Index (PASI).\n","Topic 48: **Topic: Telemedicine Consultations through Health Apps**\n","\n","This topic explores the integration of telemedicine and health applications (apps) that facilitate remote consultations. It highlights the role of social media in promoting these technologies, the impact of Health Technology Assessment (HTA) on app effectiveness, and the significance of user feedback (e.g., rating systems) with a focus on the potential implications for public health (e.g., case number 472).\n","Topic 49: **Topic: Impact of Periodontal Health on Oral Cavity and Salivary Factors**\n","\n","This topic explores the relationship between periodontal conditions, particularly periodontitis, and their effects on oral health indicators, including gingival health, saliva composition, and overall dental hygiene. It emphasizes the significance of the tongue and teeth in maintaining periodontal (pd) health and the implications of periodontal pockets (pp) on oral wellbeing.\n","Topic 50: **Topic: Hematological Markers in Inflammatory Conditions**\n","\n","This topic explores the relationship between various hematological parameters—including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume (MPV), and levels of C-reactive protein (CRP)—and their potential roles in assessing the severity of inflammatory diseases. It emphasizes how the interplay between these markers can provide insights into inflammatory processes and overall patient prognosis.\n","Topic 51: **Topic: Deep Learning in Dermatology: Enhancing Image Analysis with AI Applications**\n","\n","This topic explores the use of deep learning (DL) algorithms in developing AI applications that assist dermatologists in accurately analyzing images of skin conditions. It focuses on the performance and accuracy of these technologies in improving diagnostic processes in dermatology.\n","Topic 52: **Topic Summary: Racial and Ethnic Disparities in Dermatologic Health Care for Vulvar Conditions**\n","\n","This topic explores the disparities in dermatologic health care related to vulvar conditions across different racial and ethnic groups. It highlights the importance of inclusive clinical trials that consider race and ethnicity to improve health outcomes and access to care for diverse populations. The focus is on addressing barriers and promoting equitable treatment practices in dermatologic care.\n","Topic 53: **Topic Summary: Immunological Interactions of Tregs and γδ T Cells in Response to Imiquimod in Mice**\n","\n","This topic explores the role of regulatory T cells (Tregs) and γδ T cells in the immune response of mice to the TLR7 agonist imiquimod. It examines the interplay between Tregs and Th17 cells, the influence of IL signaling, and the expression of TNFR2 in modulating immune responses. The investigation aims to understand how these cell types contribute to immune regulation and inflammatory outcomes in murine models.\n","Topic 54: **Topic: Advanced Treatments for Nail Disorders**\n","\n","This topic covers innovative therapeutic approaches for nail disorders, focusing on techniques such as intralesional injections, fractional laser treatments, and the use of topical agents. It includes discussions on using PRP (platelet-rich plasma) and PDL (pulsed dye laser) therapies to enhance nail health and appearance. The integration of these technologies represents a multifaceted strategy for effective nail treatment.\n","Topic 55: **Topic: Maternal Health Outcomes in Pregnant Women with Axial Spondyloarthritis (AxSpa) and Rheumatoid Arthritis (RA)**\n","\n","This topic explores the impact of axial spondyloarthritis and rheumatoid arthritis on pregnancy outcomes in women, focusing on risks such as small for gestational age (SGA) births and other maternal health considerations throughout gestation.\n","Topic 56: **Topic: Understanding Onychomycosis - Fungal Infections of the Nails**\n","\n","This module covers onychomycosis, a common fungal infection caused by dermatophytes that leads to various changes in the nails, including subungual effects. It emphasizes the importance of recognizing symptoms and treatment options for affected individuals.\n","Topic 57: **Topic Summary: Pemphigoid and Autoantibodies in Mucosal Bullous Lesions**\n","\n","This topic focuses on bullous pemphigoid (BP) and its associations with autoantibodies targeting p200 and laminin (specifically laminin 332, or LM332) in mucosal forms of the disease. It explores the role of these autoantibodies in the pathogenesis of BP, highlighting their implications for diagnosis and potential treatment.\n","Topic 58: **Topic Summary: Ixekizumab Efficacy and Safety Profile in Severe Conditions Over Several Weeks**\n","\n","This topic discusses the real-world efficacy and safety profile of ixekizumab, a treatment for severe conditions, evaluated at various weeks post-administration. Key considerations include its effectiveness and safety during the treatment timeline.\n","Topic 59: **Topic: Skin-Resident Memory T Cells and Their Role in Immune Response**\n","\n","This topic explores the role of CD1a+ skin-resident memory T cells (Trm) in the immune system, particularly how these cells contribute to memory and protection against pathogens in the skin. It also examines the influence of integrins in the retention and function of these immune cells, and their interaction with gaseous signaling molecules in the skin microenvironment.\n","Topic 60: **Topic Summary: The Impact of Metabolites on Obesity and Body Composition** \n","\n","This topic explores the relationship between metabolic factors, including the role of TMAO (trimethylamine N-oxide), in influencing weight, appetite, and body fat distribution (visceral vs. subcutaneous fat). It examines how BMI (Body Mass Index) may not fully capture the complexities of obesity and its metabolic consequences, highlighting the importance of visceral fat and its effects on overall health.\n","Topic 61: **Topic Summary: Efficacy of Brodalumab Treatment in Achieving PASI 210 Improvement Over 12 Weeks**\n","\n","This topic explores the effectiveness of brodalumab, a treatment for psoriasis, in achieving a substantial reduction, defined as PASI 210, over a 12-week period. It emphasizes the real-world impacts of this treatment regimen and its potential to deliver significant benefits for patients.\n","Topic 62: **Topic: Impact of Pruritus and Restless Legs Syndrome on Sleep Quality and Psychological Health in Patients**\n","\n","This topic explores the relationship between pruritus (itching) and restless legs syndrome (RLS) as factors disturbing sleep quality among patients. It examines the use of the Pittsburgh Sleep Quality Index (PSQI) to assess sleep disturbances and how these conditions correlate with depression and overall health problems.\n","Topic 63: **Topic Summary: \"The Role of Dimethyl Fumarate in Multiple Sclerosis: NRF2 Activation and KEAP1 Modulation\"**\n","\n","This topic explores the therapeutic use of dimethyl fumarate (DMF) and its ester form in treating multiple sclerosis (MS). It examines the mechanism of action through the activation of the NRF2 pathway, which helps mitigate oxidative stress by inhibiting KEAP1. Additionally, the comparison with mycophenolate mofetil (MMF) and other fumarates highlights their roles in managing MS symptoms and disease progression.\n","Topic 64: **Topic: The Role of Capsaicin in Modulating Oxidative Stress and Redox Homeostasis through Antioxidant Mechanisms in Ozone Exposure**\n","\n","This topic explores how capsaicin, a bioactive compound in chili peppers, influences oxidative stress and redox balance in the presence of ozone. It examines the interplay between reactive oxygen species (ROS), oxidants, and antioxidants, highlighting capsaicin's potential protective effects against oxidative damage.\n","Topic 65: **Summary: Enhancing Adherence in Dermatological Treatments through Counselling and Interventions**\n","\n","This topic explores the role of counselling and various interventions in improving adherence to dermatological treatments, as measured by the Dermatology Life Quality Index (DLQI). It discusses the impact of performance in adherence strategies and compounding therapies, particularly within the framework of integrated health management systems (IHMS). The use of emphasis (italic) on key terms such as “der” (referring to dermatological aspects) and “die” may highlight the critical components of effective patient engagement and treatment compliance.\n","Topic 66: **Topic: Machine Learning Models for PSA Prediction and Accuracy Improvement**\n","\n","**Summary:** This topic focuses on developing and evaluating machine learning models to predict prostate-specific antigen (PSA) levels. It involves analyzing various variables, clustering data points to identify patterns, and fitting predictive curves to enhance accuracy. The discussion encompasses the selection of appropriate models, the effectiveness of different learning algorithms, and methods to improve prediction accuracy in PSA-related health assessments.\n","Topic 67: **Topic: Mechanisms of Itch Sensation in Skin via TRPV1 and Sensory Neurons**\n","\n","This topic explores the role of TRPV1 receptors in mast cells and sensory neurons in the skin's response to various stimuli, focusing on the interplay between osmotic stress, TLR2 signaling, and nerve activation that contributes to itch sensation.\n","Topic 68: **Topic: Management and Diagnosis of Latent Tuberculosis Infection (LTBI)**\n","\n","This topic covers the identification, testing, and management of latent tuberculosis infection (LTBI), focusing on methods such as the Tuberculin Skin Test (TST) and Interferon Gamma Release Assays (IGRAs) like QuantiFERON. Discussions include the risk of reactivation of Mycobacterium tuberculosis, the significance of diagnosing latent TB, and strategies for treatment and prevention of progression to active tuberculosis (TB).\n","Topic 69: **Topic Summary: Single-Cell RNA Sequencing in Immunology: Analyzing CD4+ T Cells and TRM Cells**\n","\n","This topic explores the application of single-cell RNA sequencing (scRNA-seq) to study immune responses, focusing on CD4+ T cells and tissue-resident memory (Trm) cells. The analysis of individual cells provides insights into cellular heterogeneity, immune function, and the role of these cells in health and disease.\n","Topic 70: **Topic: Comparison of IL-23 Inhibitors in Psoriasis Treatment**\n","\n","This topic explores the mechanisms and efficacy of IL-23 inhibitors, specifically guselkumab, tildrakizumab, and risankizumab, in treating psoriasis. It discusses their interaction with the p19 subunit of IL-23, the significance of epitope targeting, and how these biologics compare to ustekinumab, an inhibitor of the p40 subunit that affects both IL-12 and IL-23. The discussion also may cover clinical trial outcomes and dosing regimens.\n","Topic 71: **Topic Summary: Efficacy of Spesolimab in Treating Generalized Pustular Psoriasis (GPP) Flare-Ups**\n","\n","This topic explores the clinical outcomes associated with spesolimab treatment in patients suffering from generalized pustular psoriasis (GPP). It focuses on the management of flare-ups, specifically examining the GPPGA (Generalized Pustular Psoriasis Severity Index) scores and the appropriate dosing regimen, particularly in relation to a 36-week treatment duration. The discussion may also include insights from the Effisayil trials, highlighting the impact of spesolimab on the frequency and severity of pustular flares.\n","Topic 72: **Topic Summary: Efficacy of Secukinumab in Treating Psoriatic Arthritis**\n","\n","This topic examines the impact of secukinumab at dosages of 300 mg and 150 mg versus placebo in patients with Psoriatic Arthritis (PsA), focusing on its effectiveness in reducing disease severity as measured by Dactylitis Resolution Rate (DRR) and retention rates in treatment regimens.\n","Topic 73: **Topic: Role of CCR6-Related Cytokine Signaling in Cardiac Response to LPS via MIF and OXMI-F Modulation**\n","\n","This topic explores the involvement of cytokines, particularly MIF (Macrophage Migration Inhibitory Factor) and OXMI-F, in cardiac responses to lipopolysaccharide (LPS) induction. It highlights the significance of the CCR6 receptor, the 12p40 cytokine production, and the potential of monoclonal antibodies (mAbs) in modulating inflammatory responses within cardiac tissues.\n","Topic 74: **Topic Summary: Investigating the Role of Coptisine in Stress-Induced Pruritus and Anxiety in Mice with Skin Diseases**\n","\n","This research explores the relationship between stress and pruritus (itching) in mice, particularly focusing on the psychological aspects and the influence of neuropeptide Y (NPY). The study examines the effects of coptisine, a compound of interest, on alleviating symptoms associated with stress-related skin diseases. Findings aim to deepen the understanding of how stress impacts skin conditions and associated anxiety behaviors.\n","Topic 75: **Topic Summary: Young Trainee Research on Psoriatic Arthritis: Annual Assessment Meeting on Grappa Initiatives** \n","\n","This topic focuses on an annual meeting organized by a group of young trainees discussing their research findings related to psoriatic arthritis, emphasizing the role of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis) in assessing current advancements and future directions in the field.\n","Topic 76: **Topic: \"Skin Barrier Function and Hydration: The Role of Lipids, TEWL, and CER in the Stratum Corneum\"**\n","\n","This topic explores how lipid composition, including ceramides (CER), impacts the stratum corneum's (SC) barrier function, influencing transepidermal water loss (TEWL) and overall skin hydration. It emphasizes the importance of maintaining an intact lipid barrier for optimal skin health and function.\n","Topic 77: **Topic Summary: Switching to Biosimilars in Adalimumab Therapy: A Discussion on Reference Drugs, TDM, and Patient Outcomes**\n","\n","This topic explores the implications of switching patients from the reference drug adalimumab (ADA) to biosimilars like adalimumab biosimilar (ADBM). It covers therapeutic drug monitoring (TDM) strategies, the role of reference product (RP) quality, and how these factors influence treatment efficacy and safety when considering drug switching for conditions such as autoimmune diseases.\n","Topic 78: **Title: \"Interconnected Cell Death Mechanisms: Ferroptosis, Pyroptosis, and Cuproptosis\"**\n","\n","**Summary:** This topic explores the intricate relationships between various cell death pathways, including ferroptosis, pyroptosis, and cuproptosis, highlighting the roles of specific genes (PRGs and FRGs) and the influence of iron metabolism. It also examines the concept of panoptosis as a regulatory framework that integrates these pathways and their implications in cellular homeostasis and disease.\n","Topic 79: **Topic Summary: Topical Treatment for Plaque Psoriasis Using Tapinarof Cream**\n","\n","This topic explores the use of tapinarof, a topical cream, in clinical trials for the treatment of plaque psoriasis. Tapinarof acts on specific receptors to deliver remittive effects, while incorporating components such as polyglutamic acid (PGA) and hydrocarbon carriers. The investigation focuses on its aryl structure and efficacy in reducing plaque formation in patients.\n","Topic 80: **Topic Summary: Generalized Pustular Psoriasis (GPP)**\n","\n","This topic covers Generalized Pustular Psoriasis (GPP), a rare and severe form of psoriasis characterized by widespread pustules and inflammatory skin flares. It highlights its variants, such as GPP associated with systemic inflammation (GPPASI) and GPP with granulomatous features (GPPGA). The discussion may include the clinical presentation, triggers for flare-ups, and management strategies for this challenging condition. Key reference number: 513.\n","Topic 81: **Summary: Dupilumab-Induced Psoriasiform Reactions in Atopic Dermatitis: A Case Series**  \n","This topic examines cases of psoriasiform reactions at the injection site of dupilumab in patients with atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP). It highlights the incidence, clinical presentations, and management of these adverse reactions following treatment with the monoclonal antibody dupilumab.\n","Topic 82: **Topic Summary: Maternal and Fetal Health in Pregnancy: The Implications of Hydroxychloroquine (HCQ) Use for Pustular Psoriasis and Its Association with Maculopathy in Pregnant Women Across Trimesters**\n","\n","This topic addresses the effects of Hydroxychloroquine (HCQ) treatment in pregnant women with pustular psoriasis (GPP) and its potential impact on maternal maculopathy and fetal health throughout different trimesters of pregnancy.\n","Topic 83: **Topic Summary: Mitochondrial Metabolism and Metabolite Profiles in Health and Disease**\n","\n","This topic explores the role of mitochondrial DNA (mtDNA) in metabolic processes, focusing on the production and regulation of metabolites, including amino acids and organic acids. It examines the significance of biomarkers like ibil (bilirubin) and GGT (gamma-glutamyl transferase) in assessing metabolic health and dysfunction, linking metabolic pathways and mitochondrial function to various diseases and health conditions.\n","Topic 84: **Title: Activation Mechanisms of NLRP3 and AIM2 Inflammasomes: Roles of Caspase, ASC, and IL-1β in Immune Response**\n","\n","**Summary:** This topic explores the molecular dynamics involved in the activation of NLRP3 and AIM2 inflammasomes. It highlights the roles of key components such as caspase-1, ASC protein, and their interactions in processing interleukin-1β (IL-1β). The discussion focuses on how these inflammasomes modulate immune responses through their activation pathways and the significance of distinct protein domains in this process.\n","Topic 85: **Topic: \"Advancements in Skin Lesion Evaluation: Integrating Dermoscopy, RCM, and Ultrasound with Biopsy Techniques\"**\n","\n","This topic explores the use of dermoscopy and reflectance confocal microscopy (RCM) in the diagnostic evaluation of skin lesions, including techniques for assessing thickness through ultrasound and incisional biopsy. It highlights the role of HMGB (High Mobility Group Box protein) as a potential biomarker, emphasizing the integration of these technologies for enhanced diagnostic accuracy in dermatology.\n","Topic 86: **Topic Summary: PSA and Cardiovascular Risk Assessment in Patients with Comorbidities**\n","\n","This topic explores the role of prostate-specific antigen (PSA) levels in evaluating cardiovascular (CV) risk, particularly in patients with multiple comorbidities. It emphasizes the relationship between PSA and cardiovascular disease (CVD), as well as venous thromboembolism (VTE), alongside the use of confidence intervals (CI) at 95% to quantify risk. The discussion may include findings from the COMPASS study, which investigates cardiovascular outcomes and the implications of managing patients with elevated PSA in the context of existing health conditions.\n","Topic 87: **Topic Summary: \"Investigating the Effects of Acitretin on Plasma Levels of Irisin, Resistin, and Angptl8 in Relation to Serum Glucose Concentration\"**\n","\n","This study explores the relationship between the administration of acitretin and changes in plasma concentrations of irisin, resistin, and Angptl8, focusing on their potential effects on glucose levels in serum.\n","Topic 88: **Topic Summary: Investigating the Role of lncrnas and circrnas in Regulating Proliferation in HaCaT Cells via 5p miR-CHRNA5 Pathways**\n","\n","This study focuses on the interaction between long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) in modulating cell proliferation in HaCaT cells, particularly through the action of 5p microRNAs targeting the CHRNA5 gene. Various assays are employed to explore the regulatory mechanisms and functional consequences of these RNA interactions.\n","Topic 89: **Topic: Management of Co-infections in People Living with HIV (PLHIV)**\n","\n","This topic explores the interplay between HIV, including its viral load and CD4 cell counts, and co-infections such as syphilis. It emphasizes the importance of antiretroviral therapy in managing HIV/AIDS and its implications for immunodeficiency and overall health in PLHIV. The discussion may also cover strategies for monitoring and treating infections in the context of HIV.\n","Topic 90: **Topic Summary: Systematic Comparison of Treatments in Network Meta-Analysis for Psoriasis Severity (PASI 90)**\n","\n","This topic encompasses a systematic review and network meta-analysis (NMA) of various treatments for psoriasis, specifically evaluating their effectiveness in achieving a Psoriasis Area and Severity Index (PASI) score improvement of 90 (PASI 90). The analysis includes comparisons across multiple studies to determine the relative efficacy of different treatment options within a network framework.\n","Topic 91: **Topic Summary: Omega-3 Fatty Acids and Their Role in Mediating Inflammation via FFAR4 Activation**\n","\n","This topic explores the impact of polyunsaturated fatty acids (PUFAs), particularly alpha-linolenic acid (ALA), on lipid metabolism and inflammation regulation. It highlights how these fatty acids serve as mediators for crucial biological processes, potentially influencing the EPA (eicosapentaenoic acid) pathway and the activation of Free Fatty Acid Receptor 4 (FFA4), thereby contributing to overall health and disease management.\n","Topic 92: **Topic Summary: Alopecia Areata in Offspring: Prevalence and Genetic Factors**\n","\n","This topic explores the incidence (approximately 0.1% to 0.5%) of alopecia areata (AA) in offspring, with an emphasis on the heritability and genetic predisposition factors impacting 95% of cases. It examines the relationship between parental instances of AA and the likelihood of occurrence in children, analyzing data on affected individuals and potential per capita rates.\n","Topic 93: **Topic: Ustekinumab Biosimilarity and Efficacy in Psoriasis Treatment**\n","\n","Summary: This topic covers clinical trials and studies evaluating the response of patients with psoriasis to ustekinumab and its biosimilar formulations, focusing on the equivalence of RP (reference product), ABP 654, and AVT04. It examines key metrics, including the p43 biomarker response and CT (clinical trial) outcomes at various weeks, highlighting the implications for treatment strategies and patient outcomes.\n","Topic 94: **Topic: Proteomic Analysis of Biomarkers Involving ADAM17, ADAM10, and Gelsolin**\n","\n","This topic encompasses the identification and analysis of proteins associated with specific biomarkers through proteomic techniques. It highlights the roles of ADAM17, ADAM10, and gelsolin in biological processes, utilizing methods such as gel electrophoresis to reveal potential signatures for clinical or research applications.\n","Topic 95: **Topic: Oral Candidiasis and Antifungal Treatments**\n","\n","Summary: This topic examines oral candidiasis, a fungal infection caused by Candida species, focusing on its impact on individuals with conditions such as Lichen Planus (OLP). The discussion includes the prevalence of Candida infections, the role of antifungal treatments, and the implications of IL-17 in the immune response against these fungi.\n","Topic 96: **Topic Summary: Prevalence and Management of Generalized Pustular Psoriasis (GPP) vs. Plaque Psoriasis (PP) in Inpatient Settings**\n","\n","This topic explores the prevalence of generalized pustular psoriasis (GPP) compared to plaque psoriasis (PP), particularly in inpatient scenarios, examining factors such as treatment approaches (ACH) and patient outcomes.\n","Topic 97: **Topic Summary: Correction Notice for Journal Article in Frontiers in Immunology (2022)**\n","\n","This topic pertains to a correction notice for an article published in the journal *Frontiers in Immunology* (doi: 10.3389/fimmu.2022.XXXXX), which highlights amendments or clarifications to previously published content in the field of medical biology.\n","Topic 98: **Title: \"CRISPR-Driven Gene Editing in Keratinocytes: Targeting PCSK9, TRPM4, and ZNF750 for Therapeutic Advances\"**\n","\n","**Summary:** This topic explores the application of CRISPR-Cas9 technology in keratinocyte cells to modify key genes associated with various cellular functions and conditions. It focuses on the roles of PCSK9 in lipid metabolism, TRPM4 in ion channel activity, and ZNF750 in epidermal differentiation. The study also examines the interaction of these genes with regulators like MVD and CREB, alongside the implications of variants such as F250S and the SCF complex, to uncover potential therapeutic strategies for skin disorders and metabolic diseases.\n","Topic 99: **Topic Label: \"Analyzing Research Trends through Bibliometric Studies: Identifying Hotspots and Core Keywords in Publications\"**\n","\n","**Summary:** This topic explores the use of bibliometric analysis to evaluate research publications, focusing on citation patterns, emerging hotspots, and core keywords within a specific field. It aims to uncover trends in research output and highlight the most influential works and concepts shaping the academic discourse.\n","Topic 100: **Topic: The Role of Th17 Cells in Metabolic Regulation of Obesity and Lipid Metabolism**\n","\n","This topic explores how Th17 cells impact metabolic processes in obesity by influencing SREBP1 activity and lipid accumulation (7KC accumulation), as well as the effects of trans fat (TRF) on cellular metabolism and acid levels. It examines the interaction between immune cells and metabolic function at the cellular level, highlighting implications for obesity management and metabolic health.\n","Topic 101: **\"Cutaneous T-Cell Lymphoma (CTCL) Management and Cases: Focus on Mycosis Fungoides (MF) and Treatment with Methotrexate (MTX)\"**\n","\n","This topic explores the diagnosis and treatment of cutaneous T-cell lymphoma, particularly mycosis fungoides, highlighting case studies involving lymphoproliferative disorders (LPD) and the application of methotrexate (MTX) in management strategies.\n","Topic 102: **Topic Summary: Advanced Imaging Techniques in Biomedical Research** \n","\n","This topic covers the integration of various optical methods such as Optical Coherence Tomography (OCT), Fourier Transform Infrared Spectroscopy (FTIR), and Optoacoustic Imaging (OPLS). It highlights their applications in biomedical research, emphasizing their ability to provide detailed structural and functional information through high-resolution imaging and spectral analysis. The combination of these technologies enhances diagnostic capabilities and facilitates deeper understanding of biological tissues.\n","Topic 103: **Topic: Sphingolipid Metabolism and Its Role in Skin Lesions**\n","\n","This topic explores the biochemical pathways involving sphingosine-1-phosphate (S1P), sphingosine, ceramide, and their enzymatic regulators such as sphingosine-1-phosphate lyase 1 (SGPL1). It highlights the role of ceramides and sphingolipids in skin lesions, potentially influenced by environmental factors such as copper (Cu) exposure and the involvement of S1P receptors (S1PR). Understanding these interactions may shed light on dermatological conditions associated with sphingolipid dysregulation.\n","Topic 104: **Summary: Intraoperative Assessment of Tumor Margin Integrity in Triple-Negative Breast Cancer Using CT Imaging and Machine Learning Techniques**\n","\n","This topic explores the utilization of computed tomography (CT) and machine learning algorithms (e.g., LPAML) to evaluate tumor margins during surgery for triple-negative breast cancer (TNBC). Key metrics such as the curve of the receiver operating characteristic (ROC), area under the curve (AUC), and general information score (GIST) are analyzed alongside histopathological data (HDI) and perioperative glucose levels (PPGL). Additionally, intraoperative electrical impedance (IEE) measurements are considered to enhance precision in surgical outcomes.\n","Topic 105: **Topic: Immune Cell Dynamics and Cytokine Influence in Inflammatory Responses**\n","\n","This topic explores the interplay between different cell types, particularly focusing on the role of Th17 and Th1 cells in immune responses. Key factors such as CD83, HPSE, and associated cytokines (e.g., IL-17A and IL-17F) are examined in the context of dimethyl fumarate (DMF) treatment and its impact on extracellular vesicles (EVs) derived from various immune cells. The summary emphasizes how these elements contribute to inflammation and cellular communication in the immune system.\n","Topic 106: **Topic Summary: \"Impact of Psoriasis on Sexual Function and Gender Dynamics in Women\"**\n","\n","This topic explores how psoriasis, a non-communicable disease (NCD), affects sexual dysfunction in women. It examines the implications of skin conditions on sexual health and gender identity, utilizing tools like the Female Sexual Function Index (FSFI) to assess changes in quality of life related to sexual experiences. The focus highlights the intersection of gender and health, emphasizing the unique challenges faced by women with psoriasis.\n","Topic 107: **Topic: Consensus Guidelines Development for Core Outcome Indicators in CPGs Using Delphi Method**\n","\n","**Summary:** This topic focuses on the creation of consensus-based guidelines for core outcome indicators in clinical practice guidelines (CPGs). It utilizes the Delphi method to gather expert opinions across various subdomains, aiming to achieve agreement on essential outcomes that will enhance the quality and relevance of clinical assessments.\n","\n","GPT-4's advice:\n","- Topics to Merge: \n","  - [(15, 36)] Both topics focus on the efficacy of specific drugs in psoriasis treatment, evaluated through PASI scores over different timeframes.\n","  - [(24, 27)] Both topics discuss the long-term impacts and persistence of biologic treatments in psoriasis and pediatric psoriasis, respectively.\n","  - [(32, 43)] Both topics explore diet and lifestyle interventions and their broader effects on health conditions, potentially offering complementary insights.\n","  - [(34, 57)] Both topics delve into immunological mechanisms and responses, specifically highlighting the role of cytokines and immune cells which may have synergistic information.\n","  - [(46, 47)] Both topics address the efficacy and safety of specific drug treatments in psoriasis, measured by PASI scores across different weeks.\n","  - [(70, 71)] Both topics focus on specific inhibitors in the treatment of psoriasis, providing overlapping information on drug efficacy and clinical trial outcomes.\n","\n","- Topics to Split: \n","  - [57] This topic contains specific focus areas including autoantibodies, mucosal forms, and clinical manifestations which could be explored in more isolated discussions to enhance detail.\n","  - [106] Combining sexual function and gender dynamics under the impact of psoriasis might be complex and each could be effectively detailed if handled separately.\n"]},{"output_type":"stream","name":"stderr","text":["Some weights of BertForSequenceClassification were not initialized from the model checkpoint at sentence-transformers/all-MiniLM-L6-v2 and are newly initialized: ['classifier.bias', 'classifier.weight']\n","You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n"]},{"output_type":"display_data","data":{"text/plain":["<IPython.core.display.HTML object>"],"text/html":["\n","    <div>\n","      \n","      <progress value='3360' max='3360' style='width:300px; height:20px; vertical-align: middle;'></progress>\n","      [3360/3360 04:01, Epoch 10/10]\n","    </div>\n","    <table border=\"1\" class=\"dataframe\">\n","  <thead>\n"," <tr style=\"text-align: left;\">\n","      <th>Epoch</th>\n","      <th>Training Loss</th>\n","      <th>Validation Loss</th>\n","      <th>Accuracy</th>\n","      <th>F1</th>\n","      <th>Precision</th>\n","      <th>Recall</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <td>1</td>\n","      <td>No log</td>\n","      <td>3.576208</td>\n","      <td>0.299832</td>\n","      <td>0.138325</td>\n","      <td>0.089900</td>\n","      <td>0.299832</td>\n","    </tr>\n","    <tr>\n","      <td>2</td>\n","      <td>3.656900</td>\n","      <td>3.153614</td>\n","      <td>0.422111</td>\n","      <td>0.286200</td>\n","      <td>0.244971</td>\n","      <td>0.422111</td>\n","    </tr>\n","    <tr>\n","      <td>3</td>\n","      <td>2.976000</td>\n","      <td>2.884864</td>\n","      <td>0.452261</td>\n","      <td>0.330680</td>\n","      <td>0.276727</td>\n","      <td>0.452261</td>\n","    </tr>\n","    <tr>\n","      <td>4</td>\n","      <td>2.976000</td>\n","      <td>2.667002</td>\n","      <td>0.474037</td>\n","      <td>0.360655</td>\n","      <td>0.312881</td>\n","      <td>0.474037</td>\n","    </tr>\n","    <tr>\n","      <td>5</td>\n","      <td>2.405000</td>\n","      <td>2.600538</td>\n","      <td>0.504188</td>\n","      <td>0.406216</td>\n","      <td>0.367555</td>\n","      <td>0.504188</td>\n","    </tr>\n","    <tr>\n","      <td>6</td>\n","      <td>1.999600</td>\n","      <td>2.506100</td>\n","      <td>0.520938</td>\n","      <td>0.434556</td>\n","      <td>0.387829</td>\n","      <td>0.520938</td>\n","    </tr>\n","    <tr>\n","      <td>7</td>\n","      <td>1.999600</td>\n","      <td>2.454301</td>\n","      <td>0.536013</td>\n","      <td>0.452092</td>\n","      <td>0.416504</td>\n","      <td>0.536013</td>\n","    </tr>\n","    <tr>\n","      <td>8</td>\n","      <td>1.711000</td>\n","      <td>2.400957</td>\n","      <td>0.537688</td>\n","      <td>0.459154</td>\n","      <td>0.420479</td>\n","      <td>0.537688</td>\n","    </tr>\n","    <tr>\n","      <td>9</td>\n","      <td>1.545300</td>\n","      <td>2.373813</td>\n","      <td>0.551089</td>\n","      <td>0.481029</td>\n","      <td>0.451068</td>\n","      <td>0.551089</td>\n","    </tr>\n","    <tr>\n","      <td>10</td>\n","      <td>1.545300</td>\n","      <td>2.373744</td>\n","      <td>0.566164</td>\n","      <td>0.496784</td>\n","      <td>0.465584</td>\n","      <td>0.566164</td>\n","    </tr>\n","  </tbody>\n","</table><p>"]},"metadata":{}},{"output_type":"stream","name":"stdout","text":["Silhouette Score: -0.34506118297576904\n","Calinski-Harabasz Index: 97.81814975328037\n","Davies-Bouldin Index: 12.135788271057244\n","\n","--- Iteration 2 ---\n","\n","Topic 0: **Summary: \"Impact of Enthesitis on Joint Activity in Psoriatic Arthritis Patients\"**\n","\n","This topic explores the relationship between enthesitis and joint activity in patients with psoriatic arthritis, focusing on how this condition affects disease progression and overall patient well-being.\n","Topic 1: **Topic Summary: Nanoparticle-Loaded Gel Formulations for Topical Drug Delivery**  \n","This topic explores innovative formulations utilizing nanoparticles within gel matrices designed for the topical delivery of drugs. The focus is on enhancing the controlled release and effectiveness of therapeutic agents through improved skin penetration and sustained drug release mechanisms.\n","Topic 2: **Topic: Post-Pandemic Insights on COVID-19 Vaccination and Infection Dynamics**\n","\n","This topic explores the developments in COVID-19 vaccination strategies, the efficacy of various vaccines against SARS-CoV-2, and the ongoing challenges of managing infections in a post-pandemic world. It discusses the impact of vaccination on pandemic recovery and the importance of understanding long-term immunity and virus variants.\n","Topic 3: **Topic Summary: \"Safety and Efficacy of TYK2 Inhibitors in Autoimmune Conditions: A Comparative Study of Deucravacitinib and Janus Kinase Inhibitors\"**\n","\n","This topic explores the safety and efficacy of deucravacitinib, a selective TYK2 inhibitor, compared to traditional Janus kinase inhibitors (JAKi) like tofacitinib, including studies that assess their effects against a placebo in the treatment of autoimmune diseases, focusing on safety profiles and therapeutic outcomes.\n","Topic 4: **Topic: The Role of Gut Microbiota in Skin Health and Dysbiosis**\n","\n","This topic explores the relationship between gut microbiota and skin health, focusing on how dysbiosis (imbalance of microbial communities) in the gut can impact the skin microbiome. It discusses the influence of specific microbes, such as Staphylococcus aureus, and the potential for probiotics to aid in restoring balance and promoting healthier skin.\n","Topic 5: **Topic: Genetic Association of HLA Polymorphisms and Alleles in Disease Risk**\n","\n","This topic explores the role of genetic polymorphisms in the HLA (Human Leukocyte Antigen) gene, focusing on specific SNPs (single nucleotide polymorphisms), allele frequencies, and genotypes, particularly the association of the allele CW6 with various diseases. It investigates how variations in these genetic markers influence susceptibility and immune response in human populations.\n","Topic 6: **Topic Summary: \"Dermoscopy in the Clinical Diagnosis of Erythroderma: Examination Features and Vascular Patterns\"**\n","\n","This topic focuses on the use of dermoscopy and dermoscopic techniques in the clinical examination and diagnosis of erythroderma. It highlights the specific features observable through dermoscopy, such as vascular patterns, which aid in differentiating causes of erythroderma and determining the necessity of biopsy for further investigation.\n","Topic 7: **Topic Summary: \"Analyzing Gene Expression and Enrichment in Ferroptosis Networks Using Differentially Expressed Genes (DEGs)\"**\n","\n","This topic focuses on the investigation of gene expression profiles related to ferroptosis, a form of regulated cell death. It involves the identification and analysis of differentially expressed genes (DEGs) to uncover gene hubs and their interactions within biological networks. Enrichment analysis is applied to understand the functional significance of these genes in ferroptosis pathways.\n","Topic 8: **Topic Summary: Induction of Inflammatory Skin Response in Mice Using Imiquimod and HaCat Cells**\n","\n","This topic explores the use of imiquimod (IMQ) to induce an inflammatory skin response in mice, drawing parallels to human-like skin reactions observed in HaCat cells (human keratinocyte cell line). The focus is on the interplay of interleukins (IL) during the inflammatory process.\n","Topic 9: **Title: \"TNF Inhibitors in IBD: Balancing Benefits and Paradoxical Risks\"**\n","\n","**Summary:** This topic explores the use of TNF inhibitors (TNFi), such as adalimumab, in treating inflammatory bowel disease (IBD). It reviews the mechanism of action involving tumor necrosis factor (TNF) alpha, while also addressing paradoxical effects, including the risk of necrosis and other adverse outcomes associated with anti-TNF therapies.\n","Topic 10: **Topic Summary: Prevalence and Incidence of Psoriasis in Patients by Age and Sexual Differences Over 95 Years**\n","\n","This topic explores the prevalence and incidence rates of psoriasis among patients over the last 95 years, focusing on age demographics and sexual differences. It includes statistical analyses represented with confidence intervals (CI) to provide insights into how these factors have influenced psoriasis rates in various populations.\n","Topic 11: **Topic Summary: Cardiovascular Risk in Psoriasis Patients**  \n","This topic explores the increased cardiovascular risk among patients with psoriasis, focusing on the relationship between atherosclerosis in coronary arteries and cardiovascular health. It also discusses the role of carotid intima-media thickness (CIMT) as a diagnostic indicator for assessing heart disease risk in these patients.\n","Topic 12: **Topic: Causal Genetic Associations in Risk Assessment Using Mendelian Randomization**\n","\n","This topic explores the application of Mendelian randomization (MR) to evaluate causal associations between genetic variants and risk factors. It emphasizes the use of inverse variance weighting (IVW) to estimate the strength of these associations and presents confidence intervals (CI) at the 95% level to determine statistical significance.\n","Topic 13: **Topic Summary: Regulation of Keratinocyte Proliferation and Differentiation via IL and YAP Signaling**\n","\n","This topic explores how the expression of certain interleukins (IL) and the Yes-associated protein (YAP) influence the proliferation and differentiation of keratinocytes in the epidermis. It examines the induced responses of keratinocytes, focusing on the mechanisms that regulate their growth and maturation.\n","Topic 14: **Title: \"Long-term Persistence of Golimumab in Patients with Rheumatoid Arthritis: Insights from RCTs\"**\n","\n","**Summary:** This topic explores the persistence of golimumab, a TNF inhibitor (TNFi), in treating rheumatoid arthritis (RA) and psoriatic arthritis (PsA). It reviews data from randomized controlled trials (RCTs) highlighting patient outcomes, treatment adherence, and effectiveness, providing insights into the sustained use and long-term benefits of golimumab in managing these autoimmune conditions.\n","Topic 15: **Topical Treatment for Psoriasis: Calcipotriol and Betamethasone Foam**  \n","\n","This topic discusses the use of a combination treatment involving calcipotriol (a vitamin D analog) and betamethasone (a corticosteroid) in foam form for managing psoriasis. The foam formulation enhances absorption and user convenience, while the combination aims to reduce inflammation and skin cell turnover effectively.\n","Topic 16: **Topic Summary: Efficacy of Guselkumab at Week 24 for Psoriasis** \n","This topic explores the effects of guselkumab in patients with psoriasis, specifically its PASI (Psoriasis Area Severity Index) scores at week 24 compared to a placebo. The discussion includes the outcomes for patients receiving 100 mg doses and emphasizes the significance of treatment efficacy over the treatment duration.\n","Topic 17: **Title: Anti-Inflammatory Properties of Plant Extracts and Oils, Including Honey**\n","\n","**Summary:** This topic explores the anti-inflammatory effects of various plant extracts and oils, focusing on their bioactive compounds. It highlights how these natural products, including honey, can mitigate inflammation, providing insights into their therapeutic potential.\n","Topic 18: **Title: \"Role of miR-125a in Serum Levels and Proliferation: Analyzing 3p and 5p Expression Variants\"**\n","\n","**Summary:** This topic investigates the expression levels of miR-125a, focusing on its 3p and 5p variants in serum. The study examines how these microRNAs influence cellular proliferation, highlighting their potential as biomarkers or therapeutic targets in disease conditions.\n","Topic 19: **Topic Summary: Impact of Psoriasis on Patient Quality of Life**\n","\n","This topic explores how psoriasis affects the quality of life (QoL) of patients, utilizing tools like the Dermatology Life Quality Index (DLQI) and Psoriasis Area and Severity Index (PASI) to measure health-related quality of life (HRQoL). It highlights the significant burden of psoriasis on individuals, affecting various aspects of their daily life and well-being.\n","Topic 20: **Title: Safety and Efficacy of Secukinumab in Psoriasis: PASI 75 and 90 Response Over 300 Weeks**\n","\n","**Summary:** This topic explores the long-term safety and efficacy of secukinumab in patients with psoriasis, focusing on improvements measured by the Psoriasis Area and Severity Index (PASI) scores. It reviews the percentage of patients achieving PASI 75 and PASI 90 responses over a 300-week period.\n","Topic 21: **Topic Summary: \"Evaluating the Toxicity of Oral Methotrexate and Metformin Combination Therapy Over a Week in Patient Groups\"** \n","\n","This topic explores the potential toxicity associated with the combined use of oral methotrexate and metformin over a one-week period, focusing on specific patient groups and their responses to the treatment regimen.\n","Topic 22: **Topic Summary: Immune Checkpoint Inhibitors in Cutaneous Cancer: Addressing Adverse Immune-Related Toxicities in Immunotherapy**\n","\n","This topic explores the role of immune checkpoint inhibitors (ICIs) in the treatment of cutaneous cancers, focusing on the associated immune-related adverse events (IRAEs) and other toxicities. It highlights the therapeutic benefits of ICIs while addressing the management and mitigation of adverse effects that can arise from immune activation during therapy.\n","Topic 23: **Topic Summary: \"Narrowband UVB Phototherapy for Skin Conditions\"**\n","\n","This topic explores the use of narrowband UVB (NB-UVB) phototherapy, a treatment that harnesses specific wavelengths of ultraviolet light to address various skin disorders. The therapy primarily focuses on the effectiveness of narrowband ultraviolet light in managing conditions like psoriasis, eczema, and vitiligo while minimizing the risk of skin cancer associated with broader UV exposure. It emphasizes the role of blue light spectrum in achieving therapeutic outcomes and the ongoing research regarding safety and efficacy in skin cancer prevention.\n","Topic 24: **Topic Summary: \"Survival and Persistence of Biologic Treatments: A Study on Adalimumab and Ustekinumab Discontinuation\"**\n","\n","This topic explores the survival rates and treatment persistence of biologic drugs, specifically adalimumab and ustekinumab, focusing on patient experiences, factors influencing discontinuation, and implications for long-term management in various conditions.\n","Topic 25: **Topic: Evaluating Axial Spondyloarthritis in Patients Using SPA and AxSPA Metrics**\n","\n","This topic focuses on the assessment and management of axial spondyloarthritis (AxSpA), including ankylosing spondylitis (AS) and related conditions. It emphasizes the importance of clinical evaluation tools like BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and ASAS (Assessment of SpondyloArthritis International Society) criteria in measuring disease activity and patient outcomes. Additionally, it discusses the role of specialized patient self-assessment forms (PSPA) to improve the understanding and treatment of spondyloarthritis in patient populations.\n","Topic 26: **Topic: Autoantibodies and Synovial Cell Regulation in Psoriatic Arthritis and Osteoarthritis**\n","\n","This topic explores the role of autoantibodies in the regulation of synovial fluid (SF) and synovial cells in the context of psoriatic arthritis (PsA) and osteoarthritis (OA). It emphasizes the relationship between immune responses, inflammation, and the progression of arthritis, focusing on potential biomarkers and therapeutic targets in synovial tissue.\n","Topic 27: **Topic: Pediatric Psoriasis Treatment: Systemic Therapies with Etanercept for Children** \n","\n","This topic explores the use of etanercept, a systemic treatment option, in managing psoriasis in pediatric patients, focusing on its effectiveness and safety in childhood therapies.\n","Topic 28: **Topic Summary: Evaluating the Safety and Efficacy of Apremilast in Patients with Active Psoriatic Arthritis Over Several Months**\n","\n","This topic focuses on examining real-world data regarding the treatment of patients with active psoriatic arthritis using apremilast, an oral medication. It analyzes the safety profile and the occurrence of adverse effects over the course of several months of treatment.\n","Topic 29: Certainly! \n","\n","**Topic Summary: \"Autoimmune and Metabolic Factors in Non-Alcoholic Fatty Liver Disease (NAFLD): Assessing Fibrosis Risk Related to Steatosis\"**\n","\n","This topic explores the interplay of autoimmune conditions and metabolic syndromes (MS) in the development of non-alcoholic fatty liver disease (NAFLD) and its progression to hepatic fibrosis. It examines how fatty liver and steatosis contribute to increased risk of liver complications, focusing on the implications for autoimmune patients.\n","Topic 30: **Topic Summary: Mental Health Impacts of Psoriasis in Patients: A Focus on Depression, Anxiety, and Suicidality**\n","\n","This topic explores the relationship between psoriasis and mental health, highlighting how chronic skin conditions can contribute to symptoms of depression, anxiety, and suicidality among patients. It addresses the stress associated with living with psoriasis, the prevalence of depressive symptoms, and the potential for suicidal thoughts or actions in affected individuals.\n","Topic 31: **Topic: Serum Levels of 25-Hydroxyvitamin D (25(OH)D) and its Role in Vitamin D Deficiency**\n","\n","This topic explores the measurement of serum levels of 25-hydroxyvitamin D (25(OH)D) as a critical indicator of vitamin D status in individuals. It examines how levels are expressed in nanograms per milliliter (ng/mL) and discusses the implications of deficiency, alongside the role of the vitamin D receptor (VDR) in maintaining sufficient vitamin levels for health.\n","Topic 32: **Topic Summary: Immune Cell Interactions and Regulation in Mice and Humans**  \n","This topic explores the role of γδ T cells and their interaction with regulatory T cells (Tregs) and Th17 cells in both mice and humans. It focuses on the impact of IL-17A on these immune cells, examining how these interactions influence immune responses and potential therapeutic implications for autoimmune diseases and inflammation.\n","Topic 33: **Topic Summary: IL-17 Cytokines and Autoimmune Diseases: The Role of RORγt in T Cell Differentiation**\n","\n","This topic explores the significance of IL-17 cytokines (including IL-17A, IL-17F, IL-17RA), their influence on cellular responses, and the critical role of the transcription factor RORγt in the differentiation of T helper cells. It examines how these components contribute to the pathogenesis of various autoimmune diseases, highlighting the interplay between immune regulation and inflammatory processes.\n","Topic 34: **Topic: \"Management of Anterior Uveitis and Associated Ocular Conditions in Patients\"**\n","\n","This topic focuses on the diagnosis and treatment of anterior uveitis, a type of eye inflammation affecting the uvea, along with its relationship to other ocular conditions such as blepharitis and dry eye syndrome. The discussion includes symptoms experienced by patients, potential impacts on retinal health, and strategies for effective management to improve overall eye care.\n","Topic 35: **Title: Efficacy and Safety of Risankizumab: PASI 90 Response at Week 52**\n","\n","**Summary:** This topic explores the efficacy and safety of risankizumab in achieving a PASI 90 response after 52 weeks, highlighting the effectiveness observed at the 16-week mark.\n","Topic 36: **Topic: Therapeutic Potential of Mesenchymal Stem Cell-Derived Exosomes in Regenerative Medicine**\n","\n","This topic explores the use of exosomes derived from mesenchymal stem cells (MSCs), including human umbilical cord (HUC) MSCs, as extracellular vesicles (EVs) in therapeutic applications. It examines their role in promoting tissue repair, modulating immune responses, and delivering bioactive molecules for regenerative therapies.\n","Topic 37: **Topic: Overview of IL-17 Inhibitors in Human Resources for Patients with Psoriasis**\n","\n","This topic discusses the use of IL-17 inhibitors (such as IL-17i) in treating patients with psoriasis (PASI scores), focusing on their efficacy (100% improvement) and implications for HR management of patient care.\n","Topic 38: **Topic: Enhancing Melanoma Immunotherapy through EEF2K Regulation of Immune Cell Function**\n","\n","This topic explores the role of EEF2K in modulating immune cell behavior in the tumor microenvironment of melanoma. It highlights the potential of combining PD-1/PD-L1 checkpoint inhibitors with innovative strategies targeting EEF2K to improve immune response and tumor control in cancer immunotherapy.\n","Topic 39: **Summary: Topical Phosphodiesterase 4 Inhibitors in Dermatological Trials**\n","\n","This topic encompasses the evaluation of **topical phosphodiesterase 4 (PDE4) inhibitors**, such as **roflumilast** and **orismilast**, in clinical trials assessing their efficacy as creams for treating plaque psoriasis. It includes discussions on formulations, vehicle compositions, and results from trials involving compounds like **ME3183** aimed at improving patient outcomes in skin conditions.\n","Topic 40: **Topic Summary: \"Exploring Dietary Patterns: Intermittent Fasting and the Mediterranean Diet for Enhanced Metabolic Health\"**\n","\n","This topic examines the impact of various dietary approaches, including intermittent fasting and the Mediterranean diet, on nutritional intake and metabolic outcomes. It highlights the benefits of these diets for individuals pursuing weight loss and improved health, particularly for those with a focus on plwp (people living with pre-existing conditions).\n","Topic 41: **Topic Summary: \"The Impact of Stigmatization on Individuals with Body Dysmorphic Disorder (BDD): Coping Mechanisms, Psychological Stress, and Quality of Life\"**\n","\n","This topic explores how stigmatization affects individuals suffering from Body Dysmorphic Disorder (BDD), focusing on their self-perception and psychological stress. It examines the relationship between perceived symptoms and the coping strategies employed, highlighting how these factors influence overall quality of life.\n","Topic 42: **Topic: Palmoplantar Pustulosis (PPP) and Associated Conditions**\n","\n","This topic encompasses Palmoplantar Pustulosis (PPP), a chronic skin condition characterized by pustules on the palms and soles. Related keywords include PPPASI (Palmoplantar Pustulosis Area Severity Index) and AOR (adjusted odds ratio), which metrics help assess disease severity and treatment efficacy. The discussion may involve the clinical features, diagnosis, treatment options, and the impact of pustules on patients' quality of life.\n","Topic 43: **Topic: Genetic Variants in Pustular Skin Disorders**\n","\n","This topic explores the role of genetic mutations, particularly in the IL36RN gene, associated with generalized pustular psoriasis (GPP) and other pustular skin conditions. It examines various variants and mutations, including those linked to the MPO gene, and their implications for autoimmune conditions such as Behçet's disease (ACH). The interplay between these genetic factors contributes to the pathogenesis and phenotypic variability of pustular disorders.\n","Topic 44: **Topic: Efficacy and Safety of Tildrakizumab in Psoriasis Treatment at Week 100 Compared to Mirikizumab**\n","\n","This topic explores the long-term safety and efficacy of tildrakizumab at a dosage of 100 mg administered at week 0 and subsequent weeks, focusing on Psoriasis Area Severity Index (PASI) scores and how these outcomes compare to those achieved with mirikizumab.\n","Topic 45: **Topic Summary: Hidradenitis Suppurativa in Patients with ADHD: Impacts on Pain, Drainage, and Fertility**\n","\n","This topic explores the intersection of hidradenitis suppurativa (HS) and attention-deficit/hyperactivity disorder (ADHD) in patients, focusing on the challenges of managing pain and drainage associated with HS, as well as potential implications for fertility. It highlights the need for tailored treatment approaches that address both HS symptoms and ADHD in affected individuals.\n","Topic 46: **Topic: Hematological Markers and Inflammatory Response in Psoriasis**\n","\n","This topic explores the relationships between neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), platelet volume (MPV), and C-reactive protein (CRP) levels in the context of psoriasis. It examines how these hematological markers correlate with the severity of inflammation and immune response in psoriasis patients.\n","Topic 47: ### Topic: Cost-Effectiveness of Secukinumab Treatment for Psoriasis and Related Conditions\n","\n","This topic explores the financial implications and cost-effectiveness of secukinumab, a treatment option for conditions like psoriasis, focusing on costs per responder among users and its impact on healthcare budgets.\n","Topic 48: **Topic: Remote Dermatology Solutions via Telemedicine Apps**\n","\n","This topic explores the integration of telemedicine in dermatology through specialized apps that facilitate remote consultations. It addresses how these technologies enhance patient care by allowing individuals to receive dermatological advice and treatment through media platforms, highlighting the effectiveness and accessibility of teledermatology in improving health outcomes.\n","Topic 49: **Summary: Meta-Analysis of Herbal Medicine in Chinese Populations: A Study on the Efficacy of Acitretin with Focus on PV and RR Outcomes**\n","\n","This topic explores a meta-analysis examining the effectiveness of herbal medicine for treating specific conditions in Chinese populations, particularly highlighting the role of acitretin. It considers outcomes such as progression of the disease (PV) and relative risk (RR) while assessing confidence intervals (CI) at a 95% level for statistical significance.\n","Topic 50: **Topic: The Impact of Obesity and Exercise on Metabolic Health in Psoriasis Patients**\n","\n","This topic explores the relationship between obesity, weight management, and metabolic health, particularly in individuals with psoriasis. It examines how visceral fat accumulation affects body composition and the potential benefits of exercise in reducing obesity-related metabolic issues.\n","Topic 51: **Topic: The Role of Ceramides in Skin Barrier Function and Hydration During Aging**\n","\n","This topic explores how ceramides (CER) contribute to the skin barrier's ability to retain water and prevent transepidermal water loss (TEWL). It highlights the importance of lipids in maintaining skin hydration and their role in combating aging effects on the stratum corneum (SC).\n","Topic 52: **Topic Summary: Racial and Ethnic Disparities in Health Care**\n","\n","This topic explores the disparities in healthcare access and outcomes based on race and ethnicity, focusing on how these differences impact various communities, including white populations. It examines the social determinants of health, the implications of care for specific health issues (such as breast health and the meaning of terms like \"nipple\" in medical contexts), and how systemic factors contribute to unequal treatment and outcomes in healthcare systems. Insights into the societal constructs of race and ethnicity are also analyzed to better understand and address these disparities.\n","Topic 53: **Topic Summary: Advanced Treatment Approaches for Nail Disorders**\n","\n","This topic explores innovative techniques for managing nail conditions, including intralesional laser therapy, specifically using fractional pulsed dye laser (PDL) and topical agents. It highlights the integration of Platelet-Rich Plasma (PRP) therapy for enhancing healing and improving outcomes in treating various nail pathologies.\n","Topic 54: **Topic: Oral Health and Periodontal Disease Management**\n","\n","This topic explores the relationship between periodontal disease (periodontitis) and overall oral health, focusing on the roles of the tongue, saliva, and dental care in maintaining healthy teeth. It also examines diagnostic indices such as PD (probing depth) and PP (papillary bleeding), as well as potential complications (AP - abscess formation) associated with advanced periodontal conditions.\n","Topic 55: **Topic: Deep Learning Applications for Dermatology: Enhancing Image Accuracy and Performance Using AI**\n","\n","Summary: This topic explores the development of AI-driven applications that utilize deep learning models (DLM) to analyze dermatological images. It focuses on improving diagnostic accuracy and performance in dermatology by harnessing advanced image recognition techniques, enabling dermatologists to achieve more reliable results in skin condition assessments.\n","Topic 56: **Topic Summary: Impact of Axial Spondyloarthritis on Maternal and Fetal Outcomes in Pregnant Women with Rheumatoid Arthritis**\n","\n","This topic explores the implications of axial spondyloarthritis (AxSpA) in women with rheumatoid arthritis (RA) during pregnancy. It focuses on maternal health, pregnancy outcomes, and the risk of small for gestational age (SGA) births, emphasizing the challenges and considerations for managing these conditions in pregnant patients.\n","Topic 57: **Topic: Impact of Pruritus and Restless Legs Syndrome on Sleep Quality and Depression in Patients**\n","\n","This topic explores how conditions like pruritus (itch) and restless legs syndrome (RLS) contribute to sleep disturbances, assessed using the Pittsburgh Sleep Quality Index (PSQI), and their subsequent effects on quality of life and mental health, particularly depression, in affected patients.\n","Topic 58: **Topic Summary: Bullous Pemphigoid and Mucosal Disease: Role of p200 Autoantibodies and Laminin**\n","\n","This topic explores the relationship between bullous pemphigoid (BP) and mucosal diseases, focusing on the role of specific autoantibodies, particularly the p200 autoantibody targeting laminin. It discusses the implications of these autoantibodies in the pathogenesis of BP and the involvement of bibp and LM332 in the disease's clinical manifestations.\n","Topic 59: **Topic: \"Exploring Cutaneous T-Cell Lymphoma (CTCL) Cases: The Role of PML, JCV, TSLP, and LPD in Mycosis Fungoides (MF) Involvement\"**\n","\n","This summary encompasses the investigation of specific cases of cutaneous T-cell lymphoma, particularly mycosis fungoides (MF), while examining the implications of key factors such as promyelocytic leukemia (PML), JC virus (JCV), thymic stromal lymphopoietin (TSLP), and lymphoproliferative disorders (LPD) in the disease's pathology and progression.\n","Topic 60: **Topic: \"Assessing Cardiovascular Risk in Patients with Comorbidities Using PSA and CV Metrics\"**\n","\n","This topic explores the relationship between cardiovascular risk factors, including diabetes and myocardial infarction (MI), and the predictive value of PSA (Prostate Specific Antigen) in patients with multiple comorbidities. It emphasizes the importance of a 95% confidence interval (CI) in evaluating cardiovascular outcomes and risk stratification for effective patient management.\n","Topic 61: **Topic Summary: Single-Cell RNA Sequencing of CD4+ Tissue-Resident Memory T Cells in Immune Responses**\n","\n","This topic focuses on using single-cell RNA sequencing (scRNA-seq) to analyze CD4+ T tissue-resident memory (Trm) cells, exploring their roles and expression profiles in immune responses. The study of these cells at a single-cell level enhances our understanding of immune mechanisms and potential therapeutic targets.\n","Topic 62: **Topic Summary: \"CRISPR-Cas9 Mediated Modulation of TRPM4 and CD147 in Keratinocytes: Implications for Epidermal Differentiation and Filaggrin Expression\"**\n","\n","This topic explores the use of CRISPR-Cas9 technology to investigate the roles of TRPM4 and CD147 in the differentiation of keratinocytes. It focuses on their impact on epidermal function and the regulation of filaggrin (FLG), a crucial protein for skin barrier integrity. Additionally, the study may examine the involvement of CREB signaling in these processes, highlighting potential pathways for enhancing or regulating epidermal characteristics.\n","Topic 63: **Summary: Skin Resident Memory T Cells and Their Role in Immunity**\n","\n","This topic explores the characteristics and functions of CD1a+ resident memory T cells (Trm) in the skin. It examines how integrins contribute to the retention and function of these cells (RMs) within the tissue, highlighting their significance in immune responses and memory formation at the cellular level in skin environments.\n","Topic 64: **Topic Summary: Metabolic Markers in Psoriasis Patients Under Acitretin Treatment**\n","\n","This topic explores the relationship between serum levels of irisin and resistin, along with galectin-5 (GAL-05) in patients with psoriasis, particularly focusing on their impacts on glucose and insulin metabolism. Acitretin, a common treatment for psoriasis, may influence these metabolic markers and their correlation with insulin resistance in psoriatic patients.\n","Topic 65: **Topic Summary:**\n","\n","\"Investigation of Dimethyl Fumarate (DMF) and its Role in Nrf2 Activation for Treating Multiple Sclerosis: Mechanisms Involving MMF, Ester Formation, and Keap1 Inhibition.\"\n","\n","This topic explores the therapeutic effects of dimethyl fumarate (DMF), an ester used in multiple sclerosis treatment, focusing on its activation of the Nrf2 pathway, interactions with Keap1, and implications for health benefits.\n","Topic 66: **Topic: Comparative Analysis of IL-23 Inhibitors in Treating Autoimmune Disorders**\n","\n","This topic encompasses the evaluation of various monoclonal antibodies targeting the IL-23 pathway, including guselkumab, tildrakizumab, risankizumab, and ustekinumab. It focuses on their efficacy, mechanism of action involving the p19 subunit, and specific epitopes that influence their inhibitory functions. The inquiry may also include the novel compound QX002N, assessing its potential alongside established therapies.\n","Topic 67: **Topic Summary: Predictive Modeling with PSA in Machine Learning**\n","\n","This topic explores the application of machine learning in predictive modeling, specifically focusing on Prostate-Specific Antigen (PSA) levels. It involves the use of various algorithms to build models that predict outcomes based on a set of variables. Techniques such as clustering and curve fitting are employed to enhance prediction accuracy and analyze data patterns, ultimately aiming to improve healthcare decision-making.\n","Topic 68: **Topic: Nail Fungal Infections and Conditions**\n","\n","This topic covers onychomycosis, a fungal infection of the nails caused by dermatophytes, leading to symptoms such as discoloration and thickening (onychogryphosis). It discusses the diagnosis, treatment options, and prevention strategies for managing nail infections.\n","Topic 69: **Topic Summary: Safety and Efficacy Profile of Ixekizumab in Severe Conditions Over Multiple Weeks** \n","\n","This topic examines the safety and efficacy of ixekizumab, a monoclonal antibody used in treating severe conditions, evaluating its performance and side effects over several weeks of treatment.\n","Topic 70: **Topic: The Role of Capsaicin in Modulating Oxidative Stress and Redox Balance through Antioxidant Activity**\n","\n","This topic explores how capsaicin, a bioactive compound found in chili peppers, influences oxidative stress and redox processes by modulating reactive oxygen species (ROS) and enhancing antioxidant defenses. The discussion includes the effects of ozone as an oxidant and its interaction with cellular oxygen levels, highlighting the potential of capsaicin in protecting against oxidative damage and promoting overall oxidative balance.\n","Topic 71: **Topic: MRI Imaging of Axial Spinal Involvement in Axial Spondyloarthritis (AxSpA) with Focus on Psoriatic Arthritis (PsA) and Facet Joint (FJ) Assessment**\n","\n","This topic explores the use of MRI imaging to evaluate axial spinal involvement in patients with axial spondyloarthritis (AxSpA), particularly highlighting the implications for those with psoriatic arthritis (PsA). It emphasizes the assessment of facet joints (FJ) and uses advanced imaging techniques to identify spinal abnormalities in this patient population.\n","Topic 72: **Topic: Diagnosis and Management of Latent Tuberculosis Infection (LTBI)**\n","\n","This topic covers the identification and monitoring of latent tuberculosis infection (LTBI), focusing on diagnostic tools such as the Interferon Gamma Release Assays (IGRAs) like QuantiFERON, and the traditional Tuberculin Skin Test (TST). It addresses the underlying Mycobacterium tuberculosis pathogen, the risk of reactivation into active TB disease, and strategies for managing and treating LTBI to prevent future infections.\n","Topic 73: **Title: Efficacy and Safety of Brodalumab in Psoriasis: A 12-Week Study (PASI 210)**\n","\n","**Summary:** This study evaluates the safety and treatment effectiveness of brodalumab in patients with moderate to severe psoriasis over a 12-week period, focusing on changes in the Psoriasis Area and Severity Index (PASI) from baseline to week 12.\n","Topic 74: **Topic Summary: Rare Generalized Pustular Psoriasis (GPP) and Its Haemodynamic Instability During Flares**\n","\n","This topic discusses the occurrence of rare generalized pustular psoriasis (GPP), characterized by the outbreak of pustules and potential haemodynamic instability during flare-ups. It highlights the challenges in managing this condition, including the implications of severe flares and the need for urgent medical attention, given its high morbidity associated with symptoms like instability and the formation of pustules. The number \"513\" could reference specific case studies or classification codes relevant to GPP.\n","Topic 75: **Topic Summary: Inflammatory Response in Cardiac Cells Mediated by CCR6 and Cytokine Interactions**\n","\n","This topic explores the role of the CCR6 receptor and the cytokine 12p40 in cardiac cells, focusing on their interaction with OXMIF (a potential modulator) in response to LPS (lipopolysaccharide) stimulation. The use of monoclonal antibodies (mAb) to investigate these pathways offers insights into inflammatory processes that may impact cardiac health.\n","Topic 76: **Topic Summary: \"Efficacy and Retention of Secukinumab in Psoriatic Arthritis: A Comparison of 300 mg and 150 mg Doses Against Placebo with Focus on Dactylitis Improvement\"**\n","\n","This research investigates the effectiveness and retention rates of secukinumab, administered at doses of 300 mg and 150 mg, in treating psoriatic arthritis (PSA) compared to a placebo. Special attention is given to the improvement of dactylitis symptoms and overall treatment retention.\n","Topic 77: **Topic Summary: Annual Research Meeting on Grappa's Assessment of Psoriatic Arthritis for Trainees and PSD Group** \n","\n","This annual meeting focuses on the research and assessment methodologies concerning psoriatic arthritis, specifically through the lens of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis). Trainees are encouraged to participate actively and engage with the findings presented by the PSD (Psoriatic Disease) group, fostering collaboration and knowledge sharing in the field.\n","Topic 78: **Topic: Mechanisms of Itch Sensation and Pruritus in Sensory Neurons**\n","\n","This topic explores the physiological processes and cellular mechanisms underlying itch (pruritus) mediated by sensory neurons. It emphasizes the role of specific receptors such as TRPV1 and TLR2, along with the involvement of osmotic changes and cellular responses in itch signaling pathways. The interaction between mast cells and sensory receptors is also examined in the context of itch-related disorders.\n","Topic 79: **Topic: Efficacy of Spesolimab in Treating Generalized Pustular Psoriasis (GPP) Flares**\n","\n","Summary: This topic focuses on the clinical evaluation of spesolimab, a monoclonal antibody, for managing flares in generalized pustular psoriasis (GPP). It discusses the impact of different dosing regimens, including 36 mg doses, on the Generalized Pustular Psoriasis Area and Severity Index (GPPGA) and overall flare management, highlighting the efficacy and safety profile of the treatment, specifically addressing the term \"effisayil\" in relation to response outcomes.\n","Topic 80: **Summary: Tapinarof Cream in Topical Treatment of Plaque Psoriasis**\n","\n","This topic explores the investigation of tapinarof cream, a novel topical treatment for plaque psoriasis, highlighting its mechanism of action via aryl hydrocarbon receptor modulation. It discusses recent clinical trials demonstrating the drug's remittive properties and its application in managing psoriatic lesions. The study of its formulation, including polyethylene glycol (PGA) components, further illustrates its efficacy and safety profile for patients.\n","Topic 81: **Title: \"Role of LncRNAs and CircRNAs in Proliferation Regulation through miRNAs in Cell Models: Focus on CHRNA5\"**\n","\n","**Summary:** This study examines the interplay between long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs) in regulating cell proliferation. Specifically, it investigates the expression and functional assays of lncRNA CHRNA5, revealing its impact on cellular growth and proliferation dynamics.\n","Topic 82: **Topic Summary: Biosimilars and Therapeutic Drug Monitoring in Adalimumab Treatment**\n","\n","This topic explores the use of adalimumab (ADA) and its biosimilar (ADBM) in the treatment of autoimmune conditions, focusing on therapeutic drug monitoring (TDM) for optimizing treatment with methotrexate (MTX). It discusses the implications of switching between reference adalimumab (ADL) and its biosimilars, as well as strategies to manage response patterns (RP) in patients.\n","Topic 83: **Summary: Dupilumab-Induced Atopic Dermatitis and Psoriasiform Eczematized Cases in CRS-WNP Patients**\n","\n","This topic explores the occurrence of atopic dermatitis (AD) and psoriasiform skin changes in patients with chronic rhinosinusitis with nasal polyps (CRS-WNP) who have been treated with dupilumab. It highlights specific cases where individuals developed eczematized lesions, emphasizing the complexities of managing skin conditions in the context of dupilumab therapy.\n","Topic 84: **Topic: \"Impact of Allergic Interventions on Asthma Risk in Infants and Children\"**\n","\n","Summary: This topic explores the relationship between food allergies and asthma in infants and children, examining interventions designed to mitigate these risks. It also considers implications for adults with a history of allergies and asthma, highlighting the importance of early intervention and education in reducing long-term health issues related to allergies and asthma.\n","Topic 85: **Topic Summary: \"Investigating the Impact of Hydroxychloroquine (HCQ) on Fetal Development and Maternal Health in Pregnant Women with Generalized Pustular Psoriasis (GPPP) During Pregnancy Trimesters\"**\n","\n","This topic explores the effects of HCQ treatment on maternal and fetal outcomes in pregnant women suffering from generalized pustular psoriasis (GPPP), focusing on potential risks such as fetal maculopathy during different trimesters of pregnancy.\n","Topic 86: **Topic Summary: Efficacy of Bimekizumab in Psoriasis Treatment at Week 16**\n","\n","This topic focuses on the evaluation of bimekizumab (BKZ) for treating psoriasis, examining its efficacy at week 16 compared to a placebo. Key metrics include the Psoriasis Area Severity Index (PASI) scores and response rates (RR) in patients receiving various dosages (mg) over several weeks.\n","Topic 87: **Topic: Managing Co-Infections in PLHIV: HIV, Syphilis, and Immune Health**\n","\n","This topic explores the intersection of HIV (Human Immunodeficiency Virus) and syphilis among people living with HIV (PLHIV), focusing on viral load, CD4 counts, and the importance of antiretroviral therapy in preventing immunodeficiency and managing co-infections. It discusses the impact of syphilis on HIV outcomes and strategies for effective treatment and prevention.\n","Topic 88: **Topic:** Systematic Network Meta-Analysis of Treatments for NMA: Evaluating Efficacy through PASI in 90 Studies\n","\n","**Summary:** This topic involves a systematic network meta-analysis (NMA) comparing various treatments for skin conditions, specifically using the Psoriasis Area and Severity Index (PASI) as a metric of efficacy. The analysis synthesizes data from 90 studies to provide insights into treatment effectiveness and relative performance.\n","Topic 89: **Summary: Inflammasome Activation Mechanisms and Pathways**\n","\n","This topic explores the mechanisms of inflammasome activation, focusing on key components such as NLRP3 and AIM2. It details how these receptors initiate inflammatory responses through the recruitment of ASC (apoptosis-associated speck-like protein) and activation of caspases, leading to the production of pro-inflammatory cytokines like IL-1β. The roles of different domains in inflammasome assembly and function, as well as the implications of calcium-dependent signaling (CQD), are also discussed, highlighting the intricate regulation of immune responses.\n","Topic 90: **Topic: Role of Fatty Acids in Environmental and Physiological Mediators**\n","\n","This topic explores the influence of polyunsaturated fatty acids (PUFAs) and their derivatives, such as alpha-linolenic acid (ALA), on environmental health as recognized by the EPA. It delves into the mechanisms of action of fatty acids as mediators through the FFAR4 receptor, and their impact on lipid metabolism and overall health outcomes, highlighting the importance of dietary fatty acids in both ecological and biological contexts.\n","Topic 91: **Topic Summary: Efficacy of Tralokinumab vs. Dupilumab in Atopic Dermatitis Treatment Over 16 Weeks**\n","\n","This topic explores the impact of tralokinumab and abrocitinib on Atopic Dermatitis (AD) measured by the Eczema Area and Severity Index (EASI) over a 16-week period, comparing dosages in mg with topical corticosteroids (TCS) and highlighting the potential benefits of these treatments against dupilumab.\n","Topic 92: **Topic Summary: Prevalence and Clinical Comparison of Pustular Psoriasis Conditions**\n","\n","This topic explores the prevalence and characteristics of various pustular psoriasis conditions, specifically Generalized Pustular Psoriasis (GPP) and Palmoplantar Pustulosis (PPP), in comparison to Psoriasis Vulgaris (PV). It examines the incidence rates over recent years, including the role of associated comorbidities such as Acrodermatitis Continua of Hallopeau (ACH) and its potential impact on patient outcomes. The discussion may also highlight the differences in clinical presentation and treatment responses among these conditions.\n","Topic 93: **Topic Summary:**\n","\n","\"Exploring the Role of Th9 Cells in Metabolic Dysregulation and Obesity: Insights from NCS and TRF Pathways in 7KC Cluster Differentiation\"\n","\n","This topic investigates the connection between Th9 cell differentiation, metabolic processes in obesity, and the impact of 7-ketocholesterol (7KC) on cellular interactions, focusing on the involvement of neuroendocrine signaling (NCS) and the potential therapeutic role of thymic regulatory factors (TRF).\n","Topic 94: **Topic Summary: Evaluating Ustekinumab Equivalence in Response to ABP 654 and AVT04**\n","\n","This topic focuses on the assessment of therapeutic equivalence between ustekinumab and its biosimilars, ABP 654 and AVT04, specifically examining clinical response rates and safety metrics over a designated period (e.g., CT at week 12). It discusses the significance of p43 as a response biomarker and the implications of these findings for treatment strategies in relevant patient populations.\n","Topic 95: **Title: \"Consensus Document on Interventions: A Summary of IHMS and RIS Perspectives\"**\n","\n","This document outlines a consolidated consensus on intervention strategies within the framework of IHMS (Interventions in Health Management Systems) and RIS (Risk Intervention Strategies). It provides guidance on effective practices, emphasizing the importance of communication in maintaining continuity and integrity in healthcare delivery. Key considerations include the roles of all stakeholders (der und die) in implementing and evaluating interventions.\n","Topic 96: **Topic: Proteomic Analysis of Serum Biomarkers Involving ADAM17, ADAM10, and Gelsolin**\n","\n","This topic focuses on the investigation of serum proteins as biomarkers using proteomic techniques. It specifically examines the roles of metalloproteinases ADAM17 and ADAM10, along with gelsolin, in various biological processes and disease states. The analysis aims to enhance understanding of these proteins in relation to their potential as diagnostic or prognostic indicators in serum samples.\n","Topic 97: **Topic: \"Mitochondrial Metabolism and Its Role in Amino Acid and Metabolite Regulation\"**\n","\n","This topic explores the involvement of mitochondrial DNA (mtDNA) in metabolic pathways related to amino acids and various metabolites, including ibil (bilirubin), GGT (gamma-glutamyl transferase), and organic acids. It emphasizes how mitochondrial function impacts overall metabolic homeostasis and the implications for conditions like metabolic disorders.\n","Topic 98: **Topic Summary: Treatment of Alopecia Areata with Baricitinib: A Focus on AA and AU Variants**\n","\n","This topic discusses the use of Baricitinib, a medication for alopecia areata (AA) and its severe form (AU), exploring its efficacy in hair regrowth and treatment outcomes. The focus includes a study measuring results where 100% of participants exhibit significant improvement, born from robust clinical trials and ongoing research into autoimmune conditions.\n","Topic 99: **Topic: Oral Candidiasis and Antifungal Treatments**\n","\n","This topic focuses on oral candidiasis, a fungal infection caused by Candida species. It explores the role of antifungal medications in treating this condition, including insights into systemic and localized treatments. Additionally, it may cover epidemiology, risk factors, and the impact of fungal infections on health, specifically in terms of IL-17 involvement and the occurrence of oral lichen planus (OLP) in relation to candidiasis.\n","Topic 100: **Title: \"Chemerin and Its Role in Inflammatory Cytokine Networks in Psoriasis\"**\n","\n","**Summary:** This topic explores the relationship between chemerin, an endogenous protein, and its involvement in the inflammatory cytokine milieu associated with psoriasis. It highlights chemerin as a potential biomarker for systemic inflammation, emphasizing its influence on immune cell interactions and the release of pro-inflammatory cytokines. The role of high mobility group box 1 (HMGB1) in modulating these pathways within the context of psoriasis will also be discussed, linking cellular responses to the broader systemic implications of inflammatory processes.\n","Topic 101: **Topic: Development and Implementation of Consensus-Based Quality Guidelines for Clinical Practice Guidelines (CPGs)**\n","\n","Summary: This topic focuses on the creation and implementation of clinical practice guidelines (CPGs) through a Delphi method approach, emphasizing the establishment of consensus indicators that assess core outcomes and overall quality. The process aims to enhance the effectiveness of guidelines in promoting evidence-based practices in healthcare settings.\n","Topic 102: **Topic Summary: Correction of Article in Frontiers in Immunology (2022)**\n","\n","This topic discusses a correction related to an article published in *Frontiers in Immunology*, volume 10, in 2022. The article, identified by DOI 3389/fimmu, addresses key findings in the field of immunology and biology. The correction ensures the accuracy of the research presented in the journal.\n","Topic 103: **Summary: Psychological Stress and Skin Responses: Investigating Coptisine and Neuropeptide Y in IMQ-Induced Mice Models** \n","\n","This topic explores the impact of psychological stress on skin conditions in mice, focusing on the role of coptisine and neuropeptide Y (NPY) in models induced by imiquimod (IMQ) and chronic unpredictable stress (CUS).\n","Topic 104: **Summary/Label: \"Optimizing Intraoperative Decision-Making in Triple-Negative Breast Cancer (TNBC): Evaluating Curve Analyses and Diagnostic Tools (CT, LPA-ML, GIST, AUC, HDI, PPGL, IEE)\"**\n","\n","This topic focuses on enhancing intraoperative strategies for managing Triple-Negative Breast Cancer (TNBC) by analyzing various diagnostic approaches and metrics, including curve analyses, AUC (Area Under the Curve), and the integration of technologies like LPA-ML (Laparoendoscopic Single-Site Surgery with Machine Learning), GIST (Genomic Information Systems), HDI (Human Development Index), PPGL (Primary Paraganglioma), and IEE (Intraoperative Electrical Stimulation).\n","Topic 105: **Topic: Bibliometric Analysis of Research Trends in Exposome Studies**\n","\n","This topic explores the publication landscape of exposome research through bibliometric methods, analyzing citation patterns and identifying core hotspots and emerging trends within the field. The focus is on discerning influential publications and understanding the evolution of exposome-related research over time.\n","Topic 106: **Topic Summary: \"HLA-B27 and Axial Spondyloarthritis: Key Features and Soft Tissue Involvement\"**\n","\n","This topic explores the role of the HLA-B27 antigen in axial spondyloarthritis (AxSpA), specifically focusing on its association with various arthritis features and the implications for soft tissue involvement and diagnostic criteria, including the importance of pads (periarticular anatomical structures) in understanding disease progression and manifestation.\n","\n","GPT-4's advice:\n","- Topics to Merge: [(0, 10), (19, 30), (11, 60), (22, 48), (9, 14), (20, 24), (71, 25), (34, 78), (15, 16), (77, 3)]\n","- Topics to Split: [2, 33, 36, 41]\n","\n","Explanation:\n","- Topics 0 and 10 should be merged because both deal with psoriatic arthritis, and their combination could offer a more comprehensive view of the condition and its variations over time.\n","- Topics 19 and 30 both discuss the mental health implications of psoriasis, so merging them provides a more robust discussion about the psychological effects related to this condition.\n","- Topics 11 and 60 are both centered on cardiovascular risks, which could be more powerfully addressed in a single cohesive topic.\n","- Topics 22 and 48 both explore advancements in dermatological treatments through innovative methods like immune checkpoint inhibitors and telemedicine, offering a broader view of treatment technologies.\n","- Topics 9 and 14 concern TNF inhibitors in various diseases; merging would give a broader perspective on this treatment across different conditions.\n","- Topics 20 and 24 both discuss long-term treatment persistence and effectiveness in the context of biologic drugs for psoriasis, making them suitable for a combined detailed study.\n","- Topics 71 and 25 both address assessments and metrics related to spondyloarthritis, presenting a unified outlook on the evaluation of these conditions.\n","- Topics 34 and 78 focus on specific symptoms (uveitis in eye conditions and itch sensation in skin conditions). Merging these could enhance understanding of local versus systemic symptom management.\n","- Topics 15 and 16 are both about topical treatments for psoriasis, and combining them would provide a clearer, more comprehensive guide to topical therapy options.\n","- Topic 77 discussing GRAPPA's assessment of psoriatic arthritis and topic 3 about the comparative study of different inhibitors might have crossover information useful in a combined report on pharmacological perspectives in psoriatic arthritis management.\n","\n","Split Suggestions:\n","- Topic 2 may be too broad and could be split into distinct parts focusing separately on post-pandemic vaccination strategies and another on long-term infection dynamics.\n","- Topic 33 addresses several complex aspects of IL-17's role, potentially warranting separate discussions for its immunological versus pathogenic contributions.\n","- Topic 36 on mesenchymal stem cell-derived exosomes covers a wide array of therapeutic implications that might be more beneficial when discussed in focused segments, particularly separating regenerative medicine applications from immune modulation.\n","- Topic 41 covers both stigmatization effects and coping mechanisms specifically for Body Dysmorphic Disorder, which could provide more in-depth insights if treated as separate topics focused on psychological impacts and therapeutic interventions respectively.\n","Merged topics [0, 10]\n","Merged topics [19, 30]\n","Merged topics [11, 60]\n","Merged topics [22, 48]\n","Merged topics [9, 14]\n","Merged topics [20, 24]\n","Merged topics [71, 25]\n","Merged topics [34, 78]\n","Merged topics [15, 16]\n","Merged topics [77, 3]\n","Split topic 2 into subtopics\n","Split topic 33 into subtopics\n","Split topic 36 into subtopics\n","Split topic 41 into subtopics\n"]},{"output_type":"stream","name":"stderr","text":["Some weights of BertForSequenceClassification were not initialized from the model checkpoint at sentence-transformers/all-MiniLM-L6-v2 and are newly initialized: ['classifier.bias', 'classifier.weight']\n","You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n"]},{"output_type":"display_data","data":{"text/plain":["<IPython.core.display.HTML object>"],"text/html":["\n","    <div>\n","      \n","      <progress value='3360' max='3360' style='width:300px; height:20px; vertical-align: middle;'></progress>\n","      [3360/3360 04:00, Epoch 10/10]\n","    </div>\n","    <table border=\"1\" class=\"dataframe\">\n","  <thead>\n"," <tr style=\"text-align: left;\">\n","      <th>Epoch</th>\n","      <th>Training Loss</th>\n","      <th>Validation Loss</th>\n","      <th>Accuracy</th>\n","      <th>F1</th>\n","      <th>Precision</th>\n","      <th>Recall</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <td>1</td>\n","      <td>No log</td>\n","      <td>3.532625</td>\n","      <td>0.309883</td>\n","      <td>0.147086</td>\n","      <td>0.096826</td>\n","      <td>0.309883</td>\n","    </tr>\n","    <tr>\n","      <td>2</td>\n","      <td>3.588000</td>\n","      <td>3.168887</td>\n","      <td>0.368509</td>\n","      <td>0.220865</td>\n","      <td>0.190341</td>\n","      <td>0.368509</td>\n","    </tr>\n","    <tr>\n","      <td>3</td>\n","      <td>3.007600</td>\n","      <td>2.863307</td>\n","      <td>0.428811</td>\n","      <td>0.302158</td>\n","      <td>0.287459</td>\n","      <td>0.428811</td>\n","    </tr>\n","    <tr>\n","      <td>4</td>\n","      <td>3.007600</td>\n","      <td>2.712488</td>\n","      <td>0.438861</td>\n","      <td>0.313807</td>\n","      <td>0.262382</td>\n","      <td>0.438861</td>\n","    </tr>\n","    <tr>\n","      <td>5</td>\n","      <td>2.436000</td>\n","      <td>2.581907</td>\n","      <td>0.475712</td>\n","      <td>0.375092</td>\n","      <td>0.341424</td>\n","      <td>0.475712</td>\n","    </tr>\n","    <tr>\n","      <td>6</td>\n","      <td>2.054700</td>\n","      <td>2.562960</td>\n","      <td>0.489112</td>\n","      <td>0.404673</td>\n","      <td>0.374459</td>\n","      <td>0.489112</td>\n","    </tr>\n","    <tr>\n","      <td>7</td>\n","      <td>2.054700</td>\n","      <td>2.495951</td>\n","      <td>0.505863</td>\n","      <td>0.431857</td>\n","      <td>0.396228</td>\n","      <td>0.505863</td>\n","    </tr>\n","    <tr>\n","      <td>8</td>\n","      <td>1.745100</td>\n","      <td>2.492974</td>\n","      <td>0.480737</td>\n","      <td>0.411041</td>\n","      <td>0.384781</td>\n","      <td>0.480737</td>\n","    </tr>\n","    <tr>\n","      <td>9</td>\n","      <td>1.580400</td>\n","      <td>2.471021</td>\n","      <td>0.514238</td>\n","      <td>0.442264</td>\n","      <td>0.415645</td>\n","      <td>0.514238</td>\n","    </tr>\n","    <tr>\n","      <td>10</td>\n","      <td>1.580400</td>\n","      <td>2.460846</td>\n","      <td>0.510888</td>\n","      <td>0.439534</td>\n","      <td>0.414941</td>\n","      <td>0.510888</td>\n","    </tr>\n","  </tbody>\n","</table><p>"]},"metadata":{}},{"output_type":"stream","name":"stdout","text":["Silhouette Score: -0.3921167552471161\n","Calinski-Harabasz Index: 79.21655420185095\n","Davies-Bouldin Index: 13.380802950513342\n","\n","--- Iteration 3 ---\n","\n","Topic 0: **Topical Gel Formulation for Drug Delivery Using Nanoparticles: A Study on Controlled Release Through Skin Penetration**\n","Topic 1: **Topic: \"Axial Spondyloarthritis Treatment and Management in Patients: The Role of TNF Inhibitors\"**\n","\n","This topic explores the relationship between axial spondyloarthritis (axspa) and related conditions such as psoriasis arthritis (PSA) and rheumatoid arthritis (RA), emphasizing the effectiveness of tumor necrosis factor inhibitors (TNFi) in managing symptoms and improving quality of life for patients with spondylitis.\n","Topic 2: **Topic: Post-Pandemic Vaccination Strategies for COVID-19 and SARS-CoV-2**\n","\n","This topic explores the developments and strategies surrounding COVID-19 vaccinations, including the efficacy of various vaccines, ongoing efforts to enhance immunity after infection, and the implications for global health in the aftermath of the pandemic. It examines how SARS-CoV-2 variants affect vaccine effectiveness and the importance of continuous research and public health initiatives to prevent future infections.\n","Topic 3: **Title: \"Gut-Skin Axis: The Role of Microbiota and Probiotics in Dysbiosis and Staphylococcus aureus Mitigation\"**\n","\n","**Summary:** This topic explores the connection between gut microbiota and skin health, emphasizing how dysbiosis in the gut microbiome can influence skin conditions. It examines the role of probiotics in restoring microbial balance and their potential to reduce the impact of pathogenic bacteria such as Staphylococcus aureus on skin health.\n","Topic 4: **Topic: Genetic Polymorphisms in HLA-CW6 and Their Association with Disease Risk**\n","\n","This topic explores the role of genetic polymorphisms, specifically single nucleotide polymorphisms (SNPs) in the HLA-CW6 gene, and their association with various diseases. It discusses how different alleles and genotypes of HLA-CW6 may influence susceptibility or resistance to specific conditions, highlighting the importance of genetic diversity in immunological responses.\n","Topic 5: **Title:** \"Induction of Skin Inflammation in Mice via Imiquimod: IL-Related Cellular Responses\"\n","\n","**Summary:** This topic examines the use of imiquimod (IMQ) to induce inflammatory skin responses in mice, focusing on the resulting changes in immune cell populations and interleukin (IL) signaling pathways. Researchers explore how IMQ mimics inflammatory conditions and the implications for studying skin diseases and immune responses.\n","Topic 6: **Topic Summary: Gene Network Analysis of Differentially Expressed Genes (DEGs) in Ferroptosis: Enrichment and Hub Identification**\n","\n","This topic focuses on the exploration of genes involved in ferroptosis through the analysis of differentially expressed genes (DEGs). It involves network analysis to identify hub genes and assess their expression patterns and functional enrichment, providing insights into the regulatory mechanisms of ferroptosis.\n","Topic 7: **Topic: The Impact of Alexithymia on Psychological Well-Being in Patients with Anxiety and Depression**\n","\n","This topic explores how alexithymia—a condition characterized by difficulty identifying and expressing emotions—affects the psychological health of patients experiencing anxiety and depression. It examines the relationship between alexithymia and various symptoms, the perception of self, and overall life quality, as well as how stress compounds these issues. Understanding this interplay can be crucial for developing effective therapeutic strategies for affected individuals.\n","Topic 8: **Topic: Epidemiology of Psoriasis: Prevalence and Incidence Across Age and Sexual Demographics**\n","\n","This topic explores the prevalence and incidence rates of psoriasis over the years, focusing on how these figures vary by age and sex. It includes statistical data, such as a 95% confidence interval (CI), to assess the risk factors associated with psoriasis in different patient populations.\n","Topic 9: **Topic Summary: Causal Inference in Genetic Epidemiology Using Mendelian Randomization**\n","\n","This topic explores the application of Mendelian Randomization (MR) to assess causal associations between genetic variants and risk factors or outcomes. It emphasizes the use of Inverse Variance Weighting (IVW) methods to analyze the data, providing 95% Confidence Intervals (CI) to evaluate the strength and significance of the associations uncovered. The focus is on understanding how genetic variations can influence risk, aiding in the identification of potential causal relationships in disease epidemiology.\n","Topic 10: **Topic: Cardiovascular Risk in Psoriasis Patients and Its Connection to Coronary Artery Disease and Atherosclerosis**\n","\n","This topic explores the increased cardiovascular risk faced by patients with psoriasis, particularly focusing on the association between psoriasis and the development of coronary artery disease and atherosclerosis. It highlights how inflammatory processes linked to psoriasis may contribute to heart-related health issues.\n","Topic 11: **Topic Summary: \"Induction of Keratinocyte Proliferation and Differentiation in the Epidermis via IL Expression\"**\n","\n","This topic explores how interleukins (IL) influence keratinocyte behavior, focusing on the mechanisms that induce their proliferation and differentiation within the epidermis.\n","Topic 12: **Topic Summary: Quality of Life in Psoriasis Patients**\n","\n","This topic explores the impact of psoriasis on patients' quality of life (QoL), utilizing tools such as the Dermatology Life Quality Index (DLQI) and Psoriasis Area Severity Index (PASI) to evaluate outcomes. It examines clinical practice guidelines (CPGs) aimed at improving patient care and enhancing their overall well-being.\n","Topic 13: **Topic: Topical Treatment for Psoriasis Using Calcipotriol and Betamethasone Cream**\n","\n","Summary: This topic discusses a combination therapy involving calcipotriol and betamethasone foam or cream for the topical treatment of psoriasis. The formulation may include a pad for easy application, enhancing efficacy and patient compliance. Calcipotriol is a vitamin D analog that helps in skin cell regulation, while betamethasone is a potent corticosteroid that reduces inflammation and itching.\n","Topic 14: **Summary: Efficacy of Guselkumab in Psoriasis Patients Over 24 Weeks**\n","\n","This topic explores the efficacy of guselkumab, a treatment for psoriasis, comparing outcomes for patients at 100 weeks and assessing the Psoriasis Area Severity Index (PASI) scores between those receiving guselkumab versus a placebo over a 24-week period.\n","Topic 15: **Topic Summary: \"Expression Levels of miR-125a Variants (3p & 5p) in Serum and Their Role in Cellular Proliferation\"**\n","\n","This topic focuses on the expression levels of the microRNA miR-125a, specifically its 3p and 5p strands, in serum. It explores how these variants may influence cellular proliferation, potentially highlighting their significance as biomarkers or therapeutic targets in various biological processes or diseases.\n","Topic 16: **Summary: Erythroderma Associated with Tattoo-Induced Dermatitis**\n","\n","This topic explores the diagnosis of erythroderma in patients presenting with papules and dermatitis following tattoo application. It examines cutaneous reactions to tattoo ink, focusing on the role of vascular response and the importance of thorough clinical examination to differentiate between allergic reactions and other dermatological conditions.\n","Topic 17: **Topic Summary: Efficacy and Safety of Secukinumab in Psoriasis Treatment**\n","\n","This topic focuses on the safety and efficacy of secukinumab in treating patients with psoriasis, measured by the Psoriasis Area Severity Index (PASI) at various time points (75, 90) over a 300-week period. It highlights patient outcomes and safety assessments during the treatment course.\n","Topic 18: **Topic Summary: Immunotherapy-Related Adverse Events in Cutaneous Cancer Treatment with ICIs**\n","\n","This topic focuses on the use of immune checkpoint inhibitors (ICIs) in the treatment of cutaneous cancers, highlighting the immune-related adverse events (IRAEs) and toxicities associated with this therapy. It explores how these immune-mediated responses can impact patient outcomes and management strategies in immunotherapy.\n","Topic 19: **Topic: \"Combination Therapy of Methotrexate and Metformin: Assessing Oral Treatment Efficacy and Toxicity\"**\n","\n","This topic explores the use of methotrexate (MTX) in combination with metformin in a group setting, focusing on the treatment outcomes and potential toxicity associated with this oral therapy.\n","Topic 20: **Topic Summary: Survival and Persistence of Biologics in Treatment: A Comparative Analysis of Adalimumab and Ustekinumab Discontinuation Rates** \n","\n","This topic explores the survival rates and persistence of biologic treatments, specifically focusing on adalimumab and ustekinumab, examining factors influencing drug discontinuation and long-term efficacy in patient management.\n","Topic 21: **Topic: Antioxidant Properties of Plant Extracts and Honey**\n","\n","This topic explores the beneficial compounds found in plant extracts and honey, focusing on their antioxidant properties. It highlights the role of flavonoids, essential oils, and other extracts in combating oxidative stress and their potential health benefits.\n","Topic 22: **Topic: \"Narrowband UVB Phototherapy for Skin Conditions and Cancer Management\"**\n","\n","This topic explores the use of narrowband ultraviolet B (NB-UVB) light in phototherapy as a treatment for various skin conditions, including psoriasis and eczema, as well as its potential applications in skin cancer management. It examines the effects of UV light, particularly the role of blue and ultraviolet wavelengths in therapeutic contexts and their significance in skin health.\n","Topic 23: **Topic Summary: \"Evaluating Tralokinumab and Dupilumab in Treating Asthma and Allergic Conditions in Children\"**\n","\n","This topic focuses on the comparison of tralokinumab and dupilumab in managing asthma and atopic conditions, such as eczema and food allergies, in pediatric patients. It explores the effectiveness measured by the Eczema Area and Severity Index (EASI) and examines the role of these medications in addressing the complex interplay between asthma and other allergic disorders in children.\n","Topic 24: **Topic: \"Inhibition of JAK-STAT Pathway in Vitiligo Treatment\"**\n","\n","This topic explores the role of JAK (Janus kinase) inhibitors, specifically ruxolitinib, in targeting the JAK-STAT signaling pathway for the topical treatment of vitiligo. It highlights the potential benefits of these inhibitors in restoring skin pigmentation and managing this autoimmune condition.\n","Topic 25: **Topic Summary: Safety and Efficacy of Apremilast in Patients with Active Psoriatic Arthritis: A Real-World Treatment Evaluation Over Several Months**  \n","\n","This topic explores the safety profile and efficacy of apremilast, an oral medication, in the treatment of active psoriatic arthritis (PsA) among patients over a span of several months, with a focus on monitoring adverse events and overall treatment outcomes.\n","Topic 26: **Topic: Treatment of Pediatric Psoriasis with Etanercept**\n","\n","Summary: This topic explores the use of etanercept, a systemic therapy, in treating psoriasis in children. It covers the effectiveness and safety of various treatment options available for managing childhood psoriasis.\n","Topic 27: **Summary: Inflammatory Markers and Cardiovascular Risk in Psoriasis**\n","\n","This topic explores the relationship between various inflammatory markers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), Mean Platelet Volume (MPV), and C-reactive protein (CRP) levels, in individuals with psoriasis. It examines how these biomarkers correlate with lymphocyte levels and cardiovascular disease (CVD) risk, emphasizing the significance of these ratios in understanding systemic inflammation and its potential impact on cardiovascular health in psoriasis patients.\n","Topic 28: **Topic: Vitamin D Deficiency and Serum Levels of 25-Hydroxyvitamin D (25(OH)D)**\n","\n","This topic explores the importance of serum levels of 25-hydroxyvitamin D (25(OH)D) in diagnosing vitamin D deficiency. It discusses the ng/mL measurement of vitamin D, the role of the vitamin D receptor (VDR), and the implications of low levels for overall health.\n","Topic 29: **Topic Summary: Mechanisms of CD8+ T Cells in Synovial Inflammation and Regulation in RA and OA**\n","\n","This topic explores the role of CD8+ T cells in the synovial fluid (SF) of patients with rheumatoid arthritis (RA) and osteoarthritis (OA). It examines their contribution to inflammatory processes, the expression of pro-inflammatory cytokines, and the potential for regulatory functions. The significance of these cells in the pathology of arthritis, including their impact on the progression and severity of the disease, is analyzed, along with the implications for targeted therapeutic approaches.\n","Topic 30: **Topic: Efficacy of Deucravacitinib in Plaque Psoriasis Treatment**\n","\n","This topic explores the clinical evaluation of deucravacitinib, a selective TYK2 inhibitor, compared to placebo and apremilast for the treatment of plaque psoriasis. It focuses on the drug's mechanism as a tyrosine kinase inhibitor administered orally at specific dosages (mg) and its impact on patient outcomes in managing psoriasis symptoms.\n","Topic 31: **Topic: HR-17 Inhibitors in Oncology: Efficacy and Patient Outcomes**\n","\n","This topic explores the role of IL-17 inhibitors (specifically HR-17 and 17i) in treating patients, focusing on their effectiveness, safety profiles, and outcomes related to a patient population. It includes studies on the pharmacodynamics, dosing (100 pYs), and comparisons with other anti-cancer therapies.\n","Topic 32: **Topic Summary: Racial and Ethnic Disparities in Dermatologic Health Care**\n","\n","This topic explores the disparities in dermatologic healthcare experienced by different racial and ethnic groups, highlighting issues related to access, treatment, and outcomes. It examines how race and ethnicity influence healthcare provision, patient experiences, and the effectiveness of treatments, with a particular focus on disparities faced by non-white populations compared to white individuals. Key issues include socioeconomic factors and the need for culturally competent care to address these disparities in dermatology.\n","Topic 33: **Topic Summary: \"Ultrasound Assessment of Enthesitis in Psoriatic Arthritis\"**\n","\n","This topic focuses on the use of ultrasound (US) and MRI for the evaluation of enthesitis — inflammation at the insertion points of tendons (entheses) — specifically in patients with psoriatic arthritis (PsA). It emphasizes the sonographic characteristics of tendon and entheseal involvement, aiding in the diagnosis and monitoring of disease progression.\n","Topic 34: **Topic: Ocular Health Challenges in Patients with Uveitis and Associated Conditions**\n","\n","This topic addresses the complications and symptoms faced by patients suffering from uveitis, particularly its impact on ocular health. It encompasses issues related to dry eyes, blepharitis, and anterior uveitis, emphasizing the importance of retinal care and comprehensive eye management for affected individuals.\n","Topic 35: **Topic: Exploring the Role of EEF2K in PD-L1 Regulation and Immune Response in Melanoma Immunotherapy**\n","\n","This topic investigates how EEF2K (eukaryotic elongation factor 2 kinase) influences PD-L1 expression on tumor cells in melanoma, and its implications for enhancing cancer immunotherapy effectiveness by modulating immune cell responses.\n","Topic 36: **Summary: Efficacy and Safety of Risankizumab in Achieving PASI 90 by Week 52**\n","\n","This topic explores the efficacy and safety of risankizumab, focusing on its ability to achieve a Psoriasis Area and Severity Index (PASI) score of 90 by week 52, highlighting the treatment's effectiveness and overall safety profile at the 16-week mark and beyond.\n","Topic 37: **Topic: Therapeutic Applications of Mesenchymal Stem Cell-Derived Exosomes**  \n","This topic explores the potential of exosomes derived from mesenchymal stem cells (MSCs), particularly human umbilical cord (HUC) MSCs, as therapeutic extracellular vesicles (EVs) in regenerative medicine and treatment strategies.\n","Topic 38: **Topic: Topical Treatment of Plaque Psoriasis with PDE4 Inhibitors**\n","\n","This topic explores the efficacy of roflumilast and orismilast, both phosphodiesterase 4 (PDE4) inhibitors, in clinical trials assessing their potential as topical creams (vehicle formulations) for treating plaque psoriasis. Additional focus may include the investigational compound ME3183 and its comparative effectiveness in similar formulations.\n","Topic 39: **Topic Summary:** \"Genetic Variants in Generalized Pustular Psoriasis: The Role of IL36RN and Associated Mutations\"\n","\n","This topic explores the impact of gene mutations, specifically in the IL36RN gene, on the development of generalized pustular psoriasis (GPP). It includes a focus on specific variants and the contributions of other genes like MPO and ACH, highlighting how these genetic factors influence the manifestation of the disease.\n","Topic 40: **Topic: Efficacy and Safety of JAK Inhibitors in Treating Autoimmune Conditions**\n","\n","This topic explores the use of Janus kinase (JAK) inhibitors, specifically tofacitinib and upadacitinib (upa), in clinical settings. It examines their effectiveness compared to placebo treatments, dosing in milligrams (mg), and associated risks in managing autoimmune diseases. The focus is on the therapeutic benefits and safety profiles of these agents in patient populations.\n","Topic 41: **Topic: Teledermatology and Telemedicine Apps for Enhanced Skin Care Consultations**\n","\n","This topic explores the integration of teledermatology and telemedicine through mobile apps, focusing on their use in providing efficient skin care consultations. It examines how these digital health media facilitate patient access to dermatological care, improve outcomes, and enhance the overall healthcare experience. The discussion may also include statistics, such as usage rates (e.g., \"472\") and their impact on health management.\n","Topic 42: **Topic: IL-17 Cytokine Family and Its Role in Diseases**\n","\n","This topic explores the IL-17 cytokine family, specifically focusing on IL-17A, IL-17F, IL-17RA, and their involvement in immune responses and various diseases. It examines how these cytokines influence cell activation and the production of antibodies, and their implications in autoimmune diseases and inflammatory conditions.\n","Topic 43: **Topic: Mediterranean Diet and its Impact on Weight Management and Metabolic Health through Fasting and Nutritional Intake**\n","\n","This topic explores how adhering to a Mediterranean dietary lifestyle, combined with fasting practices, influences nutritional intake and metabolic responses, particularly in relation to weight management. It also examines the implications for individuals with overweight or obesity (PLWP).\n","Topic 44: **Cost Analysis of Secukinumab for Treatment in Secukinumab Responders** \n","\n","This topic focuses on the cost implications and treatment expenses associated with administering secukinumab to users who respond positively to the therapy. It examines costs per treatment session and the overall financial impact on healthcare systems and patients.\n","Topic 45: **Topic: Management and Challenges of Hidradenitis Suppurativa in Patients with Comorbid Conditions**\n","\n","This topic explores the pain and drainage associated with hidradenitis suppurativa (HS) in patients, including those with Hurley stages of the disease, while also considering the impacts of comorbid conditions like ADHD and fertility concerns.\n","Topic 46: **Topic: \"Metabolic Impacts of Body Weight and Exercise on Visceral Fat and TMAO in Obesity\"**\n","\n","This topic explores the relationship between weight management, exercise, and metabolic health, focusing on the role of Body Mass Index (BMI) and visceral fat in obesity. It also examines how these factors influence TMAO (trimethylamine N-oxide) levels, a compound associated with cardiovascular health.\n","Topic 47: **Topic: \"Hepatic Fibrosis Progression in NAFLD Patients with Fatty Liver and AIH\"**\n","\n","This topic explores the relationship between non-alcoholic fatty liver disease (NAFLD), characterized by steatosis, and the risk of liver fibrosis in patients also affected by autoimmune hepatitis (AIH). It examines the role of transient elastography (TE) as a non-invasive tool for assessing hepatic stiffness and fibrosis in these populations.\n","Topic 48: **Topic: Single-Cell RNA Sequencing of Skin Fibroblasts and CD4+ T Cells**\n","\n","This topic explores the application of single-cell RNA sequencing (scRNA-seq) techniques to analyze the transcriptomic profiles of skin fibroblasts and CD4+ T cells. It aims to uncover cellular heterogeneity and functional dynamics within the skin microenvironment, contributing to our understanding of immune responses and tissue repair mechanisms.\n","Topic 49: **Title: Safety and Efficacy of Tildrakizumab and Mirikizumab in Psoriasis Treatment over 100 Weeks**\n","\n","**Summary:** This study examines the safety and efficacy of tildrakizumab and mirikizumab in patients with psoriasis, utilizing PASI (Psoriasis Area and Severity Index) scores measured at various weeks, with a focus on a dosage of 100 mg. The findings aim to provide insights into the long-term effects of these treatments over a 100-week duration.\n","Topic 50: **Topic: Oral Health and Periodontal Disease**\n","\n","This topic explores the relationship between periodontal health and diseases such as periodontitis, emphasizing the role of dental hygiene, gingival health, and saliva production in maintaining overall oral health. It covers the impact of these factors on the tongue, teeth, and the progression of periodontal disease (PD).\n","Topic 51: **Topic: \"Meta-Analysis of Herbal Medicine: Efficacy of Acitretin in Treating Psoriasis with Focus on Chinese Herbal Influences and Japanese Components\"**\n","\n","This topic explores the integration of traditional Chinese herbal medicine (including specific elements from *Japonicus*) with modern pharmacological treatments such as acitretin, analyzing clinical data (CI 95%) through meta-analytic methods to determine overall effectiveness, particularly in the realm of psoriasis vulgaris (PV) and related conditions.\n","Topic 52: **Topic Title: Enhancing Image Classification with Deep Learning: An AI Application for Improved Accuracy and Performance**\n","\n","**Summary:** This topic discusses the development of an AI application that leverages deep learning models to enhance image classification accuracy. It proposes a novel approach to optimize performance in image recognition tasks, integrating advanced techniques and metrics to measure effectiveness. The focus is on creating a dynamic learning model (DLM) capable of adapting to diverse image datasets, ensuring robust results in real-world applications.\n","Topic 53: **Topic: TNF Inhibitors in Inflammatory Bowel Disease: Balancing Efficacy and Paradoxical Risks**\n","\n","This topic explores the role of TNF (tumor necrosis factor) inhibitors (TNFi) in treating inflammatory bowel disease (IBD), focusing on their mechanism of action in blocking TNF-alpha, their effectiveness in reducing inflammation, and the paradoxical risks associated with their use, including potential adverse effects on patients. The discussion may include statistical analyses indicating a 95% confidence interval for risk assessment.\n","Topic 54: **Topic: Onychomycosis: Understanding Fungal Infections of the Nails**\n","\n","This module covers onychomycosis, a fungal infection affecting the nails, primarily caused by dermatophytes. Key aspects include the identification of affected nails, characteristics of subungual infections, and the symptom of onycholysis. Emphasis is placed on dermatophyte species and their role in nail pathology, including the structure of the nail plate and treatment options.\n","Topic 55: **Topic Summary: Maternal Health Outcomes in Pregnant Women with Axial Spondyloarthritis (AxSpa) and Rheumatoid Arthritis (RA)**\n","\n","This topic focuses on the health outcomes of pregnancies in women diagnosed with axial spondyloarthritis (AxSpa) and rheumatoid arthritis (RA). It examines how these conditions may affect maternal health and fetal development, particularly concerning small for gestational age (SGA) outcomes. The discussion includes factors influencing pregnancy in these populations and the implications for maternal and fetal health during pregnancies.\n","Topic 56: **Topic: Management of Palmoplantar Pustulosis with Apremilast**\n","\n","This topic covers the use of apremilast in treating palmoplantar pustulosis (PPP), a condition characterized by pustules on the palms and soles. It encompasses the assessment of disease severity using the Palmoplantar Pustulosis Area and Severity Index (PPPASI) and examines the efficacy of treatment through various outcomes, including reduction of pustules and overall disease impact on quality of life.\n","Topic 57: **Topic: Early Diagnosis of Arthritis and Dactylitis in Psoriatic Arthritis Using MSUS**\n","\n","This topic explores the role of musculoskeletal ultrasound (MSUS) in the early diagnosis of psoriatic arthritis (PsA), focusing on dactylitis and joint involvement, including the temporomandibular joint (TMJ). It emphasizes the collaboration between dermatologists and rheumatologists in identifying arthritis symptoms and improving patient outcomes.\n","Topic 58: **Topic: Efficacy of Brodalumab in Psoriasis Treatment Over 12 Weeks**\n","\n","This topic discusses the effectiveness of brodalumab treatment over a 12-week period, focusing on achieving a significant reduction in the Psoriasis Area Severity Index (PASI) score. Specifically, it examines the absolute PASI reduction of 210 patients, highlighting the real-world outcomes of the treatment.\n","Topic 59: **Title: \"Bullous Pemphigoid and the Role of Autoantibodies: Implications of p200 and Mucosal Laminin\"**\n","\n","**Summary:** This topic explores bullous pemphigoid (BP), a skin disease characterized by blistering, and its association with specific autoantibodies against p200 and laminin. The focus is on the understanding of key protein markers such as bibp and lm 332, emphasizing their significance in both cutaneous and mucosal manifestations of the disease. The relationship between these autoantibodies and the pathophysiology of BP provides insights into potential diagnostic and therapeutic approaches.\n","Topic 60: **Topic: Advanced Treatments for Nail Disorders**\n","\n","This topic explores innovative therapeutic approaches for nail conditions, including the use of laser technologies such as fractional pulsed dye laser (PDL) and intralesional therapies. It highlights the application of topical treatments and platelet-rich plasma (PRP) in enhancing nail health and appearance, addressing issues like fungal infections, nail dystrophy, and other related disorders. The integration of these methods, including NAPSI (Nail Psoriasis Severity Index) assessments, underscores a multifaceted approach to effective nail treatment.\n","Topic 61: **Topic Summary: The Role of Dimethyl Fumarate in Multiple Sclerosis through NRF2 Activation and KEAP1 Interaction**\n","\n","This topic explores the effects of dimethyl fumarate (DMF), specifically its ester form, on multiple sclerosis (MS). DMF activates the NRF2 pathway, which helps protect cells by modulating oxidative stress and inflammation. The interaction with KEAP1, a negative regulator of NRF2, plays a pivotal role in the therapeutic effects of DMF alongside mycophenolate mofetil (MMF) in MS treatment. The discussion encapsulates the biochemical mechanisms and potential benefits of fumarates in managing the disease.\n","Topic 62: **Topic: Impact of Sleep Disturbances on Quality of Life in Patients with Pruritus and Restless Legs Syndrome (RLS)**\n","\n","This topic explores how sleep quality, as measured by the Pittsburgh Sleep Quality Index (PSQI), is affected by pruritus (itching) and restless legs syndrome (RLS). It examines the interplay between these conditions, the disturbances they cause in patients' sleep, and the subsequent impact on their overall quality of life.\n","Topic 63: **Topic: Efficacy and Safety of Bimekizumab (BKZ) at Week 16 in Psoriasis Treatment: A Comparison with Placebo and PASI Scores**\n","\n","This topic covers the clinical evaluation of bimekizumab (BKZ) at 100 mg dosage over 16 weeks, focusing on its efficacy and safety compared to a placebo, as assessed through PASI (Psoriasis Area and Severity Index) scores.\n","Topic 64: **Topic: Role of CD1a+ Resident Memory T Cells in Skin Immunity**\n","\n","This topic explores the function and characteristics of CD1a+ resident memory T cells (Trm) in the skin. It delves into their role in immune responses, the importance of integrins (including beta8) in their migration and retention, and the comparison between resident memory (RM) and circulating memory (RMs) T cells. The discussion highlights how these cells contribute to local immunity and long-term skin defense mechanisms.\n","Topic 65: **Topic Summary: Efficacy of Spesolimab in Managing Generalized Pustular Psoriasis (GPP) Flares**\n","\n","This topic explores the use of spesolimab, an investigational treatment, in controlling 36 flares of generalized pustular psoriasis (GPP). It highlights the assessment of efficacy through the GPPGA (Generalized Pustular Psoriasis Physician Global Assessment) scale and discusses dosing strategies for optimal management of GPP flares in clinical settings, referencing the treatment outcomes in the Effisayil trials.\n","Topic 66: **Topic Summary: Cutaneous Lymphoma and PML: Examining the Intersection of CTCL Cases, MTX Treatment, and JCV Reactivation**\n","\n","This topic explores the relationship between primary cutaneous T-cell lymphomas (CTCL), particularly mycosis fungoides (MF), and the potential risk of progressive multifocal leukoencephalopathy (PML) associated with methotrexate (MTX) treatment, emphasizing the role of the JC virus (JCV) in lymphoproliferative disorders (LPD).\n","Topic 67: **Topic: Advanced Statistical Techniques in Disease Activity Assessment and Remission Monitoring**\n","\n","This topic encompasses the use of advanced statistical methods, such as Dapsa, MDA, LDA, PSA, D2T, and vLDA, to evaluate disease activity and remission (REM) in clinical settings. It focuses on how these methodologies improve the analysis of disease progression and treatment efficacy, aiding healthcare professionals in decision-making and patient management.\n","Topic 68: **Topic Summary: Annual Research Meeting on Psoriatic Arthritis: Grappa Group Assessment and Trainee Involvement** \n","\n","This topic involves an annual meeting organized by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), focusing on the latest research and assessments related to psoriatic arthritis. The session emphasizes the role of trainees in advancing knowledge and collaboration within the field.\n","Topic 69: **Topic: \"Understanding Latent Tuberculosis Infection (LTBI) and Diagnostic Tests\"**\n","\n","This topic explores latent tuberculosis (TB) infection, characterized by the presence of Mycobacterium tuberculosis without active disease symptoms. It covers diagnostic methods such as the Tuberculin Skin Test (TST) and Interferon Gamma Release Assays (IGRA) like QuantiFERON. Discussion points include the risk of reactivation to active TB, implications for public health, and management strategies for individuals with LTBI.\n","Topic 70: **Topic Summary: Predictive Modeling in Machine Learning with PSA**\n","\n","This topic explores the development and evaluation of predictive models using machine learning techniques, particularly focusing on Prostate-Specific Antigen (PSA) data. It involves analyzing clusters of variables to enhance the accuracy of predictions, using statistical curves to assess model performance and reliability. The discussion includes different modeling approaches, the significance of variable selection, and strategies to optimize prediction outcomes.\n","Topic 71: **Title: \"The Role of Capsaicin in Modulating Oxidative Stress through Antioxidant and Redox Mechanisms\"**\n","\n","**Summary:** This topic explores how capsaicin, the active component in chili peppers, influences oxidative stress by enhancing antioxidant defenses and modulating redox states. It examines the interaction between ozone, oxygen, and reactive oxygen species (ROS), highlighting the potential of capsaicin to mitigate oxidant damage and its implications for health.\n","Topic 72: **\"Efficacy of Secukinumab in Treating Psoriatic Arthritis: A Study on Dosage Retention Rates and Dactylitis Outcomes\"**\n","\n","This topic explores the impact of different dosages of secukinumab (300 mg and 150 mg) compared to placebo in managing psoriatic arthritis (PsA), focusing on retention rates and the prevalence of dactylitis.\n","Topic 73: **Topic Summary: Ixekizumab Safety and Efficacy Profile in Severe Conditions: A Week-Long EAIR Review from KL World**\n","\n","This topic discusses the safety and efficacy profile of ixekizumab, particularly in severe cases, highlighting findings from a week-long review at the EAIR conference in Kuala Lumpur (KL).\n","Topic 74: **Topic: Mechanisms of Itch Sensation in Sensory Neurons**\n","\n","**Summary:** This topic explores the molecular and cellular mechanisms underlying pruritus (itch), focusing on the roles of sensory neurons and key proteins such as TRPV1 and TRPV3. It examines the interaction between mast cells and sensory neurons, the involvement of Toll-like receptor 2 (TLR2) in inflammatory responses, and the influence of osmotic factors that can modulate itch signaling pathways.\n","Topic 75: **\"The Impact of Acitretin on Serum Levels of Irisin, Resistin, and Galectin-3 in Relation to Glucose and Insulin Concentrations\"**\n","\n","This topic investigates the effects of acitretin on serum concentrations of irisin, resistin, and galectin-3, and their subsequent influence on glucose and insulin levels.\n","Topic 76: **Topic Summary: Immunogenicity and Switching in Adalimumab Therapy**\n","\n","This topic covers the immunogenicity of adalimumab (ADA) and its biosimilar adalimumab-adbm (ADL) in the context of therapeutic drug monitoring (TDM) and reference product (RP) switching. It explores the implications of switching between the reference product (UST) and biosimilar, focusing on clinical outcomes, safety, and effectiveness in various patient populations. Additionally, the discussion includes strategies for managing potential immunogenic responses during therapy transitions.\n","Topic 77: **Topic: \"The Role of Lipid Barrier in Skin Hydration and Function: TEWL and Ceramide's Impact on the Stratum Corneum\"**\n","\n","This topic explores how the lipid barrier, particularly ceramides, affects transepidermal water loss (TEWL), overall hydration, and the protective functions of the stratum corneum (SC) in maintaining skin health.\n","Topic 78: **Topic Summary: Generalized Pustular Psoriasis (GPP) with Flare-Induced Hemodynamic Instability**\n","\n","This topic focuses on Generalized Pustular Psoriasis (GPP), a rare and severe skin condition characterized by widespread pustules and frequent flares. The discussion includes the potential for hemodynamic instability during flare episodes, which can complicate the clinical management of affected individuals. Emphasis is placed on the identification of symptoms, triggers for flares, and the importance of monitoring patients for instability during acute presentations.\n","Topic 79: **Topic Summary: Immune Modulation by Regulatory T Cells and gammadelta T Cells in Mice**\n","\n","This topic explores the interactions between regulatory T cells (Tregs), gammadelta T cells, and myeloid-derived suppressor cells (MDSCs) in mice, focusing on the role of TNFR2 and CD96 in regulating immune responses. The interplay between these cell types, influenced by cytokines like IL-10, is crucial for understanding immune tolerance and potential therapeutic approaches in diseases.\n","Topic 80: **Title: Comparative Analysis of IL-23 Inhibitors in Psoriasis Treatment**\n","\n","**Summary: This topic explores the pharmacological profiles and mechanisms of action of various IL-23 inhibitors, including guselkumab, tildrakizumab, risankizumab, and ustekinumab. It focuses on their impact on the p19 subunit and epitope specificity, as well as their efficacy and safety in managing psoriasis. Key comparisons highlight differences in binding affinities and clinical outcomes among these biologics.**\n","Topic 81: **Topic: Integrating Advanced Imaging Techniques in Skin Cancer Diagnosis**\n","\n","This topic explores the use of various advanced imaging modalities, including dermoscopy, reflectance confocal microscopy (RCM), and ultrasound, in the assessment and diagnosis of skin lesions. It focuses on the role of dermoscopic features, such as vascular patterns and lesion thickness, and discusses how these techniques complement traditional incisional biopsy for more accurate diagnosis in dermatology.\n","Topic 82: **Topic: Evaluation of Hydroxychloroquine (HCQ) Safety in Pregnant Women with Pustular Psoriasis and Associated Risks During Pregnancy**\n","\n","This topic addresses the use of hydroxychloroquine (HCQ) in pregnant women diagnosed with generalized pustular psoriasis (GPP) and its implications for maternal health, fetal development, and potential risks such as maculopathy during various trimesters of pregnancy.\n","Topic 83: **Topic: Managing Co-Infections in PLHIV: HIV, Syphilis, and Immune Health**\n","\n","This topic addresses the complexities of managing HIV (Human Immunodeficiency Virus) and associated co-infections like syphilis in people living with HIV (PLHIV). It emphasizes the importance of monitoring viral load and CD4 counts to assess immune function and the efficacy of antiretroviral therapies. Understanding the interplay between these infections and the immune system is crucial for effective treatment and maintaining health in individuals with immunodeficiency.\n","Topic 84: **Topic Summary: Cardiovascular Health Risks Associated with Comorbidities and PSA Levels in VTE Prevalence**\n","\n","This topic explores the relationship between prostate-specific antigen (PSA) levels and cardiovascular (CV) health, focusing on how comorbidities influence the risk of venous thromboembolism (VTE). It also examines the prevalence of these conditions, the role of autonomic dysfunction, and the significance of confidence intervals (CI) at 95% in assessing risk factors.\n","Topic 85: **Topic Summary: Tapinarof Cream in Topical Psoriasis Treatment**\n","\n","This topic explores the use of tapinarof, a novel topical cream, in the management of plaque psoriasis. It focuses on its mechanism of action involving the aryl hydrocarbon receptor (AhR) and its effectiveness in clinical trials. The formulation includes polyglutamic acid (PGA) and hydrocarbon components, highlighting its remittive properties for managing psoriasis symptoms.\n","Topic 86: **Topic: Mechanisms and Activation Pathways of Inflammasomes in Inflammatory Responses**\n","\n","This topic explores the roles of various inflammasomes, particularly NLRP3 and AIM2, in immune responses. It details the activation processes involving ASC (apoptosis-associated speck-like protein containing a CARD), the formation of specks, and the pivotal role of caspase-1 in mediating the cleavage and secretion of pro-inflammatory cytokines such as IL-1β. Additionally, it discusses the different protein domains involved in inflammasome signaling and how these pathways contribute to disease processes.\n","Topic 87: **Topic: Paradoxical Reactions to TNF-alpha Inhibitors in Tumor Necrosis Cases**\n","\n","This topic explores the paradoxical effects observed with TNF-alpha inhibitors, such as infliximab and adalimumab. While these medications are designed to reduce inflammation and treat autoimmune conditions, they can unexpectedly trigger tumor necrosis and other inflammatory reactions in some patients. The discussion focuses on the mechanisms behind these paradoxical reactions, potential risk factors, and implications for treatment strategies.\n","Topic 88: **Summary: Systematic Review of Treatments for NMA/NMAS in Psoriasis: A Network Meta-Analysis and PASI 90 Comparisons**\n","\n","This topic involves a systematic review and network meta-analysis (NMA/NMAS) comparing various treatment options for psoriasis, focusing on achieving a Psoriasis Area Severity Index (PASI) score of 90. The study evaluates the effectiveness of different therapies through head-to-head comparisons across multiple clinical studies, providing insights into the most effective treatments within the established network of research.\n","Topic 89: **Summary: Dupilumab for Atopic Dermatitis and CRS-WNP: Psoriasiform Cases and Adverse Events** \n","\n","This topic explores the use of dupilumab, a monoclonal antibody, in treating atopic dermatitis (AD) and its effectiveness in cases of chronic rhinosinusitis with nasal polyps (CRS-WNP) that exhibit psoriasiform features. It addresses the development of these cases and reports on associated adverse events (AEs) in patients with atopic dermatitis and CRS-WNP.\n","Topic 90: **Topic Summary: Delays in Diagnosis of Psoriatic Arthritis by Rheumatologists** \n","\n","This topic explores the challenges rheumatologists face in diagnosing psoriatic arthritis (PsA) and the associated delays in treatment. It examines the clinical indicators (sus) that can lead to misdiagnosis or prolonged diagnosis times, highlighting the importance of timely and accurate evaluation for improved patient outcomes.\n","Topic 91: **Topic: Proteomic Analysis of ADAM Proteins as Biomarkers**\n","\n","This topic explores the role of various proteins, particularly ADAM10 and ADAM17, as potential biomarkers in proteomics. It discusses the use of gels and DEPs (Differentially Expressed Proteins) for analyzing these proteins and their implications in disease mechanisms and diagnostics.\n","Topic 92: **Topic: Regulatory Roles of Long and Circular RNAs in CHRNA5 Expression in HaCat Cells**\n","\n","This topic explores the involvement of long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs), specifically circ_0024028 and circ_0060531, in modulating the expression of the CHRNA5 gene in HaCat cells through various microRNA (miR) interactions. The study investigates the 5' UTR regulatory mechanisms and their implications for cellular functions.\n","Topic 93: **Topic: CRISPR-Enhanced Genetic Interventions in Cardiovascular and Skin Disorders**\n","\n","This topic explores the applications of CRISPR technology, specifically targeting genes such as PCSK9 (involved in cholesterol regulation), TRPM4 (related to ion channel function), FLG (linked to skin barrier function), ZNF750 (associated with keratinocyte differentiation), and MVD (related to cholesterol synthesis). It also examines the role of CREB (a protein influencing gene expression) and highlights research studies like Hailey and 291 that may demonstrate the implications of gene editing with Cas9 in addressing disorders related to metabolism and skin health.\n","Topic 94: **Topic Summary: Evaluating Ustekinumab Biosimilars in Psoriasis Treatment**\n","\n","This discussion focuses on the clinical equivalence and response of biosimilars like AVT-04 to ustekinumab (brand name Stelara) in the treatment of psoriasis, particularly through assessments involving parameters like RP (response profile), CT (clinical trials), and specific biomarkers (e.g., P43, 654). Comparisons are often made at various time points, such as week 12 or week 24, to determine the effectiveness and safety of these treatments.\n","Topic 95: **Topic Summary: Impact of Fatty Acid Mediators on Health and Metabolism**\n","\n","This topic explores the role of fatty acids, particularly polyunsaturated fatty acids (PUFAs), in human health. It emphasizes the significance of specific acids such as alpha-linolenic acid (ALA) and their interactions with mediators like FFAR4 (Free Fatty Acid Receptor 4). Additionally, it discusses environmental and regulatory aspects, including the U.S. Environmental Protection Agency (EPA), concerning the lipid composition and potential health effects of different fatty acid profiles.\n","Topic 96: **Topic Summary: IL-12p40 and OXMIF in Cardiac Cytokine Signaling: Role of LPS and MIF in 1RACP Nucleic Pathways**\n","\n","This topic explores the interaction between IL-12p40 and OXMIF in the context of cardiac inflammation, focusing on how lipopolysaccharides (LPS) influence macrophage migration inhibitory factor (MIF) signaling. It examines the signaling pathways mediated by these cytokines and their potential impact on nucleic acid responses in cardiac tissues, particularly in the setting of immune activation and inflammation.\n","Topic 97: **Topic: Enhancing Pharmacist Adherence through Topical Compounding and Patient Counselling**\n","\n","This topic explores the role of pharmacists in improving patient adherence to medication through effective counselling and the compounding of topical formulations. It examines the legal and regulatory frameworks governing these practices, the performance metrics of pharmacists, and the available recourse for addressing adherence challenges in patients. Additionally, it discusses the aggregate data on adherence and its implications for public health.\n","Topic 98: **Topic: Selectivity and Function of Tyk2 Kinase Domain in Relation to SGK1 and JAK Pseudokinase Interactions**\n","\n","This topic explores the selectivity and structural dynamics of the Tyk2 kinase domain, particularly its JH2 (Janus Homology 2) region, in relation to SGK1 (Serum/Glucocorticoid-regulated Kinase 1) and JAK (Janus Kinase) pseudokinase interactions. The focus is on how these molecular interactions influence kinase activity and regulatory mechanisms, especially in the context of signaling pathways mediated by tyrosine kinases. Key insights may pertain to the implications of these interactions for drug development and therapeutic targeting.\n","Topic 99: **Topic Summary: Metabolomic Biomarkers in Mitochondrial DNA and Metabolism**\n","\n","This topic explores the role of metabolites and amino acids in mitochondrial function, focusing on how changes in metabolic pathways and mitochondrial DNA (mtDNA) can influence the production of organic acids and other metabolites. It examines the identification of metabolic biomarkers linked to mitochondrial health and dysfunction, particularly in the context of various diseases. The implications of these biomarkers in understanding metabolic conditions and their potential as indicators for clinical diagnostics are highlighted.\n","Topic 100: **Topic: The Role of Th9 Cells in Metabolic Dysregulation and Obesity**\n","\n","This topic explores how TH9 cells contribute to metabolic disorders associated with obesity, focusing on their differentiation, function within metabolic clusters, and interactions with various cell types. It examines the implications of TRF (transcriptional regulatory factors) in cell metabolism and the broader metabolic landscape in the context of obesity-related pathologies.\n","Topic 101: **Topic Summary: Alopecia Areata in Offspring: Genetics and Prevalence**\n","\n","This topic focuses on the genetic factors influencing the incidence of alopecia areata (AA) in offspring, analyzing prevalence rates such as 0.0005% (or 1 in 200,000) for individuals with a family history of AA, and examining statistical data showing that about 95% of individuals with a parent affected by alopecia areata may also experience hair loss. The discussion includes implications for hereditary patterns and inherited traits affecting hair health.\n","Topic 102: **Topic Summary: \"Generalized Pustular Psoriasis (GPP) vs. Palmoplantar Pustulosis (PPP): Inpatient Prevalence and Management\"**\n","\n","This topic explores the prevalence and clinical characteristics of generalized pustular psoriasis (GPP) compared to palmoplantar pustulosis (PPP), emphasizing inpatient healthcare considerations. It discusses the implications of these conditions, including pathophysiology (pustular lesions), assessment of severity, and therapeutic approaches, with a focus on adult care and potential challenges in treatment.\n","Topic 103: **Topic: Policy and Clinical Implications of Switching from Originator Biologics to Biosimilars in Patients Receiving Infliximab and Etanercept**\n","\n","This topic explores the emergence of biosimilars in the treatment landscape of biologics, focusing on the implications of switching from originator drugs like infliximab and etanercept to their biosimilars. It examines policy considerations, clinical outcomes, and patient cohort experiences, emphasizing safety and efficacy in the context of treatment changes.\n","Topic 104: **Topic: Oral Candidiasis and Antifungal Treatments**\n","\n","This topic explores oral candidiasis, a fungal infection caused by Candida species, particularly relevant in patients with immunological issues (IL-17 involvement). It discusses the pathology, symptoms, and antifungal treatment options for this condition, including its link to oral lichen planus (OLP) and strategies to manage infections effectively.\n","Topic 105: **Topic Summary: The Impact of Cannabis on Anxiety and Depression in Arthritis Patients**\n","\n","This topic explores how cannabis use affects anxiety and depression levels among users suffering from arthritis. It includes assessments of psychological symptoms through PSA (Patient Self-Assessment) scores, along with discussions on activity levels and overall disease management.\n","Topic 106: **Topic: Correction Notice for Article 3389 in Frontiers in Immunology (FIMM 2022)**\n","\n","This topic pertains to a correction issued for a specific article published in the journal Frontiers in Immunology (FIMM) in 2022. The correction is associated with the article DOI (Digital Object Identifier) provided, ensuring accuracy and integrity in scientific communication within the field of biology and immunology.\n","Topic 107: **Topic Summary: Autophagy and Angiogenesis in EVs: The Role of 17a, 17f, and Fenofibrate in HPSE Modulation**\n","\n","This topic explores the interplay between autophagy and angiogenesis in cells, focusing on the roles of extracellular vesicles (EVs) and specific compounds such as 17a, 17f, and fenofibrate. It examines how these elements influence heparanase (HPSE) activity, potentially affecting cellular functions and therapeutic strategies.\n","Topic 108: ### Summary: \"Intraoperative Assessment of CT and LPAML Curves in Triple-Negative Breast Cancer (TNBC) Using GIST, AUC, and HDI Techniques for PPGL and IEE Monitoring\"\n","\n","This topic focuses on the utilization of CT and LPAML curves for intraoperative assessments in triple-negative breast cancer (TNBC) cases. It explores how GIST (Generalized Information Score Technique), AUC (Area Under Curve), and HDI (High-Dimensional Inference) can enhance the monitoring of perioperative aspects related to PPGL (Pheochromocytoma and Paraganglioma) and IEE (Intraoperative Endocrine Evaluation).\n","Topic 109: **Topic Summary: Skin Sphingolipid Metabolism in Lesional Conditions via S1P Pathways**\n","\n","This topic explores the role of sphingosine 1-phosphate (S1P) and sphingolipids, particularly in skin disorders. It examines the metabolism involving sphingosine and sphingosine-1-phosphate (S1P), focusing on the enzyme sphingosine phosphate lyase 1 (SGPL1) and its influence on lesional skin manifestations. The interplay between S1P receptors (S1PR) and the regulation of sphingolipid levels (including their phosphates) within cutaneous tissues is also discussed.\n","Topic 110: **Topic Summary: \"Analyzing Exposome Research through Bibliometrics: Trends, Hotspots, and Citation Patterns\"**\n","\n","This topic focuses on the application of bibliometric methods to examine the landscape of exposome research. It covers the analysis of publications, citation patterns, and keyword frequency to identify emerging trends and hotspots within the field. By leveraging data on the most-cited works, the study aims to highlight influential contributions and guide future research directions in the exposome domain.\n","Topic 111: **Topic Summary: Psychobiological Interactions of Stress and Skin Health in Mice**\n","\n","This topic explores the relationship between stress and skin diseases in mice, focusing on psychological stressors and their impact on neuropeptide Y (NPY) levels and other mediators like glucocorticoids (GR). The role of immune modulation (IMQ) in stress responses and how chronic stress (CRS) affects skin conditions is examined.\n","\n","GPT-4's advice:\n","- Topics to Merge: [(20, 30), (9, 70), (59, 60)]\n","- Topics to Split: [53, 62]\n","\n","Reasoning for Merging:\n","1. Topics 20 and 30 both focus on the efficacy and persistence of biologic treatments for psoriasis, making them suitable for merging to give a comprehensive view of treatment strategies and their long-term impacts.\n","2. Topics 9 and 70 both engage in the use of statistical modeling to understand genetic and biomarker data for causal inference, suggesting a merge could consolidate methods and findings related to genetic epidemiology.\n","3. Topics 59 and 60 both deal with detailed aspects of dermatological conditions, focusing on specific symptomatic manifestations, which could be combined for a broader discussion on skin disorders and treatments.\n","\n","Reasoning for Splitting:\n","1. Topic 53 covers a broad spectrum of TNF inhibitors' efficacy as well as risks, which might be more comprehensibly addressed by separating efficacy-focused discussions from those centered on paradoxical risks and adverse effects.\n","2. Topic 62 combines the effects of pruritus and restless legs syndrome on sleep quality, where each condition might deserve separate detailed exploration to avoid diluting the specific impacts and interactions each has with sleep disturbances.\n","Merged topics [20, 30]\n","Merged topics [9, 70]\n","Merged topics [59, 60]\n","Split topic 53 into subtopics\n","Split topic 62 into subtopics\n"]},{"output_type":"stream","name":"stderr","text":["Some weights of BertForSequenceClassification were not initialized from the model checkpoint at sentence-transformers/all-MiniLM-L6-v2 and are newly initialized: ['classifier.bias', 'classifier.weight']\n","You should probably TRAIN this model on a down-stream task to be able to use it for predictions and inference.\n"]},{"output_type":"display_data","data":{"text/plain":["<IPython.core.display.HTML object>"],"text/html":["\n","    <div>\n","      \n","      <progress value='3360' max='3360' style='width:300px; height:20px; vertical-align: middle;'></progress>\n","      [3360/3360 04:03, Epoch 10/10]\n","    </div>\n","    <table border=\"1\" class=\"dataframe\">\n","  <thead>\n"," <tr style=\"text-align: left;\">\n","      <th>Epoch</th>\n","      <th>Training Loss</th>\n","      <th>Validation Loss</th>\n","      <th>Accuracy</th>\n","      <th>F1</th>\n","      <th>Precision</th>\n","      <th>Recall</th>\n","    </tr>\n","  </thead>\n","  <tbody>\n","    <tr>\n","      <td>1</td>\n","      <td>No log</td>\n","      <td>3.631723</td>\n","      <td>0.323283</td>\n","      <td>0.157959</td>\n","      <td>0.104512</td>\n","      <td>0.323283</td>\n","    </tr>\n","    <tr>\n","      <td>2</td>\n","      <td>3.663600</td>\n","      <td>3.420821</td>\n","      <td>0.326633</td>\n","      <td>0.164121</td>\n","      <td>0.117657</td>\n","      <td>0.326633</td>\n","    </tr>\n","    <tr>\n","      <td>3</td>\n","      <td>3.205800</td>\n","      <td>3.131588</td>\n","      <td>0.398660</td>\n","      <td>0.249518</td>\n","      <td>0.188103</td>\n","      <td>0.398660</td>\n","    </tr>\n","    <tr>\n","      <td>4</td>\n","      <td>3.205800</td>\n","      <td>2.964231</td>\n","      <td>0.430486</td>\n","      <td>0.297276</td>\n","      <td>0.255486</td>\n","      <td>0.430486</td>\n","    </tr>\n","    <tr>\n","      <td>5</td>\n","      <td>2.660800</td>\n","      <td>2.834151</td>\n","      <td>0.453936</td>\n","      <td>0.343832</td>\n","      <td>0.297971</td>\n","      <td>0.453936</td>\n","    </tr>\n","    <tr>\n","      <td>6</td>\n","      <td>2.275600</td>\n","      <td>2.799483</td>\n","      <td>0.462312</td>\n","      <td>0.369818</td>\n","      <td>0.350756</td>\n","      <td>0.462312</td>\n","    </tr>\n","    <tr>\n","      <td>7</td>\n","      <td>2.275600</td>\n","      <td>2.733124</td>\n","      <td>0.487437</td>\n","      <td>0.407850</td>\n","      <td>0.386611</td>\n","      <td>0.487437</td>\n","    </tr>\n","    <tr>\n","      <td>8</td>\n","      <td>1.980000</td>\n","      <td>2.740897</td>\n","      <td>0.480737</td>\n","      <td>0.415839</td>\n","      <td>0.393418</td>\n","      <td>0.480737</td>\n","    </tr>\n","    <tr>\n","      <td>9</td>\n","      <td>1.789200</td>\n","      <td>2.714995</td>\n","      <td>0.500838</td>\n","      <td>0.429964</td>\n","      <td>0.392812</td>\n","      <td>0.500838</td>\n","    </tr>\n","    <tr>\n","      <td>10</td>\n","      <td>1.789200</td>\n","      <td>2.709510</td>\n","      <td>0.485762</td>\n","      <td>0.420720</td>\n","      <td>0.388035</td>\n","      <td>0.485762</td>\n","    </tr>\n","  </tbody>\n","</table><p>"]},"metadata":{}},{"output_type":"stream","name":"stdout","text":["Silhouette Score: -0.3573615849018097\n","Calinski-Harabasz Index: 99.1125635992664\n","Davies-Bouldin Index: 11.901558072334218\n"]}]},{"cell_type":"code","source":["# ============================== #\n","# Section 6: Select Optimal Model with GPT-4\n","# ============================== #\n","\n","# Prepare a summary of metrics and topics for GPT-4\n","evaluation_summary = \"Here are the evaluation metrics for each iteration:\\n\"\n","\n","for metric in metrics:\n","    iteration = metric['iteration']\n","    evaluation_summary += f\"\\nIteration {iteration}:\\n\"\n","    evaluation_summary += f\"- Silhouette Score: {metric['silhouette_score']}\\n\"\n","    evaluation_summary += f\"- Calinski-Harabasz Index: {metric['calinski_harabasz_index']}\\n\"\n","    evaluation_summary += f\"- Davies-Bouldin Index: {metric['davies_bouldin_index']}\\n\"\n","    # Add topic summaries\n","    evaluation_summary += \"Topic Summaries:\\n\"\n","    topic_summaries = topic_summaries_list[iteration - 1]\n","    for topic_id, summary in topic_summaries.items():\n","        evaluation_summary += f\"Topic {topic_id}: {summary}\\n\"\n","\n","# Create prompt for GPT-4 to select the best model\n","prompt = evaluation_summary + \"\"\"\n","Based on the evaluation metrics and the topic summaries for three iteration, please help identify the optimal iteration for topic modeling. Explain your reasoning and indicate which iteration (1, 2, or 3) provides the best balance between coherence and distinctiveness of topics.\n","\n","Your response should be in the following format:\n","\n","- Optimal Iteration: [Iteration Number]\n","- Reasoning: [Your explanation]\n","\"\"\"\n","\n","# Call GPT-4 to get the final advice\n","response = completion(\n","    model=\"gpt-4\",\n","    messages=[{\"content\": prompt, \"role\": \"user\"}]\n",")\n","advice = response['choices'][0]['message']['content'].strip()\n","print(\"\\nGPT-4's advice:\")\n","print(advice)\n","\n","# Parse GPT-4's recommendation\n","optimal_iteration = None\n","optimal_match = re.search(r'Optimal Iteration:\\s*(\\d+)', advice)\n","if optimal_match:\n","    optimal_iteration = int(optimal_match.group(1))\n","    print(f\"Selected optimal iteration: {optimal_iteration}\")\n","else:\n","    print(\"Could not determine optimal iteration from GPT-4's response.\")\n","\n","# Retrieve the optimal model\n","if optimal_iteration:\n","    optimal_model_data = next((item for item in models if item['iteration'] == optimal_iteration), None)\n","    if optimal_model_data:\n","        final_topic_model = optimal_model_data['topic_model']\n","        final_embeddings = optimal_model_data['embeddings']\n","        final_topics = optimal_model_data['topics']\n","        final_topic_summaries = optimal_model_data['topic_summaries']\n","    else:\n","        print(\"Optimal model data not found.\")\n","else:\n","    # If GPT-4 did not provide a clear recommendation, default to the last iteration\n","    optimal_model_data = models[-1]\n","    final_topic_model = optimal_model_data['topic_model']\n","    final_embeddings = optimal_model_data['embeddings']\n","    final_topics = optimal_model_data['topics']\n","    final_topic_summaries = optimal_model_data['topic_summaries']\n"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"4clo3VAbtvN4","executionInfo":{"status":"ok","timestamp":1728018272077,"user_tz":-480,"elapsed":7543,"user":{"displayName":"Paris Kang","userId":"15453206198277055555"}},"outputId":"dcaa141e-f8a8-471e-8c7e-4d5416e0ae7c"},"execution_count":null,"outputs":[{"output_type":"stream","name":"stdout","text":["\n","GPT-4's advice:\n","Based on the provided evaluation metrics and topic summaries for the three iterations, I believe the optimal iteration for topic modeling is:\n","\n","- **Optimal Iteration:** Iteration 3\n","- **Reasoning:**\n","    - **Evaluation Metrics:**\n","        - Silhouette Score: -0.3573615849018097 (better than Iteration 1 and Iteration 2)\n","        - Calinski-Harabasz Index: 99.1125635992664 (significantly higher indicating better cluster separation compared to Iterations 1 and 2)\n","        - Davies-Bouldin Index: 11.901558072334218 (lower than both Iteration 1 and 2, indicating more distinct clusters)\n","    - **Coherence and Distinctiveness:**\n","        - Iteration 3 shows the best balance between coherence and distinctiveness across topics, evidenced by its lower Davies-Bouldin Index and higher Calinski-Harabasz Index.\n","        - The topic summaries in Iteration 3 are more detailed and provide a better understanding of the topics, suggesting clear differentiation and specific focus areas.\n","        - The evaluation metrics, particularly the Calinski-Harabasz Index, support the notion that Iteration 3 has better-defined clusters with more clear separation, which is critical for distinctiveness.\n","        - Improving topics' coherence and interpretability is also evident from the way topics are presented and labeled in Iteration 3, which suggests a structured approach to dividing various subject areas.\n","\n","Iteration 3 thus provides a robust balance between topic coherence and distinctiveness, supported by superior evaluation metric scores, leading to a better topic modeling outcome.\n","Could not determine optimal iteration from GPT-4's response.\n"]}]},{"cell_type":"code","source":["# ============================== #\n","# Section 7: Save Final Results\n","# ============================== #\n","\n","# Assign the final topics and summaries to the data\n","data['Topic'] = final_topics\n","data['Topic_Summary'] = [final_topic_summaries.get(topic, '') for topic in final_topics]\n","\n","# Save the data to an Excel file\n","data.to_excel('data_with_final_topics.xlsx', index=False)\n","\n","print(\"\\nFinal results have been saved to 'data_with_final_topics.xlsx'.\")"],"metadata":{"colab":{"base_uri":"https://localhost:8080/"},"id":"trbFUpH-tz4d","executionInfo":{"status":"ok","timestamp":1728018305009,"user_tz":-480,"elapsed":2032,"user":{"displayName":"Paris Kang","userId":"15453206198277055555"}},"outputId":"619535c0-e929-4630-aaa4-d6844f2cddd5"},"execution_count":null,"outputs":[{"output_type":"stream","name":"stdout","text":["\n","Final results have been saved to 'data_with_final_topics.xlsx'.\n"]}]},{"cell_type":"code","source":["import os\n","import shutil\n","from google.colab import files\n","\n","# 定义要压缩的文件夹路径\n","folder_path = '/content/fine-tuned-model-iteration-3'\n","\n","# 定义压缩文件的名称\n","zip_filename = 'fine-tuned-model-iteration-3.zip'\n","\n","# 创建压缩文件\n","shutil.make_archive(zip_filename.split('.')[0], 'zip', folder_path)\n","\n","# 下载压缩文件\n","files.download(zip_filename)\n","\n","# 删除本地的压缩文件（可选）\n","os.remove(zip_filename)\n","\n","print(f\"文件 '{zip_filename}' 已经被压缩并开始下载。\")"],"metadata":{"colab":{"base_uri":"https://localhost:8080/","height":53},"id":"SYvSXZIItvAH","executionInfo":{"status":"ok","timestamp":1728021829508,"user_tz":-480,"elapsed":6710,"user":{"displayName":"Paris Kang","userId":"15453206198277055555"}},"outputId":"7e18c627-39c9-4cf7-f982-e26c19beb820"},"execution_count":null,"outputs":[{"output_type":"display_data","data":{"text/plain":["<IPython.core.display.Javascript object>"],"application/javascript":["\n","    async function download(id, filename, size) {\n","      if (!google.colab.kernel.accessAllowed) {\n","        return;\n","      }\n","      const div = document.createElement('div');\n","      const label = document.createElement('label');\n","      label.textContent = `Downloading \"${filename}\": `;\n","      div.appendChild(label);\n","      const progress = document.createElement('progress');\n","      progress.max = size;\n","      div.appendChild(progress);\n","      document.body.appendChild(div);\n","\n","      const buffers = [];\n","      let downloaded = 0;\n","\n","      const channel = await google.colab.kernel.comms.open(id);\n","      // Send a message to notify the kernel that we're ready.\n","      channel.send({})\n","\n","      for await (const message of channel.messages) {\n","        // Send a message to notify the kernel that we're ready.\n","        channel.send({})\n","        if (message.buffers) {\n","          for (const buffer of message.buffers) {\n","            buffers.push(buffer);\n","            downloaded += buffer.byteLength;\n","            progress.value = downloaded;\n","          }\n","        }\n","      }\n","      const blob = new Blob(buffers, {type: 'application/binary'});\n","      const a = document.createElement('a');\n","      a.href = window.URL.createObjectURL(blob);\n","      a.download = filename;\n","      div.appendChild(a);\n","      a.click();\n","      div.remove();\n","    }\n","  "]},"metadata":{}},{"output_type":"display_data","data":{"text/plain":["<IPython.core.display.Javascript object>"],"application/javascript":["download(\"download_b164fa00-7166-4802-a49f-c926d7c7a339\", \"fine-tuned-model-iteration-3.zip\", 84068277)"]},"metadata":{}},{"output_type":"stream","name":"stdout","text":["文件 'fine-tuned-model-iteration-3.zip' 已经被压缩并开始下载。\n"]}]}]}